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Abstract
Huntington’s disease (HD) is a fatal neurodegenerative disorder characterized by a pro-
gressive decline in cognitive, motor, and psychiatric functions. These symptoms are
associated with the extensive neuronal loss in the striatum of HD patients. HD is caused
by a CAG repeat expansion which translates into a polyglutamine (polyQ) stretch at
the N-terminus of the huntingtin protein (htt). The polyQ stretch induces misfolding,
cleavage and aggregation of htt. Insoluble protein aggregates are a hallmark of a num-
ber of neurodegenerative disease, which raised hope that understanding the process of
aggregation and its potential as a therapeutic target in one of the diseases may have
implications for the others.
It has been postulated that the sequestration of transcription-related proteins into
the htt aggregates causes transcriptional changes observed in HD models. To test that
hypothesis, I compiled lists of genes controlled by the transcription factors associated
with HD. These genes were spotted on cDNA microarrays that were later hybridized
with RNA extracted from cell lines expressing a mutant htt fragment. Upon induction
of expression, htt fragments formed aggregates and the cells showed reduced viability.
Transcriptional changes after the induction of htt fragment expression were monitored
and their time series analysed. In this study, no systematic changes within the groups
of genes regulated with the specific transcription factors were observed, which indicates
that targeting a specific transcription factor might not be a feasible therapeutic strategy
for treating HD.
It is well established that the formation and the accumulation of htt aggregates causes
neurotoxicity in different HD model systems. However, there is an intense debate as
to which protein structure, i.e. monomers, oligomers or aggregates of htt fragment, is
responsible for neuronal dysfunction and loss. Understanding the dynamical properties
of the htt aggregation process can help understanding the consequences of therapeutic
strategies targeting aggregation. For this purpose, I derived several mathematical models
describing htt aggregation and cell death. A core deterministic model of htt aggregation
allowed monitoring changes in the concentration of different htt conformers in the course
of the disease. Based on this core model, a stochastic model of htt aggregation was
constructed and the assumption that the toxicity is proportional to the concentration of
each htt conformer was included. The results showed that transient dynamics observed
in the system and the non-monotonic response of cell survival to a change of parameter
might lead to the non-intuitive outcome of a treatment that targets htt aggregation.
Moreover, the numerical simulations of the stochastic model show that if aggregates are
the toxic species, the onset of aggregation, marked by the overshoot in the concentration
of aggregates, is the event most likely to kill the cell. Therefore. if the cell survives the
onset of aggregation, it might have a higher life expectancy than a cell without aggregates
despite the presence of toxic aggregates. This phenomenon was termed a one-shot model.
The one-shot model could explain how aggregates could be toxic and neuroprotective at
the same time.
HD is a late onset disorder whose symptoms usually appear between 30 to 50 years
of age. It is possible to measure the functional decline of the affected brain regions in
HD patients, but what dictates the dynamics of that decline is not known. To address
the open question of the late-onset of HD, I built an enlarged deterministic model of htt
aggregation. The model showed that a nucleation process and a positive feedback loop
acting on the htt fragment release describe well the late onset of aggregation through an
intrinsic mechanism.
The principal cause of the variability of the age at onset (AO) is the length of the
CAG repeat. Still, there is a great variance in the AO even for the same CAG repeat
length. This notion prompted a search for additional genetic factors that could modify
the AO of HD. At the same time, neuronal decline in a group of neurodegenerative
diseases including HD fits well a one-hit model, in which a rare random event triggers cell
death. To study the variability of the AO, I developed a stochastic model for neuronal
death in the HD striatum based the one-hit model. In this model, it is assumed that
neurons do not die independently, but in clusters due to cross-talk between the cells,
excitotoxicity or inflammation. The model was used to explore the variability introduced
in the development of the disease by the random times of cluster deaths. The stochastic
model of neuronal death showed that a significant part of the unexplained variance can
be attributed to the intrinsic stochastic dynamics of neurodegeneration.
Keywords: Huntington’s disease, protein aggregation, transcriptional dysregulation, ma-
thematical model
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Zusammenfassung
Die Huntington’sche Krankheit (Huntington’s disease, HD) ist eine tödliche neurode-
generative Erkrankung, die durch den progressiven Verlust kognitiver, motorischer und
psychiatrischer Funktionen gekennzeichnet ist. Diese Symptome gehen bei HD-Patienten
mit einem extensiven Verlust von Neuronen im Striatum einher. Die Ursache für HD ist
eine genetische Mutation, bei der eine CAG-Wiederholungssequenz verlängert wird. Im
resultierenden Protein, das Huntingtin (htt) genannt wurde, wird diese CAG-Sequenz
in eine Polyglutamin (PolyQ)-Sequenz im N-Terminus translatiert. Die PolyQ-Sequenz
führt zur Missfaltung von htt, woraufhin es gespalten wird. Die entstehenden Fragmente
von htt bilden unlösliche Aggregate. Die Entstehung von unlöslichen Proteinaggregaten
ist ein gemeinsames Merkmal von etlichen neurodegenerativen Erkrankungen, was Anlass
zur Hoffnung gab, dass Erkenntnisse über den Aggregationsprozess und sein Potential als
therapeutischen Ansatzpunkt bei einer der Krankheiten auch Anwendungsmöglichkeiten
für die anderen Krankheiten eröffnen würden.
In Modellen für HD wurden Veränderungen der Transkription beobachtet, und es
wurde postuliert, dass diese durch die Rekrutierung von transkriptions-assoziierten Pro-
teinen in htt-Aggregate verursacht werden könnten. Um diese Hypothese zu testen, habe
ich untersucht ob die Bildung von htt-Aggregaten die Transkription von Genen, von de-
nen bekannt ist, dass sie von HD-assoziierten Transkriptionsfaktoren kontrolliert werden,
verändert. In den für diese Versuche verwendeten Zelllinien führte die Induktion der Ex-
pression eines mutierten htt-Fragments zur Bildung von htt-Aggregaten, und die Zellen
wiesen eine verminderte Vitalität auf. Zur Untersuchung der Transkription wurden die
zu untersuchenden Gene auf cDNA-Mikroarrays aufgebracht und mit RNA, welche aus
den Zellen zu unterschiedlichen Zeiten nach der Induktion der Expression des mutierten
htt-Fragments gewonnen wurde, hybridisiert. So konnte auch die Zeitabhängigkeit der
Transkription gemessen werden. Es wurden keine systematischen Veränderungen inner-
halb der durch spezifische Transkriptionsfaktoren regulierten Gengruppen gefunden, was
darauf hindeutet, dass die Fokussierung auf einen spezifischen Transkriptionsfaktor eher
nicht als sinnvolle therapeutische Strategie für die Behandlung von HD angesehen werden
kann.
Es ist bekannt, dass die Ausbildung und Ansammlung von htt-Aggregaten in ver-
schiedenen HD-Modellsystemen zum Absterben von Nervenzellen im Striatum führt. Es
herrscht jedoch rege Diskussion darüber, welche Proteinstruktur, d.h. Monomere, Oli-
gomere oder Aggregate des htt-Fragments, die neuronalen Dysfunktionen und letztend-
lich den Zelltod verursacht. Ein besseres Verständnis der Dynamik des htt-Aggregations-
prozesses könnte zur Abschätzung der Auswirkungen von therapeutischen Strategien, die
die Proteinaggregation beeinflussen, beitragen. Zu diesem Zweck habe ich mehrere ma-
thematische Modelle erstellt, welche die htt-Aggregation und den Zelltod beschreiben.
In einem deterministischen Kernmodell der htt-Aggregation konnten Veränderungen der
Konzentrationen verschiedener htt-Konformere im Krankheitsverlauf beobachtet werden.
Aufbauend auf dem Kernmodell wurde als nächstes ein stochastisches Modell der htt-
Aggregation erstellt, bei dem angenommen wurde, dass die Toxizität proportional zur
Konzentration eines jeden htt-Konformers ist. Die Ergebnisse zeigten, dass eine transien-
te Dynamik im System und die nicht-monotone Reaktion auf Parameteränderungen zu
den nicht-intuitiven Ergebnissen bei Behandlungsansätzen, welche die htt-Aggregation
beeinflussen, führen könnten. Für den Fall, dass Aggregate die toxische Form von htt
sind, zeigten die numerischen Simulationen mit dem stochastischen Modell, dass das
Einsetzen der Aggregation, welches durch ein Überschießen der Aggregatkonzentration
gekennzeichnet ist, am ehesten zum Zelltod führt. Deshalb kann eine Zelle, die das Ein-
setzen der Aggregation überlebt hat, trotz des Vorhandenseins von toxischen Aggregaten
eine höhere Lebenserwartung haben als eine Zelle ohne Aggregate. Dieses Phänomen
wurde “one-shot”-Modell genannt, und es könnte die paradoxen Befunde erklären, nach
denen Aggregate zugleich toxisch und neuroprotektiv sein können.
Die Symptome von HD manifestieren sich bei den Betroffenen üblicherweise erst im
Alter von 30 bis 50 Jahren. Es ist möglich, den Funktionsverlust der betroffenen Ge-
hirnregionen bei HD-Patienten zu messen, aber wodurch die Dynamik dieses Verlusts
verursacht wird ist nicht bekannt. Um zur Klärung dieser Frage beizutragen habe ich ein
erweitertes deterministisches Modell der htt-Aggregation erstellt. Das Modell zeigte, dass
zur Erklärung des späten Einsetzens der Aggregation ein intrisischer Mechanismus aus-
reichend ist. Dieser Mechanismus beinhaltet einen Nukleationsprozess und eine positive
Feedback-Schleife, die die Freisetzung des htt-Fragments bewirkt.
Die Hauptursache für die Variabilität des Alters bei Krankheitsausbruch (age of on-
set, AO) bei HD-Patienten ist die Länge der CAG-Wiederholungssequenz. Jedoch gibt es
auch bei Patienten mit gleicher Länge der CAG-Wiederholungssequenz eine große Vari-
anz des AO . Diese Tatsache führte zur Suche nach zusätzlichen genetischen Faktoren, die
das AO bei HD beeinflussen könnten. Gleichzeitig passt der neuronale Abbau bei einer
Gruppe neurodegenerativer Erkrankungen inklusive HD gut zu einem one-hit-Modell, bei
dem ein Zufallsereignis den Zelltod verursacht. Um die Variabilität des AO zu studieren,
habe ich ein stochastisches Modell für den neuronalen Zelltod im Striatum entwickelt,
welches auf dem one-hit-Modell basiert. In diesem Modell wird angenommen, dass Neu-
rone nicht einzeln und unabhängig voneinander sterben, sondern in Gruppen aufgrund
von Kommunikation zwischen den Zellen, Exzitotoxizität oder entzündlichen Prozessen.
Das Modell wurde dazu verwendet, die Variabilität, die in die Krankheitsentwicklung
durch gruppierten Zelltod an zufälligen Zeitpunkten eingeführt wird, zu untersuchen.
Das stochastische Modell neuronalen Zelltods zeigte, dass ein signifikanter Anteil der
nicht erklärbaren Varianz des AO der intrinsischen stochastischen Dynamik der Neuro-
degeneration zugeschrieben werden kann.
Schlagwörter: Huntington’sche Krankheit, Proteinaggregation, Veränderungen der Tran-
skription, mathematisches Modell
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Foreword
In 1872, George Huntington, whose vivid and accurate description of hereditary chorea
led to the eponymous designation of this fatal disorder as Huntington’s disease (HD),
accounts: “The treatment of chorea now most generally adopted is by purgatives, tonics,
counter-irritants, and anti-spasmodics. Bleeding used to be employed, and it is said with
good results, but it is rarely used at present, except in cases when there is much pain
in the head, or along the spine, when it may be taken moderately by cups or leeches.”
A hundred and forty years and 8000 papers later, a treatment of HD still focuses on
relieving the symptoms and preventing complications.
HD is caused by a mutation in a single gene coding for a protein that has thus been
called huntingtin (htt). The mutation is a pathological extension of a CAG repeat that
is translated in the polyglutamine stretch at the N-terminus of the htt, causing htt mis-
folding and cleavage. Cleaved htt fragments aggregate to form large and dense protein
inclusions. A number of transcription factors co-localize with the protein inclusions in
HD models. It has been postulated that sequestration of those proteins leads to tran-
scriptional dysregulation, neuronal cell dysfunction and ultimately cell death. Protein
inclusions are a hallmark of a number of neurodegenerative diseases, which raised hope
that a common therapeutic agent could be found. However, the pathogenicity of the
protein inclusions has been controversial. The question whether aggregates are harmful
or beneficial, and consequently whether one should fight them or promote them, polar-
izes HD research community. During my PhD studies I have also entered this buzzing
field of research. The experimental part of my PhD thesis deals with the transcriptional
dysregulation in HD as a consequence of htt aggregation, and theoretical part focuses on
mathematical models of htt aggregation and neuronal cell death.
1
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Chapter 1
Introduction
1.1 Living with HD
Huntingon’s disease (HD) is a progressive neurodegenerative disorder “hardly ever mani-
festing itself until adult or middle life, and then coming on gradually but surely, increasing
by degrees, and often occupying years in its development, until the hapless sufferer is but
a quivering wreck of his former self” (75).
The symptoms usually appear in an individual between 30 to 50 years of age and
progress over a period of 10 to 15 years (108). The prevalence of HD in Western Europe
and Northern America is 5 to 10 per 100,000 persons (109). Initial symptoms of HD may
include personality changes, such as increased irritability, suspiciousness, impulsiveness,
and lack of self-control. In the beginning it might be difficult to attribute those changes
to such a devastating disease as HD. However, as HD progresses, additional symptoms
develop like inability to absorb and understand new information, diminished memory re-
trieval, progressively impaired judgment and impulse control, diminished language skills
with slurred speech, difficulty swallowing, and increasingly impaired ability to plan, ini-
tiate, or perform certain purposeful movements. Many HD patients have a distinctive
manner of walking that may be unsteady, disjointed, or staggering. A dramatic weight
loss may occur due to energy expenditure from choreic movements. HD patients often
suffer from anxiety, depression, mania, obsessive-compulsive behaviors, and sleep distur-
bances. Suicide rate is high among HD patients (52).
Because of severe dementia and progressive motor dysfunction, patients with advanced
HD may become unable to walk, have poor dietary intake, eventually cease to talk, and
become unable to care for themselves. Pneumonia and heart failure are the two most
frequent primary causes of death in HD patients (154).
There are a number of interventions available today that can improve the quality of
life for HD sufferers. In the early and middle stages of the disease, medications can be
given in small doses to HD patients to help suppress the involuntary movements (29).
Depression and other psychiatric conditions in people with HD can be quite effectively
treated (151). Proper nutrition, exercise and precautions at home can help minimize
many of the potential consequences of HD (104). However, there is still no way to
postpone or slow down the progress of this fatal disorder.
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Figure 1.1: Striatal degeneration. (Left) Location of the striatum in the brain. (Right)
Comparison of a brain from a HD patient and from a control showing atrophy of the
striatum in the HD patient. (From: http://hdroster.iu.edu/AboutHD/brainAndHD.asp)
1.2 Neuropathology of HD
Inability of HD patients to control movements or plan an action is a consequence of
premature, gradual dying of medium-sized “spiny” neurons, the most abundant type of
neurons in the striatum (53). As striatal degeneration progresses, degenerative changes
occur to other brain regions connected to the striatum, in particular the globus pallidus,
the subthalamus, and the cerebral cortex. In the final stage of the disease, HD brains
weigh approx. 10–20% less than age-matched controls (66) (Figure 1.1, right panel).
Striatal medium-sized neurons are highly specialized cells that secrete gamma-amino-
butyric acid (GABA), the primary inhibitory neurotransmitter in the brain. Their se-
lective loss results in decreased inhibition of the thalamus and continuous glutamate
excitation causing random and frequent motions (Figure 1.2). Glutamate is the principal
excitatory neurotransmitter in the mammalian central nervous system. It binds to a va-
riety of excitatory amino acid receptors, which are ligand-gated ion channels. In normal
synaptic functioning, activation of excitatory amino acid receptors is transient. How-
ever, if receptor activation becomes excessive or prolonged, the target neurons become
damaged and eventually die. This process of neuronal death is called excitotoxicity and
appears to involve sustained elevations of intracellular calcium levels (48).
The striatum receives large glutamatergic input from the cerebral cortex, and it is
thus at risk of glutamate-mediated excitotoxic injury. Indeed, intrastriatal injections of
glutamate agonists (e.g. quinolinic acid) lead to neuronal depletion and a neurologic phe-
notype that is similar to HD (20). Moreover, subsets of glutamate receptors, specifically
the metabotropic glutamate receptor mGluR2, are significantly decreased in a trans-
genic mouse model of HD (37). mGluR2 receptors down-regulate glutamate release at
corticostriatal presynaptic terminals, and depletion of these receptors could lead to over-
stimulation of postsynaptic striatal neurons.
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Figure 1.2: Striatal circuitry: The striatum receives direct input from most regions of
the cerebral cortex, and indirect input from sensorimotor and motivational regions of the
brain stem via relays in the thalamus. Dysfunction of striatal-thalamo-cortical circuits
underlies the pattern of motor, behavioral and cognitive symptoms in HD.
1.3 Protein inclusions: a common theme in polyglu-
tamine disorders
Nine neurodegenerative disorders are caused by expanded CAG repeats coding for polyg-
lutamine (polyQ). They include Spinal and Bulbar Muscular Atrophy (SBMA), the first
one discovered; Huntington’s disease (HD), the most actively studied; DentatoRubral and
PallidoLuysian Atrophy (DRPLA), which is similar to HD; and several forms of Spino-
Cerebellar Ataxia (SCA). Each of the disorders is characterized by selective and progres-
sive neuronal cell death in specific regions of the brain. While the exact areas affected
in each disease differ, there is considerable overlap, including basal ganglia, brainstem
nuclei, cerebellum, and spinal motor nuclei (131).
Although the proteins causing these diseases share no homology aside from the polyQ
stretch itself, the diseases themselves share many. This led to the conclusion that the
polyQ stretch confers toxicity on the disease protein and opened the possibility that
polyQ diseases share a pathogenic mechanism. Ideally, a therapeutic approach befitting
several neurodegenerative diseases could thus be found.
All of the mutant proteins appear to undergo a conformational change and aggregate
in cells, forming characteristic inclusion bodies. Aggregation in these proteins is facili-
tated by proteolytic cleavage and covalent modifications of the disease proteins or protein
fragments. In HD, phosphorylation alters cleavage and toxicity (143) of HD-causing pro-
tein huntingtin (htt), palmitoylation is necessary for the normal function of htt (183), and
SUMOylation decreases its aggregation, increases its nuclear localization and increases
neurodegeneration in a HD fly model (158).
Therefore, boosting the refolding, preventing the proteolytic cleavage, interfering with
covalent modifications, and enhancing mutant protein clearance represent common ther-
apeutic concepts for all polyQ diseases.
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1.3.1 Identification of toxic polyglutamine species
The aggregation process generates protein complexes of different multimerization grades
and three-dimensional structures which probably differ in the level of toxicity they confer.
Low temporal and spatial resolution have limited the interpretation of past experiments
that correlated aggregate formation with neurodegeneration. Resolution of this issue is
necessary because many current studies aim to interfere with aggregate formation as a
potential treatment for HD and the other neurodegenerative disorders characterized by
protein aggregates (132).
Recently, an automated microscopic system was developed that allows to simultane-
ously follow aggregate formation, the presence of diffuse htt and cell survival in the same
neuron over a period of days. The study showed that the formation of the final forms
of aggregated htt (i.e. the inclusion bodies) prolonged survival and protected neurons,
seemingly by reducing the amount of a toxic, diffusely distributed form of mutant htt
(9). However, this does not rule out the possibility that the major toxic species are the
microaggregates, early precursors to inclusion bodies.
Identifying therapeutics to arrest the creation of the toxic species is an important
research goal in the HD field. Both aggregation inhibitors and aggregation promotors
have been shown to have beneficial effects in experimental HD models (86, 171, 27, 51).
These conflicting findings are probably due to the fact that it is very hard to specifically
interfere with the aggregation by affecting only one conformer.
1.4 A curious protein called huntingtin
In 1993, a multicentre consortium, organized by the Hereditary Disease Foundation,
discovered the HD-causing gene and the variable and prolonged sequence of nucleotides
(CAG)n that codes for the stretch of glutamine amino acids (polyQ) at the N-terminus
of htt (166). People with more than 40 glutamines in that stretch will develop HD; those
with fewer than 36 will be unaffected. Larger polyQ expansions in htt are associated
with earlier onset and increased severity of the disease (50, 153, 3). The sharp threshold
of the pathogenic polyQ length suggests that a transition to a new, stable and toxic
conformation of mutant htt triggers the disease (120).
The primary amino acid sequence of htt reveals little, as it contains only a few known
sequence motifs and no structural domains with defined functions (35). Known sequence
motifs include HEAT repeats, tandemly arranged structures that appear to serve as
flexible scaffolding on which other components can assemble, and which are found in
a number of proteins involved in intracellular transport and chromosomal segregation
(164). The other obviously important portion of htt is the polyQ region itself, which
is present in many transcription factors and aberrantly expanded in at least eight other
disease-causing proteins (126). Unlike many other proteins of a similar size (328 kDa),
htt is completely soluble. Its widespread expression and intracellular localization have
not eased the definition of its function. Here is what we know so far.
Htt is ubiquitously expressed in moderate amounts in and outside the nervous system
(169). It is essential for embryogenesis: homozygous htt knockout mice die before embry-
onic day 8.5 (111), and it is neuroprotective in brain cells exposed to various apoptotic
stimuli, such as serum deprivation, mitochondrial toxins or transfection of death genes
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(125). It stimulates brain-derived neurotrophic factor (BDNF) gene transcription through
inhibition of a silencer element (Repressor element 1, also known as neuron-restrictive
silencer element, NRSE) located in the promoter of the BDNF gene (186). Through
a similar mechanism, htt controls the transcription of many other neuronal genes that
carry a repressor silencer 1 transcription repressor factor, REST/NRSE, repeat in their
promoters (187). It also regulates fast axonal trafficking (65), vesicle transport (57), and
synaptic transmission (152).
The search for normal htt function is far from over. Recently, 234 high-confidence htt-
associated proteins have been identified (79). It will be a challenging task to determine
which of the identified interactions contribute to HD pathology and to use that knowledge
to alleviate the symptoms of HD.
One study showed that different conformations of full-length htt, distinguished by
epitope accessibility, were localized to different sets of nuclear and perinuclear organelles
(168). Together with the remarkable potential of htt to bind a variety of proteins, this
study suggest that htt has a flexible or multifunctional structure capable of assuming
specific conformations and activities depending on its subcellular location (101).
1.5 When htt becomes toxic: cellular pathogenesis
The pathogenic process begins with the synthesis of a htt protein with an expanded polyQ
tract (>36 repeats). The expanded polyQ tract alters the native conformation of htt
(120). A fraction of the abnormally folded protein is subjected to lysosomal-dependent
proteolysis, or degraded by the proteasome (82). The rest is cleaved by caspases or
calpains, producing a short N-terminal fragment that favours the aggregation process
(179, 55). The mutant proteins shifts, in part, from a monomeric random coil or β-sheet
into oligomeric β-sheets and eventually into insoluble aggregates (amyloid fibrils) (121).
The development of transgenic mouse, fly, and worm models has led to the discovery
of multiple pathways induced by the mutant htt (figure 1.3). Aggregation intermediates
inhibit proteasomal processing (146). The monomers or oligomers directly activate cas-
pases or disrupt mitochondrial function, leading to indirect activation of caspases (41).
Proto-aggregates translocate into the nucleus and recruit specific nuclear factors, co-
activators and co-repressors, inhibiting their normal activities and resulting in altered
gene transcription (126). The presence of mutant htt fragments in the nucleus is a signal
for caspase-1 up-regulation (94). As the disease progresses, caspase-3, -8, and -9 are ac-
tivated, and there is release of cytochrome c, which serves as an apoptotic trigger (136).
Also, disruption of the binding between htt and HIP-1 (htt interacting protein 1) sets
HIP-1 free to bind its partner hippi (HIP-1 protein interactor). Thus formed HIP-1/hippi
heterodimer can then recruit procaspase-8 and launch apoptosis (59).
The conformational change of mutant htt and subsequent aggregation lead to the
loss of multiple physiological functions preformed by wild-type htt. The htt mutation
reduces BDNF production, represses transcription of a number of neuronal genes, reduces
transport of mitochondria and BDNF, and alters synaptic transmission (34). A few
pathways leading to neuronal dysfunction and cell death are explained in more detail
below.
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Figure 1.3: The pathogenic mechanisms induced by mutant htt include: Impaired tran-
scription, altered vesicular transport, proteasomal impairment, clathrin-mediated endo-
cytosis dysfunction, cytoskeletal abnormalities, calcium homeostasis dysregulation, mito-
chondrial dysfunction, protein sequestration and caspase activation.
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1.5.1 Transcriptional dysregulation
Some of the most consistently observed actions of htt involve interference with gene
transcription. It has been shown that transcription factors such as p53, CREB-binding
protein (CBP), specificity protein 1 (Sp1), TAFII130, and TATA-binding protein can be
recruited to intranuclear aggregates (156, 49, 173). Many transcription factors contain
a polyQ-rich domain which has been found to enhance their activity (58). Therefore,
it was expected that the interaction between CBP, for instance, and mutant htt would
be through that polyQ domain. Surprisingly, it was shown that mutant htt interacts
with the acetyltransferase domain in CBP and thus causes reduced histone acetylation
in HD cells (157). This led to the finding that inhibition of histone deacetylase (HDAC)
or promotion of histone acetylation relieves neurodegeneration in cellular and fly models
and motor deficits in a mouse model of HD (157, 72).
Although the nucleus is thought to be a primary site for mutant htt to elicit its effect
on gene transcription, mutant htt has a decreased affinity to the cytoplasmic pool of the
nuclear receptor REST/NRSF. In HD, this leads to a decreased expression of BDNF and
other genes controlled by REST (187).
1.5.2 Mitochondrial dysfunction
Mitochondria play a central role in both apoptotic and necrotic cell death. Mitochondrial
dysfunction leads to a number of deleterious events including impaired calcium buffering,
generation of free radicals, activation of the mitochondrial permeability transition and
secondary excitotoxicity (19).
The evidence for the dysfunction of mitochondria in HD patients is abundant. HD
patients have increased lactate production in cerebral cortex and basal ganglia (77),
decreased glucose metabolism (6), and impaired complex II-III activity and aconitase in
the striatum (63). Systemic administration of mitochondrial toxins to primates leads to
the selective degeneration of the striatum (32). Metabolic defects in skeletal muscles of
HD patients might explain the observations that HD patients suffer progressive weight
loss despite increased caloric intake (96).
Recently, it was shown that mutant htt binds to the outer mitochondrial membrane
and directly increases susceptibility of mitochondria to the calcium-induced permeability
transition and cytochrome c release (41). Mutant htt also binds to and upregulates p53
leading to mitochondrial membrane depolarization (14).
1.5.3 Disrupted balance in protein folding and protein clearance
The ubiquitin-proteasome and macroautophagy-lysosome pathways are major routes to
cytosolic protein degradation. Normally, misfolded proteins are tagged with ubiquitine
and then degraded by the proteasome. However, polyQ sequences are poor substrates for
the proteasome, and highly ubiquitinated aggregates of htt are eventually targeted to the
endosomal-lysosomal organelles to be removed by autophagy. In the presence of a chronic,
aggregation-prone htt the protein folding and clearance process becomes overwhelmed.
Proteins that are normally harmless are no longer correctly folded, leading to dysfunction
in a diverse set of cellular pathways (21).
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Helping the cells to degrade the protein aggregates is a promising therapeutic option.
Toxicity induced by disruption of global balance of protein folding quality control can
be attenuated by increasing the autophagy with histone deacetylase 6, a microtubule-
associated deacetylase that interacts with polyubiquitinated proteins (116). Moreover,
treatment with rapamycin, which stimulates autophagy, reduces htt accumulation and
neurodegeneration in cell, fly and mouse models of HD (180).
1.6 The pursuit of HD cure
The central nervous system tissue has very limited regenerative capacity so it is crucial to
limit the damage caused by neuronal death. It is likely that there are many dysfunctional
neurons present at any given time in the course of HD. All the processes that are affected
by HD mutation present a potential therapeutic target. Recent studies in HD trans-
genic mice have demonstrated significant neuroprotective effects of several substances,
namely: remacemide (glutamate antagonists), coenzyme Q10 and creatine (enhancers of
mitochondrial function), minocyclin (antiapoptotic antibiotic), suberoylanilide hydrox-
amic acid (SAHA) and sodium butyrate (transcriptional modulators), and cystamine
(transglutaminase inhibitor) (93).
Different approaches like DNA vaccination and neuronal tissue transplantation have
shown the first promising results. DNA vaccination was used to present the mutant
intracellular htt to the immune system which ameliorated the diabetic phenotype of HD
mice (106). Transplanted fetal neural tissue improves HD symptoms temporarily (up to
4 years) (13).
Trials of neuroprotective treatments for HD require large numbers of patients and long
trial durations. Given the growing pipeline of potential neuroprotective agents attractive
for testing in clinical trials it is vital to develop reliable and reproducible markers of
HD onset and HD progression. The morphological brain changes that occur during the
course of HD are observable with in vivo brain imaging techniques. Many studies have
used volumetric analysis of computed tomography (CT) scans and magnetic resonance
images (MRIs) to demonstrate progressive bilateral atrophy of the striatum which may
occur gradually even years before motor symptoms appear (16, 11).
Functional brain imaging is based on the premise that focal neuronal activity is related
to either regional cerebral blood flow (rCBF), the local degree of glucose metabolism or
regional changes in receptor binding. These tests can be done repeatedly and can assess
temporal changes in the neuronal degeneration both before and after the development
of clinical symptoms. The application of several imaging techniques in parallel may
give us the opportunity to gather even more revealing information about the metabolic,
functional and neuroanatomical alterations that take place during the various stages of
the disease. Most importantly, morphometric markers may provide a sensitive and reliable
method to determine whether a drug is effective in symptomatic patients.
1.7 Thesis at a glance
HD has been a real challenge for cell biologists. A multitude of cellular processes are
afflicted in HD, which seems to be the consequence of both loss of function of wild type
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htt, and toxic gain of function of mutant htt. Moreover, results obtained using different
disease models often disagree, presumably because the models represent different stages of
HD. For example, some publications reported a large number of differentially transcribed
genes in HD model (100), whereas the others reported just a few (148). Some publications
report a correlation between the appearance of htt aggregates and cell death (184), others
report that no such correlation exists (139). Neuronal cell death underlies the appearance
of symptoms in HD patients, but a number of animal models display symptoms of HD
without any neuronal loss (118).
The HD field still abounds with open questions, and in my PhD thesis I have tried
to answer several of them. To test the hypothesis that transcriptional dysregulation in
HD stems from the sequestration of certain transcription factors into htt aggregates, I
compiled lists of genes under regulation of those factors and those genes where then
spotted on cDNA microarrays. The cDNA microarrays were hybridized with the RNA
extracted from cell lines expressing a mutant htt fragment prone to aggregation. These
experiment and the results are described in chapter 2.
Htt is expressed throughout life, but most of the HD patients do not display the disease
symptoms before 30 or even 50 years of age. In chapter 3, I introduce a deterministic
model of htt aggregation that allows us to monitor what is happening with different htt
conformations as the cellular environment changes in the course of the disease, and use
this model to explain the delayed onset of HD by an intrinsic mechanism.
The greatest controversy in the HD field revolves around the toxicity of different htt
conformations that arise in the process of aggregation. Both inhibitors and promoters of
aggregation have been shown to have beneficial effects in HD models (51, 27). In chapter
4, I present a stochastic model of htt aggregation and cell death in HD. The models allows
us to assign different toxicities to htt conformations. Using this model, I tested how the
outcome of the therapeutic strategies targeting aggregation in HD depends on the kinetic
constants of the aggregation and the toxicity of different htt conformers.
The age at onset of HD patients is mainly predicted by the polyQ repeat length.
However, for a given polyQ repeat length a wide range of ages at onset is observed. In
chapter 5, I propose that the observed variance is a consequence of an intrinsic stochastic
property of the pattern of neuronal death in the striata of HD patients.
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Chapter 2
Transcriptional Dysregulation in
Huntington’s Disease: Testing
Hypotheses with Customized Chips
2.1 Summary of the chapter
Mutant huntingtin (htt) triggers multiple pathways of neurodegeneration, including dys-
regulation of transcription. Understanding the molecular basis of transcriptional dysreg-
ulation in HD is necessary for selecting an appropriate therapeutic strategy aiming at
reversing htt-induced expression changes. Mutant htt readily aggregates with itself and
other proteins and forms insoluble protein inclusions. A number of transcription related
proteins interact with mutant htt and co-localize with htt inclusion (112, 156, 49). It
has been postulated that sequestration of these proteins by htt aggregates underlies tran-
scriptional dysregulation observed in many HD models (36). To test this hypothesis, I
compiled lists of genes controlled by the transcription factors that were shown to interact
with htt, together with lists of genes belonging to the several pathways which are impaired
in HD. cDNA microarrays spotted with the selected genes were hybridized with the RNA
extracted from the human cell line that has been stably transfected with a vector carry-
ing htt fragment coding sequence with a CAG triplet expansion in the pathological range
(83 CAGs). Upon induction of htt fragment expression, these cells form aggresome-like
inclusions and show reduced viability (176). Transcriptional changes after the induction
of htt fragment expression were monitored and their time series analyzed. In this study,
no systematic changes within the groups of genes regulated by the same transcription
factor were observed, which indicates that targeting a specific transcription factor might
not be a feasible therapeutic strategy for treating HD.
2.2 Introduction
Precise spatial and temporal patterns of gene expression are crucial for normal develop-
ment and functioning of the cell. Coordinated transcription requires the synchronization
of a number of mechanisms that depend on the trafficking and interaction of diverse
proteins, e.g. DNA-binding transcription factors, non-DNA-binding coregulators, and
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components of the basal RNA-polymerase apparatus. It is believed that dysregulation of
these mechanism presents an early even in HD pathogenesis. However, the precise causes
of transcriptional alterations in HD and how they relate to the observed phenotype remain
elusive.
2.2.1 Transcriptional dysregulation in HD
The first notion that alterations in nuclear function underlie HD pathogenesis came from
a study demonstrating that for the polyQ htt fragment to be toxic, it had to enter the
nucleus (139). Later, a number of studies have shown that mutant htt co-aggregates
with various transcription factors, like CREB-binding protein CBP, TATA-binding pro-
tein TBP, p53, Sp1, as well as with the members of basal transcriptional machinery, like
TAFII130, TFIID and TFIIF (112, 156, 73, 49, 185). Moreover, soluble mutant htt in-
hibits Sp1 binding to DNA in postmortem brain tissues of HD patients, and coexpression
of Sp1 and TAFII130 in cultured striatal cells from HD mice reverses the transcriptional
inhibition of the dopamine D2 receptor gene induced by mutant htt (49). These ob-
servations gave a push to the sequestration theory of HD pathogenesis that stated that
transcription factors, precipitated in the form of insoluble aggregates, get depleted from
the cellular pool, which causes transcriptional dysregulation and subsequent death of HD
cells (36).
Many transcription factors, like Sp1 and CBP, contain polyQ rich regions that can
act as activation domains that enable transcription factors to interact with one another
and thus regulate gene expression (165, 78). It is through the polyQ regions that mutant
htt interacts with Sp1 and TAFII130, a coactivator involved in transcriptional activation
dependent on the cAMP-responsive element (CRE)-binding protein (CREB) (95, 156).
Moreover, the expanded htt fragments suppress CREB-dependent transcriptional acti-
vation and deplete CBP from nuclear locations (112). However, it came as a surprise
that htt binds to the acetyltransferase domain of CBP, not its polyQ tract. This interac-
tion leads to a decrease in the level of histone acetylation in the cells, and consequently
to a decrease in gene transcription. These observations pointed the histone deacetylase
(HDAC) inhibitors as potential therapeutics for HD. Indeed, administration of HDAC
inhibitors has been shown to rescue lethality and photoreceptor neurodegeneration in a
Drosophila model of HD (157). Furthermore, suberoylanilide hydroxamic acid (SAHA),
a potent HDAC inhibitor, had remarkable effects in a HD mouse model (72).
2.2.2 Microarray data from different HD models
The most comprehensive analysis of transcription changes in different HDmodels has been
reported in a series of published articles (99, 100, 38, 148). In these studies, the groups
standardized experimental methods using a single microarray platform and consistent
sample preparation methods. Nevertheless, detected changes in RNA levels were specific
for each HD model used and the overlap of common altered transcripts was small. The
first paper by Luthi-Carter et al. showed that in R6/2 mice expressing only a truncated
htt fragment, a considerable number of genes have an altered pattern of expression and
that this pattern shows little sign of regional specificity (99). The second paper from
the Luthi-Carter group compared gene expression changes between mouse models of
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Figure 2.1: Normal: Htt is predominantly located in the cytoplasm. Sp1 binds to DNA
elements called GC boxes in cellular promoters. An interaction between the polyQ re-
gions in Sp1 and the TAFII130 is required for recruitment of the general transcriptional
machinery that properly positions RNA polymerase II that transcribes mRNA. In HD,
htt sequesters Sp1 and TAFII130 through the interactions of the polyQ regions. RNA
polymerase II cannot bind properly and the transcription of the dopamine receptor gene
is impaired (drawn according to the image from www.bio.davidson.edu).
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HD chip: Gene Groups
AP1-regulated genes AP2-regulated genes
AR-regulated genes Akt-regulated genes
c-myc-regulated genes C/EBP regulated genes
CREB-regulated genes E2F-regulated genes
Elk-1 regulated genes RUNX-regulated genes
Fatty acid metabolism genes Sp1-regulated genes
FOXO3 (FKHRL1)-regulated genes Sp3-regulated genes
Genes coding heat shock proteins Stat1-regulated genes
IRF1-regulated genes TFEB-regulated genes
Genes coding for vesicular transport proteins LEF1-regulated genes
Luthi-Carter data 2000 and 2002 overlap Proteasome coding genes
NFAT-regulated genes NFκB-regulated genes
p53-regulated genes
Table 2.1: cDNA array gene groups. The list comprises the transcription factors and
several cellular pathways that have been implicated in HD. A full list of genes regulated
by those transcription factors and the genes belonging to those cellular pathways can be
found in the appendix A.
HD and dentatorubral-pallidoluysian atrophy, another polyQ disease. They showed that
in the cerebella of these mice, there was a considerable overlap in the genes showing
altered gene expression (100). Thus, there might be polyQ-induced changes in gene
expression that are independent of the polyQ protein context. The paper by Chan et
al. reports that mice expressing a truncated mutant htt had many more genes with
altered expression than mice expressing a full-length mutant protein. However, none of
the three HD mice strains used in that study exhibited altered mRNA levels similar to
those observed previously in R6/2 mice, or in other HD models. The overall number
of differentially expressed genes in these study was small (38). And last, Sipione et al.
used clonal HD striatal cells and reported downregulated genes belonging to the fatty
acid metabolism pathway, vesicular trafficking and synaptic vesicle formation. Unlike in
the R6/2 mice, the expression changes in striatal cells can be seen very early after the
induction of the htt fragment (148).
In follow-up studies, age and progression-dependent changes in transcript levels during
disease progression in HD patients were characterized. Transcriptional alterations were
detectable in the blood of pre-symptomatic subjects and pronounced in the symptomatic
subjects (31). It still needs to be evaluated if those alterations could be used as biomarkers
reflecting HD progression and response to therapies.
2.3 Results
2.3.1 Selection of cDNA probes
Through literature search a list of transcription factors that might be implicated in HD
has been assembled. Transcription factors Sp1, p53 and CBP, have been shown to co-
localize with htt aggregates (49, 156). Dopaminergic and glutamatergic stimuli in stria-
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tum, that are dysregulated in HD, influence the induction of AP-1 proteins (c-Fos and
c-Jun). In striatal neurons, glutamate induces the phosphorylation of AP-1, CREB and
Elk-1, a transcription factor with pro-apoptotic function in neuronal cells, which in-
creases their transcriptional activity (144, 174). Elevated levels of the CREB-regulated
gene product, C/EBP β were found in HD mice (113). A key regulatory regions in htt
promoter are two Sp1 sites in a tandem repeat acting synergistically and an AP-2 site
(44). Expansions to over 40 CAG repeats in the first exon of the human androgen receptor
(AR) lead to spinal bulbar muscular atrophy (SBMA), another late onset neurodegen-
erative disease. It has been shown that excitotoxic aberrant Ca2+ influx activates Akt
pro-survival signaling pathway in HD patients (74). Akt is a serine/threonine protein
kinase that blocks neuronal death by regulating the expression of genes involved in cell
death and survival (60). Increased expression of inducible nitric oxide syntheses seen
in striatal cells from HD patients and HD mice, is a response to inflammatory stimuli,
such as interferon regulatory factor-1 (IRF-1) and nuclear factor κB (NF-κB) (64). It
has been shown that C-terminal fragments of htt interact with members NF-κB protein
family involved in neuronal survival and death (164). NF-κB may promote an apoptotic
response in striatal medium-sized neurons to excitotoxic insult through upregulation of
c-Myc and p53 (122). By an in vitro binding assay it has been shown that htt interacts
with PIASy (61), a nuclear-matrix associated SUMO ligase, which is a negative regulator
of transcription factors Stat1, NFκB and LEF1 (163, 135). Stat1 interacts with Runx2,
a transcription factor with polyQ tract, and inhibits its nuclear localization and tran-
scriptional activity (84). Mutant htt inhibits transcription of PGC-1α, a transcriptional
repressor of FoxO3 (138, 46). Sp1 and Sp3 are oxidative stress-induced transcription
factors in cortical neurons that positively regulate neuronal survival in HD models and
patients (134). Htt mutation leads to the aberrant interaction with calmodulin (17).
The activity of NFAT proteins is tightly regulated by the calcium/calmodulin-dependent
phosphatase calcineurin (123). Histone deacethylase inhibitors, proteins that repress the
pro-apoptotic E2F transcription factor pathway, show beneficial effects in HD models
(85). TFEB is another polyQ stretch containing transcription factor (25).
Once the list of transcription factors that might be implicated in HD was made
(Table 2.1), we started to collect the genes regulated by those transcription factors.
Genes were collected through literature search and the information from TRANSFAC, a
database on transcription factors, their genomic binding sites and DNA-binding profiles
(181). The full list of the selected genes can be found in the appendix A. Literature search
resulted in lists of genes with various identifiers. To handle those lists HomGL, a web-
based tool for comparing and unifying lists of genes with GenBank, RefSeq, UniGene, or
other identifiers was developed (Fig. 2.2) (24). Once we had a complete list of genes, the
clones corresponding to the selected genes were obtained from German Resource Cen-
ter for Genome Research (RZPD), now called ImaGenes (www.imagenes-bio.de). When
possible, clones from Human Unigene Set, a sequence-verified non-redundant cDNA col-
lection for the human genome, were obtained. The genes that were not contained in
Human Unigene Set were obtained from the human IMAGE libraries of cDNA clones,
that are often not sequence-verified.
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Figure 2.2: Homology Gene List (HomGL). HomGL is a web-based tool for comparing
gene lists with different accession numbers and identifiers and between different organ-
isms. The user interaction is realized through a web-interface for submitting, editing and
viewing lists of gene accession numbers. A user provides a list of genes with any of the
supported identifiers and retrieves a table with corresponding UniGene identifiers (24).
2.3.2 Experimental protocol
Details of the experimental protocol are given in the chapter Materials and Methods.
Here, I briefly name the experimental steps. The experimental model I used was 293 Tet-
off cell line (developed from human embryonic kidney cells) that is stably transfected with
N-terminal htt fragments with the 83 glutamines long polyQ stretch (176). Accumulation
of insoluble htt aggregates in those cells reduces the cell viability and results in the
redistribution of several stress proteins and components of the proteasome system to
the inclusion bodies (176). In this tetracycline (tet)-regulated system, when cells are
grown in the presence of doxycycline then there is no transcription of htt fragment. Htt
expression was induced by thoroughly washing the cells and adding fresh medium lacking
doxycycline. Upon induction of htt fragment, these cells form perinuclear htt aggregates.
I isolated RNA from the cells that had transcription of htt fragment induced for 0, 2 and
4 days. The quality of RNA was controlled by optical density measurements. Presence of
htt aggregates in the cultured cells was verified by Western blot analysis (Fig. 2.3). HD
microarrays containing the selected clones were spotted in the laboratory of Dr. Ulrike
Nuber in Max Planck Institute for Molecular Genetics, Berlin. Also, RNA labelling
and hybridisation, and the scanning of the hybridized HD microarrays was done in Dr.
Nuber’s lab. The analysis of microarray data was performed by Dr. Matthias Futschik
from Institute of Theoretical Biology, Humboldt University, Berlin.
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Figure 2.3: Immunoblot analysis of insoluble (pellet) protein fractions prepared from
induced and uninduced 293 Tet-Off cells. For induction of htt fragment expression, cells
were grown for 1, 2 and 4 days in the absence of doxycycline. Proteins were resolved
by SDS-PAGE, blotted onto nitrocellulose membranes, and probed with the anti-htt
antibody HD1. The htt aggregates stay at the origin of electrophoresis (left is the protein
size marker in kDa). The longer the expression of htt fragment is induced, the more
aggregates are present.
2.3.3 Expression changes within the gene groups
The main motivation for the studies with customized HD microarrays was to test whether
systematic transcriptional changes specific for the transcription factors implicated in HD
could be observed.
cDNA microarray measurements are carried out as differential hybridizations to min-
imize errors originating from cDNA spotting variability. cDNA from two different con-
ditions (here, repressed and induced transcription of htt fragment) is labelled with two
different fluorescent dyes and the two samples are co-hybridized to an array. After wash-
ing, the array is scanned at two different wavelengths to detect the relative abundance
for each condition derived from competitive hybridization. The reference sample in all
hybridisation was RNA isolated from the same cell line but grown in the presence of the
inhibitor of htt transcription. The reference sample was pooled (different RNA isolations
mixed together and labelled) so that all the microarrays were hybridised with the same
reference sample. Two conditions that were tested were 2 and 4 days of htt fragment
induction. For each condition three biological replicate samples were prepared and hy-
bridized. Dye-swap repeats were performed for each of the six co-hybridizations. Thus,
12 arrays were used in total.
Comparing two different samples hybridized to the same array involves making ad-
justments for systematic errors introduced by differences in procedures and dye intensity
effects. Here, first replicate spots were averaged and then dye-swaps were averaged. Dye
normalization was achieved by local regression. Subsequently, significance testing was
performed.
All groups of genes present on the HD microarray were analyzed in the same way
as represented in the Fig. 2.4. The MA plots in Fig. 2.4 are measurements of relative
expression of a gene (M) versus its average intensity (A). The MA plots show the usual
intensity-dependent variability in the relative expression (noise in the obtained signals
is much greater at the lower signal intensities). In all the gene groups the median and
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mean difference of the log2 intensities between the samples (2 and 4 days of htt fragment
induction) and the reference (0 days of htt fragment induction) did not significantly differ
from 0.
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Sp1 regulated genes
1
Day 2 Day 4
Day 2
X22 X23 X24
Min. -0.52235 Min. -0.510647 Min. -0.610029
1st Qu. -0.21055 1st Qu. -0.096477 1st Qu. -0.143870
Median -0.02547 Median 0.004091 Median -0.001000
Mean -0.03847 Mean -0.025010 Mean 0.008116
3rd Qu. 0.14268 3rd Qu. 0.110075 3rd Qu. 0.155039
Max. 0.47133 Max. 0.643359 Max. 0.785727
Day 4
X41 X42 X43
Min. -1.80791 Min. -3.1539 Min. -0.658429
1st Qu. -0.14543 1st Qu. -0.2197 1st Qu. -0.111723
Median -0.02567 Median -0.0775 Median 0.006748
Mean -0.08160 Mean -0.1440 Mean -0.005940
3rd Qu. 0.11461 3rd Qu. 0.1386 3rd Qu. 0.109344
Max. 1.22990 Max. 1.0576 Max. 0.695860
CREB regulated genes
1
Day 2 Day 4
Day 2
X22 X23 X24
Min. -0.898749 Min. -0.50924 Min. -0.222450
1st Qu. -0.101455 1st Qu. -0.22703 1st Qu. -0.087101
Median 0.035550 Median -0.10074 Median 0.002662
Mean 0.008616 Mean -0.08007 Mean 0.048756
3rd Qu. 0.196993 3rd Qu. 0.04713 3rd Qu. 0.064227
Max. 0.721812 Max. 0.57648 Max. 0.980373
Day 4
X41 X42 X43
Min. -3.09669 Min. -2.04596 Min. -0.6513867
1st Qu. -0.16885 1st Qu. -0.20662 1st Qu. -0.1485312
Median -0.02704 Median -0.10436 Median 0.0521289
Mean -0.21954 Mean -0.03979 Mean -0.0008305
3rd Qu. 0.13104 3rd Qu. 0.33361 3rd Qu. 0.1720380
Max. 0.28463 Max. 0.90975 Max. 0.5322727
Figure 2.4: Sp1 and CREB regulated genes, 2 and 4 days after the induction of htt
expression. MA plots show the mean difference of log2 intensity of the sample relative
to the control versus the mean log2 intensity of Sp1 regulated genes (upper panel) and
CREB regulated genes (lower panel) at day 2 (left panels) and day 4 (right panels). For
each panel, the statistical analysis of 3 biological replicas are shown. For all samples,
median and mean difference of log2 intensities relative to the control is not significantly
different from 0.
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2.3.4 Differentially expressed genes
In microarray data analysis, ratio calculations of significant changes in gene expression
derived from globally normalized data are performed by computing the ratio of the aver-
age of all the measurements from one condition to the reference. The z-score is calculated
by substracting the overall mean intensity from the intensity of a given gene, and divid-
ing the results by the standard deviation of all measured intensities. The z-scores only
loosely correspond to fold-changes as the change of variance is large along the intensity
axis (40). The t-test is based on normalizing the expression level change with the variance
of the mean expression levels (of the tested condition and the reference samples). If the
expression level change in comparison with the variance of the mean expression values,
one can assume there is a real difference in gene concentration.
Although no systematic changes in gene expression specific to a transcriptional factor
were observed, a number of genes showed differential expression in tested conditions (2
and 4 days of htt expression). These genes are listed in Figure 2.5 and Figure 2.6. In
differential gene expression comparisons of any given gene, there is a greater variance
in the fold-change calculation at lower signal intensities (107). To avoid false positive
results for a differential expression of genes in our samples, only genes with an average
log2 signal intensity larger than 7 (the low signal intensity cut-off is often set to 100), and
a z-score larger than 2 were considered to have significantly different expression. Within
these boundaries we observed relatively small number of differentially expressed genes.
Next, I discuss possible connections between the observed changes and HD.
Profilin, an actin-binding protein involved in dynamic turnover and restucturing of
the actin cytoskeleton, and kinesin, a protein belonging to the class of motor proteins that
move along microtubules and thus support mitosis, meiosis and axonal transport, were
shown to be down-regulated upon the induction of htt fragment. Indeed, the disruption
of axonal transport by pathogenic polyQ proteins is considered to contribute to the early
neuropathology in HD (65).
Platelet-derived growth factor A (PDGF-A), one of the proteins that regulate cell
growth and division, was shown to be down-regulated both at day 2 and at day 4 after
the htt induction. Wild-type htt is involved in transcription of brain-derived neurotrophic
factor (BDNF), and the mutation in htt leads to the loss of BDNF transcription which
is detrimental to striatal neurons (186). PDGF proteins also exert trophic effect on
developing striatal neurons and are a normal response to striatal injury. Thus, there
is hope that they might be used to counteract striatal degeneration in HD (150, 110).
Learning more about the PDGF transcriptional regulation in the presence of mutant htt
would help those attempts.
Huntingtin gene seems to be down-regulated at day 4, but the IMAGE clone spotted
on the array has no verified sequence. If correct, the sequence would correspond to the
C-terminal end of htt, and so the htt fragment induced in the experiment would not be
detected by this clone.
Comparisons between the list of differentially expressed genes from this study and
the list of differentially expressed genes from seven other microarray studies (38, 98, 100,
182, 148, 89, 7), as well as the comparisons between the seven microarray studies showed
very little overlap (Dr. Nils Bluethgen, personal communication).
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1Table 1: Differentially expressed genes 2 after the induction of htt fragment
Gene.Title Clone.ID A z.Mav z.z z.p t.t t.p M.22 M.23 M.24
ribosomal protein L31 IMAGp956B0241 11.470 0.747 8.655 +0.00E+00 1.316 0.319 0.408 -0.022 1.856
plasminogen activator in-
hibitor, type I
IMAGp956C1759 10.244 0.814 6.977 +1.51E-12 1.021 0.415 2.409 -0.032 0.066
ribosomal protein L27a IMAGp956P23126 9.749 0.547 3.427 +3.05E-04 1.726 0.227 0.369 0.109 1.164
NADH dehydrogenase
(ubiquinone
IMAGp956E1778 9.253 0.598 2.765 +2.84E-03 1.209 0.350 0.147 0.060 1.585
protective protein for
beta-galactosidase
(galactosialidosis
IMAGp956O0959 8.900 0.723 2.697 +3.49E-03 3.099 0.090 1.106 0.301 0.763
G protein pathway sup-
pressor 1
IMAGp956E0225 9.879 0.378 2.573 +5.04E-03 2.283 0.150 0.677 0.355 0.104
Mediator of receptor-
induced toxicity
HU3 p972D07273 10.048 0.312 2.365 +9.01E-03 5.902 0.028 0.229 0.298 0.410
Human interferon-
gamma (HuIFN-gamma)
mRNA, complete cds
HU3 p972B08319 9.820 -0.343 -2.243 +1.24E-02 -2.768 0.109 -0.426 -0.503 -0.099
Kinesin family member
13A
HU3 p972E09309 10.075 -0.339 -2.614 +4.47E-03 -2.553 0.125 -0.525 -0.411 -0.082
Profilin 1 IMAGp956M05195 8.795 -0.826 -2.891 +1.92E-03 -1.101 0.386 -2.325 -0.109 -0.043
Brain-specific angiogene-
sis inhibitor 1
HU3 p972F08324 9.347 -0.611 -2.992 +1.39E-03 -6.029 0.026 -0.780 -0.621 -0.430
ESTs, Moderately similar
to T47135
IMAGp998A225997 9.374 -0.617 -3.071 +1.07E-03 -1.021 0.415 -1.824 0.009 -0.035
Platelet-derived growth
factor PDGF-A
HU3 p972B09311 9.700 -0.510 -3.102 +9.60E-04 -2.596 0.122 -0.680 -0.733 -0.118
Sema domain, im-
munoglobulin domain
(Ig
IMAGp956G1970 9.929 -0.508 -3.569 +1.79E-04 -2.231 0.155 -0.406 -0.944 -0.175
Tissue inhibitor of metal-
loproteinase 2
IMAGp956E01196 10.772 -0.353 -3.686 +1.14E-04 -0.776 0.519 0.315 -0.151 -1.221
Endothelial differentia-
tion, G-protein-coupled
receptor 6
IMAGp956C0853 10.500 -0.399 -3.925 +4.33E-05 -2.278 0.150 -0.105 -0.382 -0.710
ATP synthase, H+ trans-
porting, mitochondrial F0
complex, subunit F6
IMAGp956K1353 9.724 -0.814 -5.019 +2.60E-07 -1.026 0.413 -0.164 0.115 -2.393
Figure 2.5: Differentially expressed genes 2 days after htt fragment induction. The column
labels have the following meaning: Clone.ID is Imagenes identifier, A is average (mean)
log2 intensity, z.Mav is average (mean) difference of log2 intensity of samples relative
to the control samples, z.z is intensity related z-score, z.p is p-value based on intensity
related z-score, t.t is t-score of comparison, t.p is p-value based on t-score, M22, M23 and
M24 are difference of log2 intensity of individual samples relative to the control sample.
Positive values of z.Mav correspond to up-regulated genes, and negative values of z.Mav
correspond to down-regulated genes.
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1Table 1: Differentially expressed genes 4 days after the induction of htt fragment
Gene.Title Clone.ID A z.Mav z.z z.p t.t t.p M.41 M.42 M.43
Platelet-derived growth factor
PDGF-A
HU3 p972B09311 10.239 -1.276 -7.890 +0.00E+00 -14.919 0.004 -1.107 -1.384 -1.336
Brain acid-soluble protein 1 IMAGp956H0970 8.341 -1.153 -3.027 +1.24E-03 -1.502 0.272 -0.525 -2.681 -0.253
Brain-specific angiogenesis in-
hibitor mRNA, complete cds 1
HU3 p972F08324 9.456 -1.112 -4.743 +1.05E-06 -6.257 0.025 -1.467 -0.923 -0.946
Dodecenoyl-Coenzyme A delta
isomerase (3,2 trans-enoyl-
Coenzyme A isomerase)
HU3 p972D07300 8.080 -1.047 -2.477 +6.63E-03 -11.776 0.007 -1.203 -1.041 -0.896
Huntingtin IMAGp998D0552Q2 8.853 -1.011 -3.265 +5.48E-04 -1.624 0.246 -0.513 -2.247 -0.271
Tyrosine phosphatase (PAC-1) HU3 p972A09305 9.390 -1.008 -4.175 +1.49E-05 -6.151 0.025 -0.893 -1.331 -0.800
EEN-B2-L3 mRNA, complete cds HU3 p972G10131 8.593 -0.994 -2.870 +2.05E-03 -1.120 0.379 0.110 -0.341 -2.749
Olfactory receptor, family 2, sub-
family L, member 2 (OR2L2)
IMAGp998A0913279Q3 9.155 -0.840 -3.135 +8.60E-04 -8.896 0.012 -0.884 -0.976 -0.658
Mdm2, transformed 3T3 cell dou-
ble minute 2, p53 binding protein
IMAGp998F04223Q3 9.653 -0.806 -3.761 +8.48E-05 -1.111 0.382 -0.131 -2.257 -0.031
3-phosphoglycerate dehydroge-
nase
IMAGp956K2318 8.697 -0.789 -2.376 +8.74E-03 -1.245 0.339 -0.136 -0.175 -2.055
Antigen NY-CO-28 (NY-CO-28)
mRNA, partial cds
HU3 p972D08292 8.848 -0.785 -2.532 +5.67E-03 -1.225 0.345 -0.190 -2.066 -0.100
Kinesin family member 13A HU3 p972E09309 10.608 -0.748 -5.376 +3.80E-08 -8.943 0.012 -0.740 -0.608 -0.897
MHC class I polypeptide-related
sequence A (MICA) gene
HU3 p972D03299 10.109 -0.728 -4.230 +1.17E-05 -24.765 0.002 -0.769 -0.671 -0.744
Axin (AXIN) mRNA, partial cds HU3 p972C04322 9.749 -0.712 -3.467 +2.63E-04 -8.044 0.015 -0.543 -0.842 -0.751
Human interferon-gamma
(HuIFN-gamma) mRNA, com-
plete cds
HU3 p972B08319 9.549 -0.705 -3.136 +8.56E-04 -7.869 0.016 -0.884 -0.607 -0.624
Endothelial differentiation,
G-protein-coupled receptor 6
IMAGp956C0853 11.368 -0.649 -5.904 +1.77E-09 -10.926 0.008 -0.764 -0.615 -0.567
Glial fibrillary acidic protein [hu-
man, glioma cell line U-251 MG,
mRNA]
HU3 p972H0337 11.752 -0.558 -5.154 +1.28E-07 -62.466 0.000 -0.553 -0.576 -0.546
Heat shock 70kDa protein 1B IMAGp998F1070Q3 13.890 -0.484 -4.026 +2.84E-05 -17.462 0.003 -0.458 -0.540 -0.455
Human glucose-6-phosphatase
mRNA, complete cds
HU3 p972C0213 10.073 -0.454 -2.589 +4.81E-03 -1.370 0.304 0.033 -1.088 -0.308
Porc-Pl gene similar to yeast
CDC45
HU3 p972C05319 10.795 -0.374 -2.867 +2.07E-03 -10.383 0.009 -0.438 -0.313 -0.370
Lactate dehydrogenase B gene
exon 1 and 2 (EC 1.1.1.27) (and
joined CDS)
HU3 p972E1251 12.923 -0.366 -3.022 +1.25E-03 -13.973 0.005 -0.329 -0.416 -0.351
Glyceraldehyde-3-phosphate de-
hydrogenase
IMAGp956H0677 11.076 -0.317 -2.685 +3.62E-03 -3.345 0.079 -0.355 -0.137 -0.458
Human prosomal protein P30-
33K (pros-30) mRNA, complete
cds
HU3 p972C0217 11.483 -0.307 -2.831 +2.32E-03 -1.432 0.288 -0.045 -0.732 -0.145
Human c-myc-P64 mRNA,
initiating from promoter P0,
(HLmyc3.1) partial cds
HU3 p972B12122 11.618 0.300 2.776 +2.75E-03 8.914 0.012 0.353 0.309 0.237
DnaJ (Hsp40) homolog, subfam-
ily B, member 11
HU3 p972H0998 11.02 0.324 2.626 +4.32E-03 10.085 0.010 0.388 0.294 0.290
Human tra1 mRNA for human ho-
mologue of murine tumor rejec-
tion antigen gp96
HU3 p972E1293 12.966 0.683 5.657 +7.70E-09 7.041 0.020 0.845 0.510 0.695
Epithelial membrane protein 2
(EMP2)
IMAGp956C2058 8.280 1.047 2.684 +3.63E-03 1.539 0.264 2.173 -0.178 1.147
SHC (Src homology 2 domain-
containing) transforming protein
IMAGp956C1252 8.154 1.414 3.446 +2.84E-04 1.775 0.218 2.765 1.471 0.007
Figure 2.6: Differentially expressed genes 4 days after htt fragment induction. The column
labels have the following meaning: Clone.ID is Imagenes identifier, A is average (mean)
log2 intensity, z.Mav is average (mean) difference of log2 intensity of samples relative
to the control samples, z.z is intensity related z-score, z.p is p-value based on intensity
related z-score, t.t is t-score of comparison, t.p is p-value based on t-score, M41, M42
and M43 are difference of log2 intensity of individual samples relative to the control
sample.Positive values of z.Mav correspond to upregulated genes, and negative values of
z.Mav correspond to downregulated genes.
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2.4 Discussion
Many transcriptional alterations have been reported early in HD progression (161). Un-
derstanding these early molecular mechanisms could provide an opportunity to interfere
with the effects of mutant htt before the development of disease symptoms. However,
the relevance of the transcriptional pathways implicated in HD to disease pathogenesis
remains uncertain. Different methods such as yeast two-hybrid, co-localization and im-
munoprecipitation show the interactions between the mutant htt and a number of nuclear
proteins, but the functional consequences of many of them have not been determined in
vivo. For a disease that takes decades to develop, it is clear that the pathogenic and
coping mechanisms advance in parallel. The levels of hundreds of RNA transcripts are
altered in different HD models, but it is uncertain which are the most pathogenic. More-
over, even though DNA microarray studies demonstrate a measure of selectivity in which
genes are affected, the overlap of common altered transcripts is small.
Transcriptionally active therapies would attempt to normalize the abberant tran-
scription profiles found in HD models. So far, no single transcriptional regulator has
emerged as a primary actor in HD. The basis of transcriptional dysregulation appears to
be in aberrant protein-protein interactions between mutant htt and a variety of transcrip-
tion factors. However, these protein-protein interactions do not constitute conventional
and easy targets for drug molecules (81). So far, administration of histone deacetylase
(HDAC) inhibitors, that increase the overall levels of gene expression in the cells, has
been the only successful therapeutic strategy targeting transcription dysregulation in HD
(72).
It has been suggested that the depletion of transcription factors by sequestration into
htt aggregates underlies the transcriptional changes in HD models and that restoring
normal transcriptional activity of these factors would reverse early pathological processes
in HD (36). A surprising number of diverse clinical phenotypes are due to mutations in
genes encoding transcription factors. The mechanism by which such transcription factor
defects cause disease is often haploinsufficiency, or a reduction by half in the protein
levels of the encoded transcription factor (reviewed in ref. (145)). For HD models, there
are no quantitative data about the fraction of transcription factors trapped in the htt
aggregates.
The study presented here aimed at getting the first information about the global,
transcription factor specific changes in the gene expression induced by mutant htt. I
used customized cDNA chips containing groups of genes regulated by 20 trancription
factors and 4 additional groups of genes belonging to the pathways that are affected in
HD to test whether systematic changes in expression of these groups of genes can be
observed. However, in none of the gene groups systematic trancriptional changes were
observed.
The change in gene expression induced by a small changes in the concentration of
regulatory proteins controlling a specific the gene, termed sensitivity. However, knowledge
about the sensitivity of human promoters is scarce (22, 23). To elicit their effects on
gene expression, transcriptional activators require the cooperation of a diverse family of
coregulator proteins (114). The complexity and diversity of the gene regulation is likely to
cause different sensitivity of individual promoters to the concentration of the transcription
factors involved in their regulation. This means that even if the changes in the levels of
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certain transcription factors are induced by the mutant htt, these changes might be too
small to affect a large subset of genes under the control of those transcription factors.
Mutant htt triggers multiple pathways of neurodegeneration, including dysregulation
of transcription but it is uncertain which, if any, might have a primary position in a
cascade. Transcriptional changes do occur in HD, but the cause and the consequences of
these changes remain to be elucidated. The non-intuitive format and the vast amounts
of the transcriptomics data makes it difficult to generate hypothesis based on this kind
of experimental observation. On the other hand, mathematical modelling of biological
processes requires a clear question and aim of what the model should accomplish, and is
conceptually similar to generating a hypothesis (87). I had hoped that the time-resolved
detection of changes in gene expression profiles in relation to htt aggregate formation
would provide the supporting data for building a mathematical model. However, the
transcriptional changes detected in this study do not support the tested hypothesis and
could thus not be used for mathematical modelling. Moreover, the huge differences in the
trancriptional output of different experimental HD models pose a serious question about
the validity of extrapolating the results from HD models to the pathological changes in
HD patients. Therefore, the question of transcriptional dysregulation in HD was not
further pursued. Instead, in the next chapter I formulate a simple mathematical model
of htt aggregation that forms the foundation on which I build more complex models as
a framework for evaluating the existing experimental data and conclusions about htt
aggregation.
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Chapter 3
Deterministic Models of Huntingtin
Aggregation
3.1 Summary of the chapter
Huntington’s disease (HD) is a late onset, progressive disorder. In the course of HD,
the patients slowly lose their physical and mental abilities. It is possible to measure
the functional decline of the affected brain regions in HD patients but what dictates the
dynamics of that decline is not known. Mutation in the polyglutamine (polyQ) stretch
hinders proper folding of huntingtin (htt). Misfolded htt undergoes a proteolytic cleavage
releasing a short-htt fragment with a propensity to form aggregates. Misfolding, aggrega-
tion and accumulation of specific proteins underly the pathology of HD and a number of
other neurodegenerative diseases. Understanding the dynamics of the aggregation process
in HD and related disorders, might help us formulate successful therapeutic strategies.
In this chapter, I present and analyze a simple mathematical model of htt aggregation. It
is a deterministic model that consists of a set of ordinary differential equations describ-
ing htt aggregation as a nucleation process. This model allows us to monitor how the
variables of the model: full-length htt, and monomers, oligomers and aggregates of htt
fragment change in time, what steady state such a system acquires, and how the change
in parameters affects the system. In the model, I use htt fragment release rate, A, as
a sensor of environmental changes and a bifurcation parameter. First, I analyze a core
model of htt aggregation in which A has a constant value. I determined the steady states
of the system and their stability depending on the value of A. As the value of A changes,
the system goes through two bifurcation points, corresponding to the two nucleation
events: the onset of oligomerization and the onset of aggregation. Second, I extend the
core model of htt aggregation and include the dependence of A on the concentrations of
enzymes involved in htt cleavage in striatal cells. Caspase-mediated htt cleavage process
involves regulation via positive feedback loop. I conclude that a nucleation process and a
positive feedback loop acting on the htt fragment release rate describe well the late onset
of aggregation through an intrinsic mechanism.
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3.2 Introduction
The most striking feature of mutant htt is its tendency to form insoluble protein ag-
gregates with a fibrilar morphology (47, 140). The formation of protein aggregates is a
hallmark of a number of neurodegenerative diseases: Alzheimer’s disease with β-amyloid
in plaques, Parkinson’s disease with α-synuclein in Lewy bodies, and frontotemporal de-
mentia with mutant tau. These diseases share multiple pathogenic mechanisms: loss of
physiological activity of the misfolded protein, neurotoxicity of the aggregation species,
and chronic brain inflammation triggered by the accumulation of protein deposits (132).
Small molecules are being developed that inhibit aggregation of β-amyloid (28), α-
synuclein (92), and htt (51). A great hope is that the development of a therapy for one
of the diseases may have implications for the others. Understanding the mechanisms of
aggregation of the disease proteins might be a step toward fulfilling that hope.
3.2.1 Mechanism of htt aggregation
The late onset of HD was first explained by the cumulative damage hypothesis, according
to which affected neurons die when a critical amount of damage is reached. As a conse-
quence, the probability of the neurons to die would increase with age. Surprisingly, in a
number of neurodegenerative disease, including HD, it was shown that the probability of
the neurons to die was constant in time (43). This result, which implies that cell death is
caused by a random, rare event, together with the finding that the time before the onset
of aggregation is inversely proportional to the length of the polyQ repeat (141), led to
now established hypothesis that the aggregation of htt is a nucleation-dependent process
(119).
Nucleation is a sudden phase-transition phenomenon where the first steps are ener-
getically less favoured than continuation of growth. Nuclei of molecular aggregates are
unstable when very small because of their large ratio of surface area to volume. Perutz
et al. (119) proposed that initial nucleation of intracellular aggregates is the event that
leads to cell death. The growth rate of the aggregate, once nucleated, is typically of the
order of tens of micrometers per second (119). For any process that occurs on a timescale
of years, the controlling step will thus be nucleation, not growth.
3.2.2 Toxic fragment hypothesis
Htt was the first neuronal protein shown to be a caspase substrate (62), with defined
sites for caspase-3, caspase-2, and caspase-6 (177). Calpains, from the family of cystein
proteases, further cleave htt fragments (55). Toxicity of caspase-resistant mutant htt is
markedly reduced in transfected cells (178). Proteolytic cleavage of the mutant htt that
generates aggregation-prone N-terminal fragments denotes a key event in HD pathogen-
esis (103). Caspase-mediated cleavage of full-length mutant htt precedes the neuronal
dysfunction and selective neurodegeneration in HD (179), and the toxicity of caspase-
resistant mutant htt is markedly reduced in transfected cells (178). Unlike the full length
mutant htt, a short N-terminal htt fragment released by cleavage faces no steric hin-
drance to form the new aggregation-prone secondary structure. Perutz was the first to
propose that the sharp threshold in the pathogenic polyQ length stems from the struc-
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tural transition of the mutant htt fragment to a β-sheet structure prone to aggregation
(120, 121).
In HD patients, the cleavage of a full-length htt and a release of a htt fragment
is a complex process. Proteases acting on mutant htt generate cleaved products that
differentially build up cytoplasmic and nuclear inclusions. Smaller fragments appear
solely responsible for amassing nuclear aggregates, while cytoplasmic inclusions contain
fragments of various lengths (97).
3.2.3 Selective vulnerability: role of caspase-2
Mutant htt is expressed in all cell types tested so far (147). However, only specific areas
of the brain are affected by this mutation. In HD, selective neural death leads to the
choreic movements and dementia. The most vulnerable cells are medium spiny neurons
in the striatum, which are the first to die. What renders these cells more susceptible
to toxic effects of the mutation has not yet been fully understood. However, it has
been recently shown that wild-type htt upregulates the transcription of brain-derived
neurotrophic factor (BDNF), a pro-survival factor produced by cortical neurons. This
beneficial activity of htt is lost when the protein becomes mutated (186). Decreased
levels of BDNF in the striatum and cortex of HD transgenic mice upregulate caspase-2
(71), a default executioner as well as initiator caspase in neuronal cells deprived of nerve
growth factor (170). Activated caspase-2 causes the mitochondrial pores to open and
cytochrome c to be released (127, 117). These findings suggest that caspase-2 is involved
in the selective neuronal cell death in the striatum and cortex of HD patients.
3.2.4 Mathematical analysis of dynamical systems
When life scientists talk about models they usually refer to experimental systems that
show a characteristic behaviour and therefore are useful to study the underlying mech-
anisms. Similarly, systems biology models are analytical tools whose purpose is to give
insight into mechanisms and reveal what determines a particular behaviour with the aim
to eventually predict that behaviour (87).
Various biological systems have been modelled, with the aim of better articulating
how the underlying dynamics contribute to observed cellular behaviour. Modelling can
be carried out at various levels of details. The choice depends on the nature of questions
to be addressed.
The process of htt aggregation can be described as a dynamical system, but the exact
kinetics are unknown. We are thus interested in the qualitative behaviour of the system
as the parameters change rather than quantitative changes. The first step in studying
the qualitative behaviour of the system is to find its steady states, i.e. the states at which
the variables have a rate of change equals to zero. Once the steady states are identified,
it is necessary to determine their stability. A steady state is locally stable if solutions
with any initial conditions sufficiently close to the steady state converge toward that
steady state. The steady state is unstable if there exists a solution with arbitrarily close
initial conditions that does not converge to the steady state. A formal way to analyze
the stability of a nonlinear system is to linearize it around the fixed point, and study
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the behavior of the linear system. In the vicinity of the steady state, both nonlinear and
linear systems will behave in the same way.
Parameters are quantities in the system that do not change dynamically in time, un-
like dynamical variables, but may be changed by a drug or other external factors. A
qualitative change in the dynamics of a system in dependence upon the value of a pa-
rameter is called a bifurcation. The parameter is thus called bifurcation parameter, and
the threshold value where the bifurcation occurs is called bifurcation point. A nucleation
process is well described by a transcritical bifurcation. A transcritical bifurcation is char-
acterised by an exchange in stability between two steady-states. Below the bifurcation
point, one steady-state (e.g. htt monomers) is stable, and the other one (e.g. htt ag-
gregates) unstable. At the bifurcation point, the two steady states merge, and exchange
stability: the unstable steady-state becomes stable and the stable steady state becomes
unstable (80). Transcritical bifurcations are relevant for switch-like phenomena (162, 1).
In the model for aggregation presented here, there are two transcritical bifurcations that
correspond to the nucleation of oligomers and aggregates.
3.3 Mathematical Models
To express aggregation kinetics in terms of ordinary differential equation (ODE), we
assume that molecular concentrations are continuous (it ignores the discrete nature of
molecules), that reactions occur in a homogeneous, well-stirred volume and that these
reactions occur in a deterministic manner. This is a common form of biological model
and can represent both the transient dynamics and the long-term steady-state behavior
of a system if the above approximations hold (4).
I use two levels of description of the htt aggregation: a core model, and an extended
model. The core model consist of a set of four ODEs describing the change in the
concentration of: the full-length mutant htt, and the monomers, the oligomers and the
aggregates of the cleaved htt fragment. This simple system can be analytically solved.
The bifurcation parameter was the htt fragment release rate, A, and thus the steady
state analysis defines the values of A for which the oligomers and the aggregates are
stable (Figure 3.1).
In the extended model, the release rate A is caspase-activity dependent, and the
caspase activity is modeled explicitly. Thus the model consists of a set of 6 ODEs, with
the full-length htt, the monomers, the oligomers and the aggregates of the cleaved htt
fragment, a procaspase-2, and a caspase-2 as variables. The evolution of this system over
time shows that the delay in the onset of aggregation can be explained by an intrinsic
mechanism.
3.3.1 Core model for htt aggregation
The core model for htt aggregation consists of 4 variables: the concentrations of full
length mutant htt Htt, N-terminal htt fragment Mhtt, htt fragment oligomer Ohtt, and
htt fragment aggregate Ahtt (Figure 3.1). Misfolded htt is a substrate for a proteolytic
cleavage reaction in which short, N-terminal fragments that are prone to aggregation
are released. Htt misfolding and aggregation follows a reversible nucleation mechanism
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Table 3.1: List of parameters for the core model
Parameter Value Description
kh 1.0 Htt synthesis rate
kdh 0.5 Htt proteasomal degradation rate
kde 0.2 Htt fragment proteasomal degradation rate
kn 0.4 Rate of formation of oligomers
k−1n 0.01 Rate of release of monomers from oligomers
kdn 0.1 Proteasomal degradation of oligomers
ka 0.4 Rate of aggregation of oligomers
k−1a 0.01 Rate of release of oligomer from aggregates
kda 0.02 Removal rate of aggregates by autophagy
modulated by environmental factors. A number of transgenic HD cell and mouse models
express only N-terminal htt fragment at a constant rate. In the core model, this is equiva-
lent to considering that the release of a htt fragment, A, has a constant value. Monomeric
fragments start to aggregate through a number of intermediate oligomeric structures Ohtt.
Both monomeric and oligomeric structures are substrates for proteasomal degradation.
As the oligomeric structures get bigger they become more resistant to proteasomal degra-
dation, thus the corresponding rates decrease (Table 3.1). The proteasomal machinery
cannot digest big aggregates, so the cell removes them by autophagy.
Htt cleavage
rate A
Proteasomal
degradation Autophagy
PolyQ
Mhtt Ohtt Ahtt
Synthesis
Htt
Figure 3.1: Core model for htt aggregation. Mutant full-length htt, Htt, is cleaved and
a short N-terminal htt fragment, Mhtt, is released with a constant rate A. Htt fragments
aggregate and form htt oligomers, Ohtt, which further aggregate and form htt aggregates,
Ahtt. Full-length htt, monomers and oligomers of htt fragments are degraded by the
proteasome, and aggregates are removed by autophagy.
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Table 3.2: Steady states of the core model.
STST1 STST2 STST3
Htt
kh
A+ kdh
kh
A+ kdh
kh
A+ kdh
M ihtt
AHtt
kde
kdn + k−1n
kn
AHtt+ k−1n O3htt
knO3htt + kde
Oihtt 0
AHtt− kdeM2htt
kdn
k−1a + kda
ka
Aihtt 0 0
O3htt
kda
[knM3htt − (kdn + k−1n )]
Now the differential equations for the 4 variables considered can be written down.
dHtt
dt = kh − AHtt− kdhHtt, (3.1)
dMhtt
dt = AHtt− knMhttOhtt + k
−1
n Ohtt − kdeMhtt , (3.2)
dOhtt
dt = knMhttOhtt − kaOhttAhtt + k
−1
a Ahtt − [k−1n + kdn]Ohtt, (3.3)
dAhtt
dt = kaOhttAhtt − [k
−1
a + kda]Ahtt . (3.4)
3.3.2 Steady states of the core model
First, the steady states of the system are determined, i.e. the states at which the variables
have a rate of change equal to zero, by setting the right hand sides of the equations to
zero.
From Equation 3.4, two steady states are visible, A∗htt = 0 (I) or A∗htt 6= 0 (II). Two
paths can be followed.
Case (I) A∗htt = 0. The steady state oligomer concentration satisfies
knMhttOhtt − [k−1n + kdn]Ohtt = 0.
Two steady states are possible for Ohtt.
Subcase (Ia) O∗htt = 0. In this case, M∗htt = A·Htt
∗
kde
.
Subcase (Ib) O∗htt 6= 0. The second steady state for Ohtt gives M∗htt = k
−1
n +kdn
kn
. It this
case O∗htt = A·Htt−kdeMhttkdn .
Case (II) A∗htt 6= 0. Here, Equation 3.4 gives O∗htt = k
−1
a +kda
ka
. Equation 3.3 can be
solved for Ahtt
A∗htt =
Ohtt
kda
(
knMhtt −
(
k−1n + kdn
))
.
The steady state of Htt is independent of the the other variables, Htt∗ = kh
A+kdh for
all cases. The three steady states (Ia), (Ib) and (II), are denoted as STST1, STST2 and
STST3, and listed in Table 3.2. The superscripts i in M ihtt, Oihtt and Aihtt refer to the ith
steady state (STSTi, i = 1...3).
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Table 3.3: Stability analysis of the core model.
STST1 STST2 STST3
A < A1 λ < 0 R(λ2,2+3) > 0 λ > 0
A1 < A < A2 λ1,3 > 0 R(λ) < 0 λ > 0
A > A2 λ1,3 > 0 λ2,4 > 0 R(λ) < 0
For any set parameter values, one steady state is stable, and two are unstable. Sta-
bility changes from STST1 to STST2 through a transcritical bifurcation when A = A1,
where
A1 =
kdha
knkh − a, (3.5)
with a = kde(kdn + k−1n ).
Similarly, stability changes from STST2 to STST3 when A = A2, where,
A2 =
kdh(a+ b)
knkh − (a+ b) , (3.6)
a = kde(kdn + k−1n ),
b = kdnkn
k−1a + kda
ka
.
The detailed stability and bifurcation analysis is in Appendix A.
When the rate A of htt release is low, htt monomers are present in a concentration
too small for oligomeric structures to be stable, and STST1 is stable. As A increases, the
system goes to STST2, where oligomers become stable but aggregates are still unstable.
A further increase in A brings the system to STST3 where all three entities, monomers,
oligomers, and aggregates, are present. Two threshold levels of caspase activity A1 and A2
(Equations 3.5–3.6) define transcritical bifurcation points, where an exchange in stability
from one steady state to another occurs. The transition from one steady state to the other
must be continuous, and only changes from STST1 to STST2 and STST2 to STST3 are
possible. This requirement excludes bistable behaviour of the system.
3.3.3 Extended model for htt aggregation
The extended model is introduced to model the caspase-induced change in the release
rate of htt fragment A. This change could bring the core model through the successive
transcritical bifurcations by an intrinsic mechanism. In the core model, A was a bifurca-
tion parameter that was changed without explicitly formulation where this change comes
from.
Downstream of the first exon of htt there are several consensus sequences recognized
by caspase-3, caspase-2, and caspase-6 (177). In different cell and animal models benefits
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of inhibiting each of these proteases have been shown (178, 56). In the extended model
of htt aggregation, caspase-2 is assigned as a representative cleavage enzyme, because
of its involvement in the selective neuronal death in the striatum (71). However, the
formulation of the model is not specific to caspase-2.
Several groups have shown that procaspases are not just inactive isoforms of caspases,
but that they also have a catalytic activity, though at a much lower level than the caspases
(159). Mutant full-length htt may provide a suitable substrate for a basal activity of
procaspase-2, since it binds to procaspase-2 (71). Although procaspase-2 does not require
cleavage for the initial acquisition of activity, dimerization and intersubunit cleavage is
required to generate levels of activity that could induce cell death (15).
Caspase-dependent release of toxic htt fragment initiates a number of processes dam-
aging to the cell. This leads to the activation of caspases in HD cells. Activated caspases
have an even higher rate of mutant htt cleavage. It is very likely that such a positive
feedback loop exists in HD cells, but its importance is not known. In the extended model
I analyzed the effect of a representative positive feedback loop on the time of the onset
of aggregation.
Biochemical reactions
Caspase-dependent release of toxic htt fragment and caspase activation are described by
the following reactions. The variables are: Htt full length htt, P pro-caspase, C caspase,
Mhtt htt fragment (Figure 3.2).
Htt+ P
θ1
 HttP [Htt][P ] = θ1[HttP ], (3.7)
HttP + P
θ2
 PHttP [HttP ][P ] = θ2[PHttP ], (3.8)
PHttP
k1→Mhtt + C + C, (3.9)
Htt+ C
θ3
 HttC [Htt][C] = θ3[HttC], (3.10)
HttC
k3→MhttMhtt + C, (3.11)
The reactions 3.7, 3.8, 3.10 occur on a very fast time scale compared to the changes in
the concentration of the variables in our model (Htt, Mhtt, P and C). We can therefore
assume that intermediate complexes are approximately at their equilibrium. The rates
of production of active caspase C and htt fragment Mhtt can thus be written as functions
of concentration in Equations 3.7, 3.8, and 3.10. Namely,
d[C]
dt = 2k1[PHttP ] and
d[Mhtt]
dt = k1[PHttP ] + k3[HttC],
We can substitute intermediate complexes using the equilibrium equations for the reac-
tions 3.7, 3.8, 3.10.
d[C]
dt = 2k1
[Htt][P ]2
θ1θ2
and d[Mhtt]dt = k1
[Htt][P ]2
θ1θ2
+ k3
[Htt][C]
θ3
,
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In the above equations [Htt] represents the concentration of the free htt, i.e. htt that
is not part of any intermediate complex. The conservation law states that the total htt
concentration is
HttT = [Htt] + [HttP ] + [PHttP ] + [HttC],
HttT = [Htt] +
[Htt][P ]
θ1
+ [Htt][P ]
2
θ1θ2
+ [Htt][C]
θ3
,
and solving for [Htt] yields
[Htt] = HttT1 + [P ]/θ1 + [C]/θ3 + [P ]2/θ1θ2
.
We assume that procaspase-2 is synthesised and degraded at constant rates. In the
model, active caspase-2 is released by two processes: a complex reaction between htt and
procaspase-2 at the rate rpe, and the activation of procaspase-2 due to i.e. trophic factor
deprivation in the striatum at the rate rpr. The equations are as follows
rpe = kpe
HttP 2
1 +K1P +K2C +K23P 2
, (3.12)
rpr = kprP 2, (3.13)
Htt is cleaved by caspase-2 at a rate
rce = kce
HttC
1 +K1P +K2C +K23P 2
. (3.14)
In the core model presented earlier, A is constant, which allows an analytical treatment
of that system. In the extended model this can be done by setting P and C to constant
values. Assuming constant caspase activity, the nonlinear rates rce and rpe as rce + rpe =
Htt · A are re-expressed as, with A as the caspase-mediated Htt cleavage rate,
A = kceC + kpeP
2
1 +K1P +K2C +K23P 2
. (3.15)
System of equations
The extended model for htt aggregation is composed of 6 variables: full length mutant htt
Htt, N-terminal htt fragmentMhtt , htt oligomers Ohtt, htt aggregates Ahtt , procaspase-2 P ,
and caspase-2 C (Figure 3.2). Procaspase- and caspase-2 cleave mutant htt and release htt
fragment. Htt fragments form oligomers through a nucleation process (rate proportional
to the concentration of oligomers), and are degraded at a constant rate. Oligomers are
formed by binding of htt fragments, they form aggregates at a rate proportional to the
aggregate concentration, and are degraded at a constant rate. Aggregates are formed
by binding of oligomers, and are degraded by autophagy at a constant rate. For the
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Figure 3.2: Model for caspase-2 mediated htt aggregation. A mutation in htt results a
loss of function which leads to the activation of caspase-2. Mutant htt is cleaved by both
procaspase-2 and caspase-2, and htt fragment is released. Interactions of procaspase-2
and htt release htt fragment and initiate autocatalysis of procaspase-2 into caspase-2.
Htt fragments aggregate through a succession of oligomeric structures. Full-lenght htt,
monomers and oligomers of htt fragments are degraded by the proteasome, and aggregates
are removed by autophagy.
Table 3.4: List of additional parameters for the extended model
Parameter Value Description
kp 0.005 Procaspase-2 synthesis rate
kdp 0.005 Procaspase-2 degradation rate
kdc 0.02 Caspase-2 degradation rate
kce 2.0 Maximal caspase-2 mediated cleavage rate
kpe 0.01 Maximal procaspase-2 mediated cleavage rate
kpr 0.01 Proteolytic cleavage rate of procaspase-2
Ki 1.0 Saturation constants of cleavage rates (i = 1, ..., 3)
parameters that are present in the core model same values were used as listed in the
Table 3.1. The additional parameters of extended model are listed in the Table 3.4
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Now the differential equations for the 6 variables considered can be written down.
dHtt
dt = kh − rce − rpe − kdhHtt, (3.16)
dMhtt
dt = rce + rpe − knMhttOhtt + k
−1
n Ohtt − kdeMhtt , (3.17)
dOhtt
dt = knMhttOhtt − kaOhttAhtt + k
−1
a Ahtt − [k−1n + kdn]Ohtt, (3.18)
dAhtt
dt = kaOhttAhtt − [k
−1
a + kda]Ahtt , (3.19)
dP
dt = kp − 2(rpe + rpr)− kdpP, (3.20)
dC
dt = 2(rpe + rpr)− kdcC, (3.21)
where the nonlinear rates r are given by Equations 3.12, 3.13 and 3.14. Since quantitative
estimations of concentrations and time scales vary greatly depending on the experimental
setting, arbitrary time and concentration units were assigned to the parameters. The
parameter values were chosen according to qualitative estimates of aggregation kinetics.
The results shown here are representative of a wide range of parameter values as long as
htt synthesis rate kh is sufficiently large. Nonlinearities in the Equations 3.20 and 3.21,
make the steady state analysis of the extended model cumbersome to do. However, as
long as P and C change slowly, the steady states for Equations 3.17–3.19 will be the same
as in the core model.
3.4 Results
3.4.1 Behaviour of the core model for htt aggregation
The simple model allows studying the equilibrium concentration of different htt conform-
ers as the kinetic parameters vary. Parameter A, the release rate of aggregation-prone
htt fragment, is the main bifurcation parameter in our analysis. It is an important thera-
peutic target on which various caspase inhibitors and chaperons that modulate refolding
of the htt fragment act upon. With the increase in the release rate of htt fragment
A, the system goes through two transcritical bifurcations, corresponding to the onset of
oligomerization and the onset of aggregation. For each value of A, there is only one stable
steady state for each of the variables, namely: full-length htt, monomers, oligomers, and
aggregates of htt fragments (Figure 3.3, left panel). This is consistent with other models
for protein aggragetion (115).
For high cleavage rates (A > A2), the formation of aggregates is responsible for most
of the change in the total concentration; the concentration of monomers increases slowly
and the concentration of oligomers stays constant. Aggregates act as a buffer to limit the
increase in concentration of htt oligomers. Moreover, the steady state value of oligomers
(O3htt) depends only on the rates related to the formation of large aggregates ka, k−1a and
kda, and not on particular levels of monomers Mhtt or aggregates Ahtt.
In the core model, aggregates are either quickly formed (A > A2) or absent (A < A2).
To simulate slow evolution of aggregation in a cell, the release rate A was assumed
37
0 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 0.09 0.1
 0.6
 0.4
 0.2
0
0.2
0.4
0.6
0.8
1
1.2
A
C
on
ce
nt
ra
tio
n
A1 A2
0 100 200 300 400 500 600 700 800
0
0.05
0.1
time
A
0 100 200 300 400 500 600 700 800
0
0.2
0.4
0.6
0.8
co
nc
en
tra
tio
n
Mhtt
Ohtt
Ahtt
Figure 3.3: Behavior of the core model. (Left) Bifurcation diagram of aggregation. The
steady states for Mhtt (blue), Ohtt (green) and Ahtt (red) are plotted as a function of
the htt release rate A. The bifurcation analysis shows that as A varies, the system
successively goes through three steady states. For low values of A, the system is in
STST1 (only monomers are present in the system). When A is larger than the threshold
A1, the system is in STST2 (monomers and oligomers are present in the system). For
the values of A larger than the second threshold A2, the system is in STST3 (monomers,
oligomers and aggregates are present in the system). The two threshold levels A1 and
A2 define transcritical bifurcation points, where an unstable steady state (gray lines)
exchanges stability with a stable steady state (bold lines). (Right) Time courses of Mhtt
(◦), Ohtt (+), and Ahtt (·) (upper panel) and caspase-2 activity (lower panel). Increase in
the release rate of htt fragments is simulated and indicated by the gray shading (lower
panel, A=0.01, 0.03, 0.05, and 0.1).
to slowly increase in time (Figure 3.3, right panel). The concentration of aggregates
increases abruptly, when A is larger than the threshold A2 (Figure 3.3, right panel,
t ∼ 400). Further increase of A is immediately followed by an increase in the aggregate
concentration.
3.4.2 Behaviour of the extended model for htt aggregation
The simulation of the model consisting of Equations 3.16–3.21 shows that, as in the core
model for htt aggregation, an increase in caspase activity mainly affects the aggregate
and monomer concentrations (Figure 3.4, left panel). After a transient peak, monomer
and oligomer concentrations reach a steady state as aggregates start to form. With a
higher htt cleavage rate, the aggregate and monomer concentrations increase, but the
steady state concentration of oligomers remains constant. Thus, the evolution of htt
conformations in time in the extended model is well represented by the core model.
In the extended model, I introduced a representative positive feedback loop influencing
the htt release rate. This positive feedback loop could explain the delayed increase in
the htt release rate, A, in the early stage of HD. This could be and intrinsic mechanism
by which the system triggers aggregation. The proteolytic cleavage rate of procaspase-2,
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Figure 3.4: Behavior of the extended model. (Left) Time courses of Mhtt (◦), Ohtt (+),
Ahtt (·), P (×), and C (). Parameters are listed in Table 3.1 and Table 3.4. (Right)
Delay in the onset of aggregation. In the core model, for A > A2 aggregation occurs
rapidly (here A = 0.1). In the extended model the delay in the onset of aggregation
introduced by the positive feedback loop in the release of htt fragments is pronounced for
the small values of kpr. For the larger values of kpr it has little influence.
kpr, is assumed to be a sensor of the toxicity in HD cell and its surrounding (i.e. toxicity
of htt conformers or trophic factor deprivation can trigger the caspase activation). For
all values of kpr, the onset of aggregation occurs later than in the core model, which has
a constant value of A. For low values of kpr, the delay can be extended up to a certain
point, but not indefinitely. For high values of kpr, corresponding to the increased stress
experienced by HD cell, the delay becomes very small and so does the influence of a
positive feedback loop (Figure 3.4, right panel).
In the core model, depending on the value of A, there is either no aggregation at
all (A < A2), or a rapid aggregation (A > A2). The variation in the value of A is due
to the external change experienced by the cell, and this will determine the delay in the
aggregation. In the extended model, a positive feedback loop slowly leads to the onset
of aggregation even without the externally induced increase in the release rate of htt
fragment. Thus, the positive feedback loop is sufficient to explain the delay in the onset
of aggregation.
3.5 Discussion
A wide range of pathological changes in HD affecting: gene transcription, protein traffick-
ing, protein degradation, glutamatergic synaptic transmission, neurotrophic modulation
of synaptic function, mitochondrial function and oxidative metabolism, stem from the
aberrant protein-protein interactions with different htt conformations arising from the
aggregation process (67). Mathematical models presented in this chapter were the first
molecular models of htt aggregation. These models allow us to monitor the evolution of
the concentration of each htt conformer over time.
First, I analyzed the behaviour of a simple model for htt aggregation that I called the
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core model. The core model describes htt aggregation kinetics as a nucleation process.
It is a deterministic model that consists of a set of ordinary differential equations which
define the time evolution of various htt conformers, namely: full-length htt, monomers,
oligomers and aggregates of htt fragments. As the conditions in the environment worsen,
the rate of release of htt fragment, A, increases, and the system goes through two bifur-
cation points corresponding to the two nucleation events: onset of oligomerization and
onset of aggregation. Nucleation is a sudden phase-transition phenomenon where the first
steps are energetically less favoured than continuation of growth. One thermodynami-
cal study showed that the critical step for the onset of aggregation is a conformational
change of a polyQ monomer (160). In the mathematical model, the concentration of
htt monomer needs to be high enough for the probability of undergoing the structural
transition to be significant. At this threshold concentration, a transcritical bifurcation
occurs, i.e. the system goes into another stable steady state. Threshold behaviours like
switches are present in many biochemical systems and are well understood (54).
Second, I enlarged the core model to address the question: how does the system go
through the bifurcation point. The enlarged model consists of six differential equations
with the mutant htt, htt monomers, oligomers, aggregates, procaspase-2 and caspase-2
as variables. A positive feedback loop that controls the release of htt fragment could be
an intrinsic mechanism to cross the threshold in the release rate. It can also explain the
delay in the onset of aggregation as a dynamic property of the system independent of the
external influences. Indeed, mouse lines that contain a truncated form of HD gene show
abnormal symptoms before lines containing full-length htt (105).
Both the core and the enlarged model predict that environmental changes and toxic
effects of mutant htt, or the positive feedback loop, which all promote the release of
htt fragments, lead to the increase in the level of monomers and aggregates. Once the
aggregates are formed, i.e. the system is in Steady State 3, the concentration of the
oligomers is constant. If the oligomers were the most toxic htt conformer, this would
agree with the one-hit model of the cell death in different neurodegenerative diseases,
according to which a probability that disease affected neurons die is constant. The
influence of different htt conformers on cell death is the topic of the next chapter.
Few other studies have addressed the problem of aggregation in HD. Rieger et al
(124) have considered a model in which protein refolding and de-aggregation rates are
mediated by chaperones. They showed that the threshold phenomena in aggregation
can be explained by a bistable process, and that chaperones are necessary for bistability.
Bistability can explain the sudden transition to high aggregate concentration and differ
from the nucleation mechanism in two ways: (1) aggregate concentration can take either
low or high values but no intermediate, and (2) for a given set of kinetic parameters,
aggregates can be stable either at high or low concentration. In practice, however, it would
be difficult to discriminate between bistability and nucleation because of the presence of
noise, and the possible narrow range of parameter values for which the threshold transition
occurs. The nucleation model presented here does not include chaperone activity. Adding
it might also produce a bistability transition, in addition to the trancritical bifurcations.
Pallito et al. (115) considered an extensive model for β-Amyloid fibril growth associated
with Alzheimer’s disease to identify the toxic Aβ species. Their model and the one
presented here are consistent in predicting a narrow range over which oligomers exist in
the absence of large aggregates.
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Many cell and mouse models for HD show early formation of aggregates, probably
due to the strong expression and the length of polyQ stretches present in the cells. It is
natural to represent the states of these experimental models by Steady State 3, marked by
the presence of aggregates. In patients diagnosed with HD, however, a relevant question
is to determine in which state vulnerable neurons are. In the context of mathematical
modelling, therapy could allow the transition from one steady state to another, e.g. by
inhibiting or promoting aggregation. However, since the relative toxicities of individual
conformers are not yet known, it is difficult to predict the effect of such a transition. This
problem will further be studied in the next chapter.
Much effort has been involved in finding substances that interfere with aggregation,
either by direct inhibition with htt as a target, or by indirect inhibition by, for instance,
caspase inhibitors. In various cell and mouse models, caspase inhibitors have been shown
to reduce toxicity and aggregate formation (178). Interference with the later steps, i.e.
with oligomerisation and aggregation, has been shown to be beneficial for the cell as well
(137, 51). In the next chapter, I consider different assumptions concerning the toxicity of
the soluble htt fragments and aggregates and I investigate the influence of intervention
with various steps in the process of aggregation on the overall toxicity.
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Chapter 4
Stochastic Model of Huntingtin
Aggregation and Neuronal Death
4.1 Summary of the chapter
Although it is well established that the formation and the accumulation of insoluble pro-
teins causes neurotoxicity in different disease model systems, there is an intense debate
as to which protein structure is responsible for neuronal dysfunction and loss. While the
mature aggregates have long been considered the toxic agent, more recent studies con-
clude that it is the soluble oligomers that are highly cytotoxic (9). However, the question
whether mature fibrillar structures or smaller aggregation intermediates are primarily re-
sponsible for neuronal damage in patient brains has not been solved conclusively (18). In
this chapter, I present a stochastic model for htt aggregation based on the core model in-
troduced in the previous chapter. In the model, I assume that the toxicity is proportional
to the concentration of each htt conformer. Three toxicity premises were considered: (a)
htt monomers and oligomers are the toxic species, while aggregates are non toxic, (b)
all three species are equally toxic, and (c) aggregates are the only source of toxicity. An
executioner caspase serves as a toxicity sensor and functions like a switch: toxicity high
enough can provoke sudden caspase activation, leading the cell into apoptosis. I use this
extended model to explore the possible outcomes of therapies targeting different steps
in the aggregation process depending on alternative toxicity premises. The results show
that transient dynamics and non-monotonic response of the cell survival to a change of
parameter can have a great effect on the outcome of a treatment that targets htt ag-
gregation. Moreover, the stochastic model might offer an explanation of the seemingly
conflicting results used to assign either toxic or neuroprotective role to htt aggregates.
4.2 Introduction
4.2.1 Aggregates: a friend or a foe
Since the discovery of polyQ aggregates, the aggregation process has been proposed to
be central to the pathogenesis of the disease, to be a benign epiphenomenon, or even to
be neuroprotective. A striking correlation between the threshold for aggregation in vitro
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and the threshold for disease in humans (length of polyQ > 36) supported the idea that
aggregation is a pathogenic event (47, 141). However, neurons with htt inclusions do
not correspond exactly to the neurons that degenerate. For instance, inclusions are more
enriched in populations of large striatal interneurons, which survive, than in medium
spiny neurons, which are lost (88).
The process of aggregation involves the formation of at least three protein conforma-
tions: htt fragment monomers, oligomers and aggregates. Aggregates are defined by poor
solubility in aqueous or detergent solvents, aberrant cellular localisation and non-native
secondary structure. Attempts to correlate the presence of aggregates with the onset of
phenotype have been complicated by the difficulties in detecting and quantifying small
aggregated forms of polyQ, and because all possible structural conformers of the protein
are present in the system under analysis (18). Yang et al. (184) circumvented these
problems by pre-forming different polyQ aggregation species, which were then used to
transfect cells in order to examine their toxicity. They demonstrated that polyQ aggre-
gates and not the htt monomers are highly toxic when directed to the nucleus, but not
toxic if they are in the cytoplasm. On the other hand, Arrasate and coworkers performed
a survival analysis of the individual cells expressing mutant htt, and showed that it is
the amount of diffuse intracellular htt that predicted whether and when cell death would
occur. They also concluded that aggregates protect neurons by decreasing levels of the
toxic diffuse forms of mutant htt (9).
Deleterious biochemical changes observed in HD models include altered signalling
pathways, perturbed calcium homeostasis, production of reactive oxygen species, trigger-
ing of inflammatory cascades and mitochondrial dysfunction. It will be a challenge to find
out which of the htt conformations induces which of the mechanisms leading to neuronal
dysfunction in HD. Moreover, many of our current concepts about the molecular mecha-
nisms involved in htt-mediated neuronal injury have arisen from in vitro experiments and
tissue-culture studies with htt aggregates at concentrations that exceed the physiological
levels, and should therefore be considered with care until they are validated in vivo.
4.2.2 Targeting htt aggregation
There are no effective strategies to slow down or prevent the neurodegeneration result-
ing from the HD mutation. However, factors regulating the synthesis and clearance of
aggregation-prone htt represent promising therapeutic targets. Many screens for poten-
tial new HD therapeutics have been conducted in vitro and in vivo, with varying outcomes
as to whether inhibition of aggregation is beneficial or detrimental. Bodner et al. (26)
identified compounds that increase inclusion formation while simultaneously reducing
toxicity in a cellular HD model. Schiffer et al. (142) found aggregation inhibitors that
do not ameliorate htt toxicity in a Zebrafish model, suggesting that aggregate formation
is independent from the toxic effects of mutant htt. On the other hand, compounds such
as Congo Red, EGCG or C2-8 have been shown to decrease both htt aggregation and
the pathological phenotype in Drosophila or mouse models of HD in a dose-dependent
manner (137, 51, 42). It is possible that the aggregation inhibitors identified in these
studies interfere with different steps in the aggregation cascade, thus leading to the ac-
cumulation of different monomeric or oligomeric, native or misfolded htt structures. The
experimental detection and quantification of the different conformers has proven difficult
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due to their intrinsic instability and the dynamic equilibrium of the system that does not
easily allow for purification of single components. Moreover, the mechanism behind the
action of the compounds that alter htt aggregation is often not known, and it is therefore
hard to distinguish between their effects on the aggregates themselves and the effects on
some other cellular process that indirectly influence htt aggregation.
The proteasome and autophagy-lysosomal pathways are the major routes for clear-
ance of mutant htt conformers. While the narrow proteasome barrel precludes entry of
oligomers/aggregates of mutant htt (or other aggregation-prone intracellular proteins),
such substrates can be degraded by autophagy. Indeed, the autophagy inducer rapamycin
reduces the levels of soluble and aggregated htt, and attenuates its toxicity in cells, as
well as in transgenic Drosophila and mouse models (180).
Aggregation is a characteristic of abnormally folded proteins. In the cell, the heat-
shock proteins Hsp70 and Hsp40 are the two main classes of molecular chaperones that
facilitate protein folding and maintaining the proteins in a soluble conformation. PolyQ
htt fragments interact with members of Hsp40 and Hsp70 families of chaperones in a
polyQ length-dependent manner (76). The sequestration of chaperones into aggregates
decreases their available amount in the cell, and this presumably enhances abnormal pro-
tein folding (68). If the production of misfolded proteins exceeds the degradative capacity
of the cell, these polypeptides can form insoluble intracellular aggregates (90). Increasing
the potential of the cell to deal with misfolded proteins, as by overexpression or induc-
tion of the Hsp70 and Hsp40 chaperones, prevents neurodegeneration in a number of HD
models (30, 149, 33).
4.3 Mathematical model
In the last chapter, I presented models of htt aggregation that were based on ordinary
differential equations (ODEs). Models based on ODEs are approximate because they treat
molecules with continuously variable concentrations, rather than the discrete entities that
they actually are. In reality, reactions occur as a rapid succession of separate elementary
events, the exact timing of which is effectively random because of the Brownian motion
of the reactants (4). The source of stochasticity can be intrinsic, i.e. small number of
molecules, or extrinsic, i.e. external fluctuations. Here, I use a Langevin approach to
describe the release rate of the htt fragment that depends on the stochastic intracellular
fluctuations of proteolytic enzymes, which is an extrinsic source of stochasticity. Thus,
the process is described using a stochastic differential equation (SDE) (172).
The stochastic model for htt aggregation presented here is based on the core model
introduced in the previous chapter. The model is composed of 6 variables: full-length
mutant htt Htt, N-terminal htt fragments containing polyQ repeat Mhtt , htt fragment
oligomers Ohtt, htt fragment aggregates Ahtt , an executioner caspase X, and the htt
fragment release rate A (Fig. 4.1). Full-length htt is cleaved and refolded at rate A,
releasing an aggregation-prone htt fragment. Monomeric fragments Mhtt bind to each
other to form oligomeric structures Ohtt, and subsequently larger, insoluble aggregates
Ahtt. Formation of both oligomers and aggregates is described by a nucleation process.
The release of htt fragments is described as a stochastic process. The three structural
conformations of htt contribute to the overall toxicity by activating executioner caspases
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X. In the extended model presented in the previous chapter, caspases were directly
involved in the aggregation process. Here, they are used only to relate the aggregation
dynamics to cell death.
Stochastic
htt cleavage
rate A
Proteasomal
degradation Autophagy
PolyQ
Mhtt Ohtt Ahtt
Synthesis
Htt
Tox
X
Pro-caspase Caspase
Figure 4.1: Stochastic model for htt aggregation. Mutant full-length htt, Htt, is cleaved
and a short N-terminal htt fragment, Mhtt, is released with a stochastic rate A. Htt
fragments aggregate and form htt oligomers, Ohtt, which further aggregate and form htt
aggregates, Ahtt. Full-length htt, monomers and oligomers of htt fragments are degraded
by the proteasome, and aggregates are removed by autophagy. The three structural
conformations of htt contribute to the overall toxicity by activating executioner caspases
X.
Differential equations for the 5 variables considered are
dHtt
dt
=kh − AHtt− kdhHtt, (4.1)
dMhtt
dt
=AHtt− knMhttOhtt + k−1n Ohtt − kdeMhtt, (4.2)
dOhtt
dt
=knMhttOhtt − kaOhttAhtt + k−1a Ahtt − (k−1n + kdn)Ohtt, (4.3)
dAhtt
dt
=kaOhttAhtt − (k−1a + kda)Ahtt, (4.4)
dX
dt
=C0 + kxTox
X4
1 +X4 − kdxX, (4.5)
Tox =u1Mhtt + u2Ohtt + (1− u1 − u2)Ahtt. (4.6)
To quantify the effect of noise on aggregation kinetics, time-dependent noise was added
to the htt fragment release rate A. The noise is described by a stationary Gaussian process
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Table 4.1: List of parameters for the stochastic model
Parameter Value Description
kh 1.0 Htt synthesis rate
kdh 0.5 Htt proteasomal degradation rate
kde 0.2 Htt fragment proteasomal degradation rate
kn 0.4 Rate of formation of oligomers
k−1n 0.01 Rate of release of monomers from oligomers
kdn 0.1 Proteasomal degradation of oligomers
ka 0.4 Rate of formation of aggregates
k−1a 0.01 Rate of release of oligomers from aggregates
kda 0.02 Removal rate of aggregates by autophagy
C0 0.02 Basal activity of an executioner caspase
kx 0.6 Proportionality constant for htt toxicity
kdx 0.08 Degradation rate of an executioner caspase
a 0.1 Relaxation constant for the stochastic process
A∗ 1 Average value of the htt fragment release rate
S 0.5 Standard deviation of the noise term
u1 0 - 0.5 Contribution of htt monomers to toxicity
u2 0 - 0.5 Contribution of htt oligomers to toxicity
(Ornstein-Uhlenbeck process) that satisfies the Langevin equation
dA
dt
= a(A∗ − A) + SL(t). (4.7)
L(t) is a Wiener process with average 〈L(t)〉 = 0, and variance 〈L(t)L(s)〉 = δ(t − s),
and S is the standard deviation of the noise term. This process satisfies the equation
dB(t) = L(t)dt, where B(t) is a Brownian motion (172). The toxicity level Tox is a
weighted average of the concentrations Mhtt, Ohtt, and Ahtt. Three toxicity levels for the
aggregates are assumed: non-toxic (Tox=0 or u1 = u2 = 0.5), equally toxic (Tox=1/3 or
u1 = u2 = 1/3), and fully toxic (Tox=1 or u1 = u2 = 0).
4.4 Results
4.4.1 Behaviour of the stochastic model of htt aggregation
Equations 4.1–4.7 were simulated using the first-order Forward Euler method for stochas-
tic equations. Unless otherwise noted, the simulations were run for t between 0 and 480
(arbitrary units) or the time of cell death, whichever comes first. The time step, ∆t = 0.2,
was determined by reducing the time step until no significant differences were found be-
tween stochastic simulations. Parameter values are listed in the table 4.1. Figure 4.2
shows the evolution of the system over time for one cell. The sensor of toxicity is the
activity of the executioner caspase X described by a bistable switch. When X reaches a
threshold that lies midway between the lower and the upper steady state (Xthresh = 4),
the cell dies (here at t = 92). The time scale is arbitrary but it is of the order of hours,
to mimic the evolution of aggregation in cell lines.
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Figure 4.2: (Left panel) Time series of Mhtt, Ohtt, Ahtt, X, and A for one cell. The cell
dies when X reaches a predefined threshold Xthresh = 4, here at t = 92. The parameter
values are listed in the table 4.1 (here, u1 = 0.334, u2 = 0.334). (Right panel) Bistability
of caspase activity as a function of toxicity.
4.4.2 Cell survival analysis with respect to different treatment
strategies
To study which factors influence cell survival, three parameters controlling htt aggregation
and degradation, namely kde, kda, and the average value of ka and kn, avg(ka, kn) = ka+kn2 ,
were systematically varied. For each kinetic parameter, three toxicity assumptions of the
aggregates were considered: non-toxic, equally toxic to the soluble protein (monomers
and oligomers), and fully toxic. For each of the parameter/toxicity combinations, the
time of cell death was monitored (25 stochastic runs over 40 equally spaced parameter
values for each combination). Each simulation ran until cell death, as determined by the
activation of X, or until t = 480. Cells staying alive until this time point were considered
survivors. The results are shown in figures 4.3–4.5.
Removal rate of htt monomer kde
Htt monomer removal includes degradation and refolding by chaperones (assuming ir-
reversible reactions). When aggregates are non-toxic or as toxic as the soluble protein,
increasing the monomer removal rate kde improves cell survival (Fig. 4.3, middle left and
middle center panels), since the concentrations of both soluble part and aggregates are
decreasing (Fig. 4.3, upper panels). The same is true in when aggregates are fully toxic
(Fig. 4.3, middle right panel). However, in this case two clusters of time of cell death are
visible for higher values of kde (early death, or survival). In the deterministic case, one
would expect the time of death to follow the same pattern as for non-toxic aggregates and
equally toxic aggregates because both aggregates and soluble part concentrations vary in
a similar way (Fig. 4.3, upper panels). In the stochastic case, observed early death, even
for the high values of kde, may be due to a transient stochastic accumulation of aggregates
briefly creating higher toxicity. After the onset of aggregation, the source of toxicity is
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Figure 4.3: Cell survival with respect to the removal rate of htt monomers kde. (Upper
panels) Deterministic steady states for Mhtt, Ohtt, Ahtt, and soluble protein (Mhtt+Ohtt).
(Middle panels) Time of death of 25 cells for different values of kde and different aggregate
toxicity premises. (Lower panels) Detailed analysis of the case when aggregates are fully
toxic (Lower left panel) Distribution of time of cell death for kde = 0.8 for 1000 cells.
(Lower middle panel) Time of onset of aggregation against time of cell death. The lines
show that many cells start dying 20 time units after the onset of aggregation. (Lower
right panel) The time course of the aggregate concentration for 4 early dying cells (thin
gray lines) and 6 surviving cells (thick blue lines).
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Figure 4.4: Cell survival with respect to the aggregate degradation rate kda. (Upper
panels) Deterministic steady states for Mhtt, Ohtt and Ahtt (left) and toxicity levels for
three combinations (right). (Lower panels) Time of death of 25 cells for different values
of kda and different toxicity levels of aggregates. When aggregates are non-toxic, the time
of cell death depends on the value of kda in a non-monotonic way (left). When aggregates
are equally or fully toxic, increasing in kda improves cell survival (center and right).
more stable and stochasticity plays a less important role. Thus, cells that are not killed
at the onset of aggregation will survive longer.
To verify this, I looked at the time of death and time of aggregation onset of 1000
cells, for kde = 0.8. The time of cell death shows a clear bimodal distribution; cells
that just formed aggregates have a high risk of dying, whereas most cells that survived
the onset of aggregation are still alive at t = 480 (Fig. 4.3, lower left and lower center
panels). Simulations of the evolution of the aggregate concentrations in cells that die early
(Fig. 4.3, lower right panel, thin lines) and cells that die late (Fig. 4.3, lower right panel,
thick lines) show that cells that die early have a strong peak at the onset of aggregation,
while cells that survive longer have a smooth onset of aggregation. After the onset of
aggregation, all cells had a similar dynamics. For all toxicity assumptions removing htt
monomers, by degradation or refolding, was beneficial to cell survival. However, in the
case of fully toxic aggregates, transient dynamics of aggregation onset may affect the cell
survival (Fig. 4.3, lower panels).
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Degradation rate of htt aggregates kda
For non-toxic aggregates, increasing the aggregate removal rate by autophagy can lead
to increased or decreased survival (Fig. 4.4, lower left). For low values of kda, an increase
in kda is associated with a decrease in the concentration of the soluble protein; hence the
improved survival. For high values of kda, the concentration of the soluble part increases
again, leading to a decreased survival. This result can be explained by the steady state
value of the deterministic model. The steady state concentration of soluble protein is
given by (STST3 in Table 3.2):
Mhtt +Ohtt =
AHtt+ k−1n k
−1
a +kda
ka
kn
k−1a +kda
ka
+ kde
+ k
−1
a + kda
ka
. (4.8)
The first term decreases with kda while the second term increases. The first term is
dominant, but eventually reaches a plateau, allowing the increase of the second term to
dominate at high values of kda. This non-monotonic behaviour of the soluble protein
explains the bell-shaped curve of the time of cell death. Although the change in concen-
tration of the soluble protein is small, it has a dramatic effect on the time of cell death
(Fig. 4.4, upper center and lower right panels). We could expect a similar behaviour
in the case when all htt conformation are equally toxic, but for higher values of kda.
However, for the chosen parameter values, increasing kda always has a beneficial effect
(Fig. 4.4, lower center panel). As expected, if aggregates are fully toxic, increasing kda is
always beneficial (Fig. 4.4, lower right panel).
Htt fragment oligomerization and aggregation rate avg(ka,kn)
The polyQ length determines the oligomerization and aggregation rates. Different HD
models have a wide range of polyQ repeat lengths (i.e. 50–150), which might lead to
several-fold differences in the oligomerization and aggregation rates. It is likely that
compounds that cause either increase or decrease in the aggregation rates interfere with
both the oligomerization and the aggregation step. In the following, I therefore, examine
the influence of the average value of the oligomerization and aggregation rate on the cell
survival.
In the model, for non-toxic aggregates, changing the oligomerization and the ag-
gregation rates can have an opposite effect depending on the starting average value of
those rates, i.e. depending on the polyQ length in a HD model (Fig. 4.5, lower left
panel). The time until cell death is shortest around avg(kn, ka) = 0.1. Steady state
analysis of the deterministic model shows two successive transcritical bifurcations just
below avg(kn, ka) = 0.05. Around that value, the concentration of the soluble protein
increase due to the accumulation of oligomers (Fig. 4.5, upper center panel). Although
the decrease in cell survival is consistent with an increase of the concentration of the
soluble protein, the parameter values do not match. Additional factors modulating the
time of cell death, such as transient activity during onset of aggregation, may explain
this discrepancy. If aggregates are equally or fully toxic, the time of cell death decreases
in a rate-dependent manner, as expected (Fig. 4.5, lower center and right panels).
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Figure 4.5: Cell survival with respect to average rate of oligomerization and aggregation
avg(ka, kn). (Upper panels) Deterministic steady states for Mhtt, Ohtt and Ahtt (left) and
the total toxicity levels for different toxicity premises (right). (Lower panels) Time of
death of 25 cells for different values of avg(ka, kn) and different toxicity levels of aggre-
gates. For non-toxic aggregates, the time of cell death follows a v-shaped curve (left).
For equally or fully toxic aggregates, the time of cell death decreases (center and right).
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4.5 Discussion
Different therapeutic strategies targeting the aggregation process have been developed,
e.g. inhibiting protein aggregation with peptides or small molecules identified via struc-
ture-based drug design or high-throughput screening, interfering with post-translational
modifications that stimulate protein misfolding and aggregation, or upregulating molecu-
lar chaperones or aggregate-clearance mechanisms (128). The outcome of such treatments
is often used as an argument to infer the toxic protein conformation. However, the analysis
of the stochastic model for htt aggregation presented in this chapter reveals non-intuitive
effects of different therapeutic strategies on cell survival. The results show that transient
dynamics and non-monotonic changes in the concentrations of htt conformers might have
a great effect on the outcome of a treatment that targets htt aggregation. Moreover, the
stochastic model might help us explain the seemingly conflicting results used to assign
either toxic or neuroprotective role to htt aggregates.
The stochastic model for htt aggregation is built on the deterministic core model
introduced in the previous chapter. The extension of the core model is a stochastic
equation for the release rate of the htt monomers and an equation for the activation of
the executioner caspase. The core model allows monitoring of how the concentration of
each htt conformer evolves in time for a given set of parameters. Here, I assigned different
toxicity levels to htt conformers and can, therefore, monitor how the htt-induced toxicity
evolves in time. An executioner caspase detects the toxicity, and when the toxicity exceeds
a certain threshold, the caspase commits the cell to die.
Along the lines of dispute over the source of toxicity in HD cells, I considered three
toxicity premises: only the soluble htt conformers are toxic, all three conformers are
equally toxic, and only aggregates are toxic. For each case, I changed three parameters
that have been common therapeutic targets in treating HD, namely: rate of htt monomer
removal, degradation of htt aggregates, and htt oligomerization and aggregation rates,
and monitored the influence of those changes on the time of cell death. Increasing the
monomer removal rate has the expected effect of increasing cell survival, consistent with
the deterministic steady state analysis. When aggregates are toxic, however, cells behave
in two different ways, they either die early, or they survive. The early death, even for high
values of kde, may be due to a transient stochastic accumulation of aggregates causing
short-term toxicity high enough to activate the executioner caspase. If the soluble protein
is the only toxic species, increasing the degradation rate of htt aggregates can be harmful,
since it leads to the accumulation of the toxic conformers in the cell. Moreover, if the
soluble protein is the only toxic species, the effect of changing the oligomerization and
aggregation rates will depend on the initial values of those rates.
Any non-monotonic response of the cell survival to a change of parameter has impli-
cations for the corresponding therapeutic strategies. Different HD models have a wide
range of polyQ repeat lengths (50–150). The polyQ repeat length determines the rate of
aggregation, i.e. the longer the repeat, the faster the aggregation. If htt monomers and
oligomers are toxic, and aggregates are not, a system with a high oligomerization and
aggregation rate would benefit from a further increase of the aggregation rate. A system
with low aggregation rate, however, would be favored by a decrease in the rates, since the
removal of htt oligomers would decrease overall toxicity (Fig. 4.5, lower left panel). This
should be considered in the interpretations of results obtained from different experimental
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HD models.
Transient behavior denotes how a dynamical system behaves while evolving toward,
but still being far from a steady state. Transients can show complex behaviour that
bears little resemblance to the long term equilibrium dynamics. Deterministic models
introduced in the previous chapter also display transient dynamics that can be seen as
an overshoot in the concentration of aggregates at the onset of aggregation. However,
the overshoot is much weaker than in the stochastic model. Thus, introducing stochas-
ticity into the model for htt aggregation had significant consequences by potentiating the
strength of transient behaviour.
A one-hit model states that a rare, catastrophic event, rather than a prolonged ele-
vated toxicity, causes cell death in a number of neurodegenerative diseases (43). Aggre-
gation of misfolded proteins, as a nucleation process, is itself a sudden and rare event
(119). In the stochastic model, the onset of aggregation is caused by a sudden elevated
release of monomers (described by a stochastic process), which causes an overshoot in
the aggregate concentration (Fig. 4.5, lower panels). This overshoot is transient and
cannot be predicted by steady state analysis. If the aggregates are toxic, an overshoot
that is high enough can kill the cell. After the overshoot, the concentration of aggre-
gates decreases and fluctuates around an average value. If the cell survives the onset of
aggregation, a decreased aggregate concentration may not be enough to kill the cell. In
that case, a cell that is alive and contains aggregates might have a higher life expectancy
than a cell without aggregates, because it has already survived the worst condition. This
phenomenon could be termed a one-shot model. The one-shot model could explain how
aggregates could be toxic and neuroprotective at the same time.
The stochastic nature of time of cell death has important implications for the onset
and progression of the disease in patients. In the next chapter, I introduce and explore a
model for neuronal degeneration in which cells die at random times and in clusters. For
small number of clusters (strong dependences between the striatal cells) stochastic effects
become visible and contribute significantly to the variability in age of onset of HD.
54
Chapter 5
Clustered Neuronal Death and the
Variance of Age at Onset of
Huntington’s Disease
5.1 Summary of the chapter
Movement disturbances, psychological changes and dementia, usually appear in Hunt-
ington’s disease (HD) patients between 30 to 50 years of age and progress over a period
of 15 to 20 years. The principal cause of the variability of the age at onset (AO) is the
length of the CAG repeat within the gene causing HD (3). Several additional genetic
factors contribute to a lesser extent to the variance of the AO, but at least 35% of the
variance remains unexplained. HD symptoms are a consequence of premature dying of
medium-spiny neurons in the striatum. The extent of the striatal cell death provides
a basis for grading the severity of HD (175). Once around 50% of the medium-spiny
neurons are lost, motor symptoms associated with HD become noticeable, marking the
onset of the disease. In a number of neurodegenerative diseases, the neuronal death rate
can be described by an exponential kinetics (43). These observation were incorporated
in a stochastic one-hit model of cell death that is presented in this chapter. The results
of the model indicate that up to 20% of the observed variance in the AO of HD could be
explained by a stochastic pattern of cell death in the striatum of HD patients.
5.2 Introduction
The discovery of the mutation underlying HD created the possibility of determining
directly whether someone has inherited the gene for HD. In a healthy individual, the
CAG repeat length ranges from 11 to 34 repeats, whereas 37 to more than 80 repeats
have been found in HD patients (50, 3, 153). For patients at risk, predictive testing and
being informed of having a CAG expansion in the pathological range, shifts the major
unanswered question from "Will I get HD?" to "When will it manifest?". Unfortunately,
even though the CAG repeat length is highly sensitive for predicting whether someone
will develop HD, the ability to predict the age at onset (AO) of HD is only limited.
The longer the CAG repeat length, the earlier the symptoms occur and the more
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Figure 5.1: Neuropathology of HD in postmortem brains. A normal human brain is
shown on the left for comparison, and the in the brain slices to the right, the severity of
HD increases (taken from http://www.buckinstitute.org).
severe they are. However, for a given CAG repeat length, a wide range of the AO is ob-
served, making predictions of the AO difficult to use in the counseling of presymptomatic
individuals carrying a HD mutation. The CAG repeat length explains around 50% of the
variance of the AO. Several additional genetic factors that can contribute to the variance
of the AO have recently been identified. Namely, modifications in the genes encoding
transcription factor p53 and human caspase activated DNase (39), glutamate receptor 6
subunit of kainate receptor (133) and N-Methyl-d-aspartate (NMDA) receptor subunit
2B (8) explain around 4% of variance each. Still, at least 35% of the variance of the AO
remains unexplained.
Here, I put forward a novel answer to this question. I propose that the observed
variance in the AO could be an intrinsic stochastic property of the pattern of progressive
neuronal death in the striata of HD patients. The proposed mechanism is built upon the
following characteristics:
(i) The onset of the disease is determined by the extent of neuronal loss.
Premature, gradual dying of the medium spiny neurons in the striatum underlies the
development of movement disturbances, psychological changes and dementia in HD pa-
tients. The extent of atrophy and cell loss correlates with the severity of the disease.
Already 10 years before the onset of the clinical symptoms, a significant neuronal loss
is observed. By the time the specific motor disorders appear (onset of the disease), at
least 50% of the striatal neurons have been lost (12). Postmortem examinations of HD
patients revealed up to 95% of neuronal loss in the striatum (175) (Figure 5.1).
(ii) The neuronal death rate is described by an exponential kinetics. The
delay in the clinical onset of HD and other late-onset neurodegenerative diseases, has
often been assumed to reflect the occurrence of age-dependent cumulative damage (45).
A prediction of the cumulative damage hypothesis is that the probability of cell death
will increase over time. However, Clarke et al. observed that the kinetics of the metabolic
decline due to cell loss in HD patients are best described by a constant risk of cell death
(43). This translates into an exponential neuronal death kinetics, where a single event
triggers cell death and the time of death of any neuron is random. They named this
kind of kinetics a ’one-hit’ model of neuronal death. Perutz et al. proposed that initial
nucleation of intracellular aggregates is the event that leads to such a cell death kinetics
(119).
(iii) The death rate depends linearly on the CAG repeat length. A number
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of studies supports this notion, namely: the striatal volume loss measured by MRI shows
a linear correlation with the CAG repeat length (129); autoradiographic studies show
that striatal dopamine receptor binding decreases in proportion to the degree of cell loss
in early HD (10); and PET scans show a linear relationship between the CAG repeat
length and the loss of dopamine receptor binding (5).
(iv) Neuronal death occurs in clusters. Using autopsy cases of early HD, Hedreen
et al. found scattered islands of neuronal loss confined to the striosome compartment of
the striatum (69). Thieben et al. reported unevenly distributed neuronal loss (167).
Some earlier studies suggested that there was a dorsal to ventral gradient of neuronal
loss with advancing disease (175). All those studies support the idea that neurons in the
HD striatum die in clusters, corresponding to the striatal regions with similar conditions
(e.g. level of the excitotoxicity, level of neurotrophic factors, inflammation etc.).
5.3 Stochastic one-hit model for striatal cell death
in HD
Based on the characteristics of cell death in HD patients, I formulated a mathematical
model relating the age at onset (AO) of the disease to the CAG repeat length. The
neuronal death in HD follows an exponential kinetics, a process similar to radioactive
decay. The average number of surviving striatal neurons at age t, N(t), satisfies
〈N(t)〉 = N0 exp(−γ(CAG)t), (5.1)
where N0 is the initial number of neurons and CAG is the number of repeats. The
neuronal loss rate
γ(CAG) = (α + β(CAG − c0)) (5.2)
is a linear function of the CAG. The parameter α is a basal, CAG repeat-independent loss
rate, i.e. loss due to aging and additional genetic factors. The parameter β represents the
specific loss rate induced by every CAG repeat longer than c0 = 36. Only CAG repeat
lengths that are longer than 36 are evaluated with the model, since HD does not occur
for the shorter repeat lengths. In the model, the age at onset is defined as the time at
which the fraction of the initial number of neurons, N0, remaining
ρ(t) = N(t)/N0 (5.3)
drops to the critical value ρc = 0.5 (Fig. 5.2A and C). A good predictor of the average
AO is
〈AO〉 = log(1/ρc)
γ(CAG) . (5.4)
In the stochastic one-hit model, and any particular outcome of the AO will deviate from
the average AO given by Eq. 5.4.
The number of striatal neurons in human is between 1.1×108 and 2.0×108 (70). If they
die independently of each other, the variance of AO will be negligible (Figure 5.2, panels
(A) and (B)). However, if we assume that striatal neurons die in clusters, then N(t)
does not represent the number of single neurons but the number of neuronal clusters
experiencing similar external conditions. According to this hypothesis, N0, the initial
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Figure 5.2: Stochastic model of neuronal death. For a large initial number of clusters
(N0 ∼ 108) and a fixed CAG repeat length, the variance of the AO is negligible (panels
(A) and (B)). (A) The fraction of surviving neurons ρ(t) decays exponentially according
to Eq. 5.1, and the threshold ρc uniquely defines the AO. (B) The AO is predicted by
Eq. 5.4. For small initial number of clusters (N0 < 104), the variance of AO is significant
(panels (C) and (D)). (C) The fraction of surviving neurons decays randomly, and on
average the decrease is exponential as described by Eq. 5.1. Individual simulations reach
the threshold ρc at different times (three are shown, all with 56 CAG repeats). For a
given repeat length, the AO follows a distribution exemplified in the insert of panel (C).
(D) When simulations are performed, the average AO is predicted by Eq. 5.4, and the
variance of the AO is greater than zero (the error bars indicate the standard deviation of
100 runs, for every CAG repeat length between 41 and 65).
number of clusters, will be small (N0 ≤ 104), and AO will have a significant variance
(Figure 5.2, panels (C) and (D)).
5.4 Results
The results are organised as follows. First, the deterministic average AO (given by Eq. 5.4)
of the one-hit model was fitted to six data sets comprising CAG repeat lengths and the
corresponding AOs (3, 50, 83, 102, 153, 155). This fitting procedure yielded an estimate
of the variance explained by the CAG repeat length in the one-hit model.
Second, the deterministic component of the one-hit model was compared to the widely
used logarithmic model for predicting the AO, in which the log(AO) is a linear function
of the CAG repeat length. The comparison showed that the deterministic part of the
one-hit model and the logarithmic model explains the same fraction of variance in AO in
the six data sets analyzed here.
Third, the contribution of the stochastic component of the one-hit model to the vari-
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ance in the AO was assessed. The model showed that for a small number of cluster (N0),
the AO is spread around the predicted average. The variance of AO obtained by running
stochastic simulation for the CAG repeat length of each patient was then compared to
the observed variance of AO for the same repeat length. The ratio of the variance of the
simulated AO to the observed variance in patient provides an estimate of the variance
explained by the stochastic one-hit model.
5.4.1 Fitting the one-hit model for the AO
Equation 5.4 was fitted to six data sets (3, 50, 83, 102, 153, 155) using a nonlinear least-
square regression from Matlab’s statistical package. The data sets and the variance of
AO are represented in Fig. 5.3. In Eq. 5.4, the parameter α is a basal death rate of striatal
neurons that is independent of the CAG repeat length, and parameter β describes by how
much the death rate increases for each additional CAG repeat (> 36). The least-square
regression finds the values of α and β that minimize the sum of squares of the errors,
SSE,
SSE =
n∑
i=1
(yi − 〈AO〉i)2 (5.5)
where yi is the i-th observed AO, 〈AO〉i is the predicted AO corresponding to CAGi, and
n is the number of points in a data set. The total variation of the data, SST , is given by
a sum of squares of differences between the data and the mean,
SST =
n∑
i=1
(yi − y¯)2, (5.6)
where yi is the i-th observed AO and y¯ the mean of all AOs. The coefficient of deter-
mination is the fraction of the total variance explained by the model, and is given by
R2 = 1− SSESST . (5.7)
The fitted values of α and β, and the corresponding values of the coefficient of deter-
mination R2 for each data set are given in Table 5.1. By averaging over the results for
all 6 data sets, I obtain an average value of α = (10.7 ± 1.2)−3 y−1 and for β the result
is β = (0.82 ± 0.12) × 10−3 y−1 per additional CAG repeat. For example, for 45 CAG
repeats, this translates into an annual neuronal loss rate γ of 1.8%, and 3.4% for 65 CAG
repeats.
5.4.2 Fitting the logarithmic model for the AO
In previous studies (133, 130, 39), a logarithmic model was used to fit the AO to the
CAG repeat length. The model is
log(AO) = a+ b(CAG − c0). (5.8)
To be able to compare the one-hit model (defined by Eq. 5.4) to the logarithmic model,
the latter was fitted using the same six data sets and the same algorithms fromMatlab’s
statistical package. The logarithm of AO (log(AO)) was taken as the dependent variable,
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Table 5.1: Results of the regression analysis. The parameters α and β of the regression
of Eq. 5.4 are given in units of 10−3/year. Values of R2 are shown for the logarithmic
model and Eq. 5.4. Numbers next to ∆R2 are the initial numbers of cluster N0.
Data α β R2 log R2 Eq. 5.4 ∆R2 (5000) ∆R2 (500) ∆R2 (100)
Andrew 1993 (3) 9.3 0.85 0.41 0.43 0.0038 0.038 0.20
Duyao 1993 (50) 9.5 0.88 0.62 0.61 0.0032 0.032 0.17
Kieburtz 1994 (83) 12.1 0.66 0.45 0.43 0.0037 0.034 0.17
Margolis 2003 (102) 11.6 0.70 0.45 0.45 0.0035 0.035 0.18
Snell 1993 (153) 11.5 1.00 0.59 0.62 0.0054 0.057 0.30
Squitieri 2000 (155) 10.4 0.84 0.53 0.53 0.0034 0.035 0.19
Mean 10.7 0.82 0.51 0.51 0.0038 0.039 0.20
STD 1.2 0.12 0.09 0.09 0.001 0.01 0.05
the CAG repeat length as the independent variable, and a linear least-square regression
was performed for the data sets. The coefficient of determination, R2, was calculated using
the procedure described above. The results of the regression analysis are summarised in
Table 5.1. The logarithmic regressions gave an average of R2 = 0.51± 0.09, in agreement
with previous studies (39, 133, 8) and identical to the R2 calculated for the one-hit
neuronal death model (R2 = 0.51 ± 0.09). This shows that both models fit the data
equally well.
Earlier studies that used a logarithmic model have taken the residuals of the linear
regression of log(AO) to calculate R2. Here, R2 was calculated using the residuals of
AO and not log(AO), which was needed to compare the different models, therefore the
discrepancy between the R2 shown here and the values reported in other studies.
5.4.3 Estimating the variance of the AO using stochastic simu-
lations
Stochastic neuronal death was simulated using the Gillespie algorithm with the fitted
parameter values of Eq. 5.4, α and β. Stochastic simulations were used to assess the
effect of different initial numbers of clusters N0 (from 102 to 5 × 103) on the variance
of the AO. The Gillespie algorithm computes the time intervals between the deaths of
two neuronal clusters. The mean value and the variance of the time interval increases as
the number of remaining clusters decreases. The AO is defined as the time at which the
fraction of clusters ρc = 0.5 is left.
Simulated values of AO were obtained for each data point in each data set for each
initial number of clusters (Fig. 5.3, N0 = 100 and 500, STD shown). The simulated data
sets thus obtained were analyzed as follows. The variability of the simulated AOs is given
by the sum of squares of residuals of the simulated data sets, SSESTOCH . This variability
is compared to the total variability observed in the real data sets, SST by calculating
the fraction of the total variance that comes from the stochastic process is
∆R2 = SSESTOCH/SST . (5.9)
The values of ∆R2 were averaged from 10 independent runs for each initial number of
clusters (Table 5.1). The variability of ∆R2 between each independent run was very small
(results not shown). This ∆R2 measures the variance that is specific to the stochastic
one-hit kinetics of neuronal death.
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Figure 5.3: Simulation of the stochastic neuronal death model, and comparison with
data from (3, 50, 83, 102, 153, 155) (all data points are shown in small blue squares,
repeated points are overlaid). The predicted average of the AO was calculated using
Eq. 5.4 (solid black line). The standard deviation (STD) of the AO for each CAG repeat
(light blue shaded area) represents the unexplained variance of the AO. Simulations using
the CAG repeat distribution from data (n=1147) were performed for N0 = 100 and 500
(the corresponding STDs are shown by the shaded areas in salmon and dark red). The
parameters are α = 10.7 × 10−3/year, β = 0.82 × 10−3/year/CAG repeat and N0 = 100
and 500.
For a given CAG repeat, the variance of AO is inversely related to the initial number
of clusters N0. Thus, when N0 is small, intrinsic stochasticity due to clustered neuronal
death can explain more variance, as shown in Table 5.1. For N0 = 500, intrinsic stochas-
ticity represents 4% of the total variance of the AO. If the number of clusters were smaller,
the percentage of the explained variance could go up to 20% (N0 = 100).
5.5 Discussion
Soon after the discovery of the gene and the underlying mutation in HD, a strong cor-
relation between the CAG repeat length and the AO of HD was uncovered. However,
due to the large variance of the AO for the same CAG repeat length, the time of onset
remains difficult to predict. In the previous studies, logarithmic models have been used
to fit the AO to the CAG repeat length (133, 39, 8). Moreover, using the largest cohort
of HD patients analysed so far, Langbehn et al. developed a parametric survival model
to predict the probability for HD gene carriers to develop the disease given their age and
CAG repeat length (91). However, to increase the predictive power of those models, ad-
ditional factors that modulate the AO would need to be included. To date, several such
genetic modifiers of AO have been identified. Nevertheless, at least 35% of the variance
of AO remains unexplained. In this chapter, I proposed that a part of the unexplained
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variance can be explained by the intrinsic stochastic dynamics of neurodegeneration.
Since premature dying of striatal medium spiny neurons underlies the onset and pro-
gression of HD, I studied the effect of the kinetic properties of this process on the variance
of AO. I developed a mathematical model for neuronal death in the striatum, assuming
that the probability of a neuron to die is constant in time but depends on the CAG re-
peat length. The additional hypothesis in the model is that cell-cell interactions and the
inhomogeneity of the striatum affect the probability of groups of neurons to die. That
is, neurons do not die independently but rather in clusters. On these premises a predic-
tor of the AO based on the fraction of surviving striatal neurons ρ (Fig. 5.2A–D) was
formulated. Aylward et al. reported the values of ρ between 0.33 and 0.5 at the time of
diagnosis (12). Here, a fixed value of ρc = 0.5 was used. Considering a distribution of
the values of ρ at onset would result in an increased variance. In addition, there could be
a correlation between the CAG repeat length and ρc, but this has yet to be established.
Based on six data sets where the AO and the CAG repeat length were known, neuronal
death rates, the fraction of explained variance of the average AO (coefficient of determi-
nation R2) and the additional explained variance (∆R2) due to clustered stochastic death
were computed. The additional explained variance varied from 0.4% for N0 = 5000 to
20% for N0 = 100. The average annual cluster (and neuronal) loss rate ranged from 1.2%
for the pathological threshold of 37 CAG repeats to 4.7% for 80 repeats. The estimates of
α and β are consistent with the claim that neuronal half-life decreases by a factor 1.055
for every additional CAG repeat (119).
Genetic modifiers affect the variance of AO by modulating the neuronal death rate
and can be viewed as extrinsic stochasticity: γ = γCAG+ξ, where random ξ represents the
influence of additional factors. If we relate this to the one-hit model of neurodegeneration
proposed by Clarke and coworkers (43), the CAG repeat length and additional factors
will define the mutated steady-state in the vulnerable neurons, and thus determine the
probability of the neurons to die. So, for the same CAG repeat length, there would
be a distribution of the neuronal death rates and AOs caused by the difference in the
genetic modifiers. In this chapter, I propose that even for the same neuronal death rate,
the timespan needed for the critical fraction of striatal neurons to die is variable. This
variability might be an intrinsic stochastic property of the clustered neuronal death. In
principle, monozygotic twins with the HD gene living in the same conditions should
display a difference in the AO due to intrinsic factors only. Recently, twins with 49 CAG
repeats were reported to have AOs of 32 and 35 years (2). For 49 CAG repeats and
N0 = 500, our model predicts an age at onset of 32.5 ± 2.0 years.
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Chapter 6
Conclusions and Outlook
6.1 Conclusion
In my work, I used experimental and mathematical models to investigate the dynam-
ics of Huntington’s disease (HD). In both cases, it has been difficult to tell how close
these models replicate the disease in HD patients, which takes decades to manifest and
progress. Nevertheless, the models allowed us to explore possible mechanisms behind the
phenotypes and to gain better understanding of them. Complex dynamical properties
of the biological systems can make causalities difficult to interpret. When faced with
the intricate biological problems, we need synergy of different perspectives that can be
attained only by combining experimental and theoretical methods.
Research dealing with a devastating disease such as HD primarily focuses on finding
an appropriate treatment by identifying the robust principles that underly the observed
pathology. Transcriptional dysregulation has been extensively reported in various HD
models, which fueled the search for transcriptionally active therapeutics for HD. In chap-
ter 2, I addressed the question whether htt aggregation, induced in a HD cell model,
leads to systematic transcriptional changes in groups of genes regulated by transcription
factors that have been implicated in HD. In this study, no systematic expression changes
were observed, indicating that targeting a specific transcription factor might not be a
feasible therapeutic strategy for treating HD.
Htt aggregation has been a common therapeutic target. However, since no conclusive
answer as to which of the htt conformations arising from the aggregation process is
the toxic one, an appropriate therapeutic strategy is far from obvious. In chapters 3
and 4, I introduced deterministic and stochastic mathematical models describing htt
aggregation and cell death induced by different htt conformers. The steady state analysis
and the numerical simulations of the models show that transient dynamics observed in the
system and the non-monotonic response of cell survival to a change of parameter might
lead to non-intuitive outcomes of a treatment targeting htt aggregation. For instance,
numerical simulations of the stochastic model show that the outcome of a change in the htt
aggregation rate in a specific HD model depends greatly on the starting value of that rate
which is determined by the length of the polyglutamine (polyQ) tract. If htt monomers
and oligomers are toxic, and aggregates are not, a system with a high oligomerization and
aggregation rate would benefit from a furhter increase of the aggregation rate. A system
with low aggregation rate, however, would be favoured by a decrease in the rates, since the
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removal of htt oligomers would decrease the overall toxicity. This should be considered
when interpreting results obtained from HD models with different polyQ lengths.
Furthermore, the analysis of the model pointed to the following observations. If aggre-
gates are toxic, an overshoot in the aggregate concentration at the onset of aggregation
might be strong enough to trigger cell death. However, if a cell survived the onset of
aggregation, it might have a longer life expectancy than the cell without aggregates, al-
though it contains toxic aggregates, because the worst is already behind it. I conclude
that this one-shot model can explain how htt aggregates might be seen as toxic and
neuroprotective at the same time.
In chapter 5, I propose that even for the same neuronal death rate (dependent on the
polyQ repeat length), the timespan needed for the critical fraction of striatal neurons
to die (corresponding to the age at onset) is variable. This means that the existence of
additional genetic modifiers of the HD onset is not necessary to explain the variance in
the age at onset of HD. The observed variance might be a consequence of an intrinsic
stochastic nature of the clustered cell death in the striata of HD patients.
6.2 Outlook
In HD, mutation in a single gene induces complex pathological events. In the course of the
disease a multitude of cellular pathways become affected, resulting in transcriptional dys-
regulation, mitochondrial dysfunction, proteasomal inhibition, disturbed vesicular trans-
port, impaired synaptic plasticity, excitotoxicity, inflammation, oxidative damage, aber-
rant protein-protein interactions, and eventually cell death. Each of these pathways is a
potential therapeutic target. Mathematical models of the pathways affected in HD could
be a great help in evaluating the experimental results from compounds targeting those
pathways. In that case, both experimental and mathematical models need to be devel-
oped in such a way as to be able to answer a specific question and the results obtained
should be interpreted within these boundaries.
Since the rank of importance of an individual pathway on the progression of HD is not
known, it is likely that treatment strategies will focus on administering cocktails of drugs
affecting different pathways. However, cellular pathways are usually not independent, but
rather form complex networks with behaviour that is difficult to predict without compu-
tational models. Computational models of cellular networks could help to determine the
steps in those pathways that could elicit synergistic effects in a combinatorial treatment.
Having in mind that any successful HD treatment would probably last for decades, iden-
tifying the combinations of compounds that are active in non-toxic concentrations will
be an important issue in the future.
A major goal in preventing HD onset and progression is to slow down neuronal death.
Widespread inflammation and excitotoxicity in the striatum of HD patients mediate
coupled cell death in neighboring neurons. The stochastic one-hit model of cell death
presented in the chapter 5 could be further analyzed to asses the influence of the com-
pounds which reduce inflammation and thus improve the external conditions sensed by
the striatal neurons. In mathematical terms, such compounds could uncouple the clusters
of dying neurons which would decrease the neuronal death rate and delay the onset of
the disease.
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Neuroimaging techniques are becoming widely used to monitor neurodegeneration in
HD patients. These techniques are becoming an essential tool in clinical trials, since
they allow accurate measurement of the progression of the disease. However, to assess
the efficacy of any HD treatments it will be necessary to take into account the stochastic
nature of neuronal degeneration. Statistically significant results will be obtained when the
progression of the disease lies outside the confidence interval predicted by the stochastic
model for neurodegenation for a particular patient. Because of the dynamical nature of
HD, such models should form the basis of the statistical protocols in clinical trials.
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Appendix A
Materials and Methods
A.1 Experimental materials and methods
A.1.1 Cell line
HEK 293 Tet-Off cell line (Clontech) has been derived from HEK (human embryonic
kidney) cell line as a single-stable Tet-Off cell line. Previously in Prof. Erich Wanker’s
lab, this cell line was transfected with the pTetCMV-Hyg-CAG83 vector (176). Stable
transfected cell lines were selected using 150 µg/ml hygromycin. High-level transcription
of the transfected gene is induced by growing the cells in a doxycyclin-free medium.
A.1.2 Culturing of cell line
Stable transfected 293 Tet-Off cells were grown in l-glutamine free MEM with Earle’s
Salts (Life Technologies, Gaithersburg, MD) and supplemented with 10% fetal bovine
serum (FBS), 2 mM l-glutamine, 100 IU/ml penicillin plus 100 µg/ml streptomycin, 100
µg/ml G418, 150 µg/ml hygromycin B, and 10 ng/ml doxycycline in poly-l-lysine coated
cell culture flasks. Expression was induced by thoroughly washing the cells with PBS
buffer (8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 0.24g KH2PO4, distilled water till 1l) and
adding fresh medium lacking doxycycline. The medium was changed on the following
day to remove the doxycycline completely. Expression was induced for 2 and 4 days.
A.1.3 Total RNA isolation
Total RNA was isolated from the stable transfected 293 Tet-Off cells using the RNeasy
Midi Qiagen Kit, according to the manufacturer’s instructions. RNeasy Midi Qiagen Kit
includes the buffers used in this procedure.
Preparation
For all the steps RNase-free microtubes, Falcon tubes, pipettes, pipette tips and water was
used. The working surfaces and centrifuge was cleaned with Rnase Zap solution from Am-
bion to remove RNase contamination. In the fume hood 10 µl 14.3 M β-mercaptoethanol
per 1 ml RLT Lysis buffer was added. Before using for the first time, 4 volumes of ethanol
(96–100%) were added to the RPE buffer to obtain a working solution. 20 µl of freshly
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prepared RNase free DnaseI stock was added to 140 µl of RDD buffer. 70% RNase-free
ethanol was prepared.
RNA isolation
T150 flask with 3/4 confluent stable transfected HEK 293 cells (more than 107 cells)
were tripsinized for 5 min, taken in 7 ml medium, transfered to 50 ml Falcon tube,
and centrifuged for 5 min, 1800 rpm at 4◦C. The supernat was carefully aspirated, the
pellet resuspended in 5 ml PBS, and centrifuged again for 5 min, 1800 rpm at 4◦C.
The supernatant was carefully aspirated and pellet thoroughly resuspended in 2 ml of
RLT Lysis buffer by flicking the tube. Cell lysates were homogenized using Qiagen
QIAshredder spin column: 700 µl were put on a column and centrifuged for 2 min, 14000
rpm, at room temperature (RT). Homogenized lysates were transfered to 15 ml Falcon
tubes, and equal volume of 70% ethanol was added and mixed by vigorous shaking. The
sample was immediately applied to a RNeasy Midi column, the tube gently closed and
centrifuged for 5 min, 4000 rpm at RT. The flow-through was discarded. 2 ml of RW1
buffer was added to the column, the centrifuge tube gently closed and centrifuged for 5
min, 4000 rpm. The flow-through was discarded. 160µl of DNaseI in RDD buffer was
applied directly to the column, and left for 15 min at RT. Then, 2 ml of RW1 buffer were
added to the column and left for 5 min at RT. The column was then centrifuged for 5
min, 4000 rpm at RT. 2.5 ml of RPE buffer was added to the column, the column was
centrifuged for 2 min, 4000 rpm at RT, and flow-through discarded. Another 2.5 ml of
RPE buffer was added to the column, the column was centrifuged for 5 min, 4000 rpm at
RT, and flow-through discarded. To elute, RNeasy column was transferred to a new 15
ml Falcon tube. 150 µl of the RNase-free water was pippeted directly onto the RNeasy
silica-gel membrane, tube was gently closed, left for 1 min at RT, and then centrifuged
for 3 min, 4000 rpm, at RT. To obtain higher RNA concentration, the obtained eluat was
applied to the column again, and centrifuged for 3 min, 4000 rpm, at RT. Isolated RNA
was kept on -80◦C.
A.1.4 RNA quality control
The control of quality and quantity of RNA was performed using UV Photometer (Ep-
pendorf). Several dilutions of the samples were prepared and optical density (OD) was
measured at wavelengths 260 nm and 280 nm using a quartz cuvette. For exact measure-
ment OD260 value of the RNA sample should lie between 0.05 and 0.5. An OD260=1
corresponds to an RNA concentration of 40 µg/ml. The quality was checked by calcu-
lating the ratio OD260/OD280. This ratio should be between 1.8 and 2. Quality was
determined in 10 mM Tris-Puffer pH 7,4, and quantity was determined in water.
A.1.5 Preparation of supernatant and pellet protein fractions
Cells were washed and scraped in ice-cold PBS, and pelleted by centrifugation. Cell lysis
was performed on ice for 30 min in 50 mM Tris-HCl (pH 8.8), 100 mM NaCl, 5 mM
MgCl2, 0.5% NP-40, and protease inhibitors (2 mM PMSF, 10 g/ml leupeptin, 10 µg/ml
pepstatin, 1 µg/ml aprotinin, and 50 µg/ml antipain). Insoluble material was pelleted
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by centrifugation at 14000 rpm for 10 min at 4◦C. The pellet was resuspended in 100 µl
20 mM Tris-HCl (pH 8.0)/15 mM MgCl2 containing 0.5 mg/ml DNAseI and incubated
for 1 h at 37◦C. Protein of the supernatant and pellet fraction was determined using the
Bradford protein assay (Bio-Rad, Munich, Germany).
A.1.6 Immunodetection of htt aggregates
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to the
standard procedure. The gels contained 12% polyacrylamide. As a marker, Benchmark
pre-stained protein marker from Invitrogen was used.
The proteins separated on SDS-gels were blotted onto nitrocellulose membranes as
follows: The gel was put onto a nitrocellulose membrane soaked in blotting buffer (25mM
Tris-HCl pH 8.0, 192mMGlycine, 20% methanol), carefully avoiding air bubbles. On both
sides, two layers of Schleicher and Schuell GB005 filter paper (also soaked in blotting
buffer) were added, and the “sandwich” was placed on a semi-dry blotting apparatus
(Biorad) with the nitrocellulose versus the bottom and the gel facing the upper side.
Surplus buffer and possibly remaining air bubbles were removed with a rubber roll, the
apparatus assembled completely and blotting was performed at 20V for 1h.
Membranes were incubated in blocking solution 3% skim milk in TBS (20mM Tris-
HCl pH 7.4, 150mM NaCl) either for 30 min at RT or over night at 4◦C to block any
unspecific reaction of the antibodies in the following steps. The first antibody (HD1,
rabbit, prepared in Prof. Erich Wanker’s lab) was diluted 1:1000 in 3% skim milk and
incubated with the membrane for 45 min at RT. The membrane was then washed in the
washing buffer (TTBS = 0.05 % Tween 20 + TBS) 4 times 5 to 10 min, before the second
antibody (Anti-rabbit-peroxidase (POD)(Roche)) diluted 1:5000 in 3% skim milk, was
added. After 1 h incubation at RT the washing steps with TTBS and TBS were repeated,
and detection with Luminol (LumiLight) was performed: the gel was placed on a glass
plate, and covered with the solution containing Lumi-Light substrate. After 1–3 min
the excess solution was removed and the gel wrapped in a Saran-wrap carefully avoiding
bubbles. Horseradish peroxidase (POD) converts Lumi-Light substrate resulting in light
emission, and light is detected by exposure to X-Ray film (processed in dark room).
A.1.7 cDNA microarrays
This work has been done by the members of Dr. Ulrike Nuber lab from Max Planck
Institute for Molecular Genetics, Berlin.
Generation of cDNA microarrays
Human cDNA clones were obtained from the Resource Center of the German Human
Genome Project (RZPD Berlin). cDNA clones represented target genes of transcription
factors implicated in HD. Additional human cDNA clones and 34 plant cDNA clones
were included. Clone inserts were amplified under standard conditions using primers
M13for (GTA AAA CGA CGG CCA G) and M13rev (CAG GAA ACA GCT ATG AC).
Primers were obtained from MWG Biotech (Ebersberg, Germany). All PCR products
were evaluated by agarose gel electrophoresis. Purified PCR products were resuspended
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in 8 µl of 3x SSC and printed on Corning GAPS II slides by using a robotic spotting
device (SDDC-2 MicroArrayer, ESI, Toronto, Canada ChipWriter Pro, Bio-Rad, Munich,
Germany) with SMP3 pins from TeleChem International (Sunnyvale, CA).
RNA isolation and microarray hybridization
Total RNA was isolated with Trizol reagent (Invitrogen). Microarray labeling and hy-
bridization reactions were performed using the 3DNA Array 350 Expression Array De-
tection kit (Genisphere, Hatfield, PA) according to the manufacturer’s instructions. 6
independent samples collected at day 0 of the experiment were pooled and used as a
reference. RNA was isolated from 3 samples of induced cells at day 2, and 3 samples of
induced cells at day 4. 5 µg of total RNA of the reference pool (day 0) and of the single
6 samples was reverse transcribed using primers with a specific capture sequence. The
reference cDNA sample was combined with one of the 6 other cDNA samples and hy-
bridized to the microarrays in a humidified chamber at 42C for 16 hr. Dye-swap repeats
were performed for each of the 6 co-hybridizations. Thus, 12 arrays were used in total.
Slides were washed at room temperature in 2x SSC/0.2 percent SDS for 10 min, 2x SSC
for 10 min, and 0.2x SSC for 10 min. Bound cDNA was visualized by hybridization with
3DNA (dendrimers specific for respective capture sequences conjugated to either Cy3 or
Cy5) in a humidified chamber at 42C for 3 hr. Subsequently, slides were washed as before.
Image acquisition and data analysis
Fluorescence intensities of Cy3 and Cy5 were measured separately at 532 and 635 nm
with a laser scanner (Affymetrix 428 Array Scanner, Affymetrix). The resulting 16-bit
data files were imported into Microarray Suite image analysis software (version 2.0),
which runs as an extension of IPLab Spectrum software (Scanalytics, Fairfax, VA). Raw
spot intensities of Cy3 and Cy5 were locally background subtracted by the MicroArray
Suite software. Empty spots and spots carrying plant gene sequences were excluded from
further analysis.
A.1.8 Microarray data analysis
The statistical analysis of microarray data were analysed using software packages from
Bioconductor, an open source and open development software project for the analysis and
comprehension of genomic data (www.bioconductor.org). For data preprocessing, dye-
swaps were combined and subsequently adjusted by lowess normalization. The statistical
significance of fold changes i.e. z-scores were based on a intensity-dependent local pooled
error estimate. Alternatively, a Student’s t-test was applied assuming equal variances of
the two samples.
A.2 Computational and mathematical tools
All numerical computations in Chapters 3–5 were done in the Matlab environment (The
MathWorks, Naticks, MA). All Matlab’s files and scripts are available on request.
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A.2.1 Differential equations and stochastic processes
Ordinary differential equations (ODEs) were solve numerically with the medium
order adaptive method ode45. Stochastic differential equations (SDE, Langevin
equations) were simulated using a forward Euler method for SDE. Briefly, if the equation
to solve is
dy(t)
dt
= f(t, y(t)) + SL(t),
and yi is the approximation of y at time ti = hi+ t0. The parameter h is the fixed time
step. The forward integration scheme is
yi+1 = yi + hf(ti, yi) +
√
hSN,
where N is a random value drawn from a normal distribution with mean 0 and variance 1.
For the simulations in Chapter 4, the time step was reduced until no difference between
simulations were seen (h=0.02).
Stochastic clustered neuronal death process was simulated using a Gillespie
algorithm. The number of cluster N(t) is a stochastic process in which the probability
of each cluster to die is independent of the others, and is distributed according to an
exponential distribution with parameter γ. No birth is possible, so cluster death follows
a kinetic similar to a first order degradation of a chemical:
N
γ−→ ∅.
The Gillespie algorithm allows computing time trajectories of N(t) that are statistically
exact, i.e. the simulations have the same statistical properties as the real stochastic
process. The algorithm is outlined as follows:
% Initialization
N(1)=N_0, t(1)=t0, i=1;
% Main loop
while N(i)>0 and t(i)<tfinal
Determine the time until the next cluster death dt.
If N(i) clusters are present, the time of the next
cluster death is exponentially distributed with
parameter N(i)*gamma.
Update N (decrease N by 1): N(i+1)=N(i-1).
Update t: t(i+1)=t(i+dt).
Update i: i=i+1;.
end
The age of onset is determined by the time at which N = ρ. The variance of AO
is estimated by multiple stochastic runs. There is an analytical expression for the mean
and variance of the death process but it is of limited used for large N since it involves
factorials.
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A.2.2 Statistical analysis
Statistical analysis was performed with the statistical package of Matlab. Parameter
fitting was done with the least-square fitting algorithm nlinfit from Matlab. The coef-
ficient of determination was calculated from the residuals (errors) given as an output by
nonlinfit.
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Appendix B
Mathematical Analysis
B.1 Stability analysis of the core model
The linearised equations around the steady state are given by the Jacobian matrix.
J =

−A− kdh 0 0 0
A −knOhtt − kde −knMhtt + k−1n 0
0 knOhtt knMhtt − kaAhtt − (k−1n +kdn) −kaOhtt + k−1a
0 0 kaAhtt kaOhtt − (k−1a + kda)
 .
(B.1)
The Jacobian matrix evaluated at Steady State 1 is
J1 =

−A− kdh 0 0 0
A −kde −knA kh
A+ kdh
+ k−1n 0
0 0 knA
kde
kh
A+ kdh
− (k−1n +kdn) k−1a
0 0 0 −(k−1a + kda)
 . (B.2)
The eigenvalue equation det (J1 − λI) = 0 is the 4th order polynomial
(−A− kdh − λ) (−kde − λ)
(
knA
kde
kh
A+ kdh
− (k−1n + kdn)− λ
)
(
−(k−1a + kda)− λ
)
= 0. (B.3)
The four eigenvalues of Steady State 1 are
λ1,1 = −A− kdh,
λ1,2 = −kde,
λ1,3 =
knA
kde
kh
A+ kdh
− (k−1n + kdn),
λ1,4 = −(k−1a + kda).
For Steady State 1 to be stable, the following condition needs to be met (λ1,3 = 0),
knA
kde
kh
A+ kdh
< (k−1n + kdn).
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This condition states that a bifurcation occurs at
A1 =
kdha
knkh − a, (Bif 1)
with a = kde(kdn + k−1n ).
At this value, the first two steady states collide with each other, a good indication of a
transcritical bifurcation. The Jacobian matrix at Steady State 2 is
J2 =

−A− kdh 0 0 0
A −knO2htt − kde −kdn 0
0 knO2htt 0 −kaO2htt + k−1a
0 0 0 kaO2htt − (k−1a + kda)
 . (B.4)
The associated characteristic equation is
(−A− kdh − λ)
{(
−knO2htt − kde − λ
)
(−λ)
(
kaOhtt − (k−1a + kda)− λ
)
+kdnknO2htt
(
kaO
2
htt − (k−1a + kda)− λ
)}
= 0. (B.5)
The eigenvalues are
λ2,1 = −A− kdh,
λ2,2+3 =
1
2
[
−knO2htt − kde ±
√
(knO2htt + kde)2 − 4kdnknO2htt
]
,
λ2,4 = kaO2htt − (k−1a + kda).
For A < A1, O2htt < 0, and R(λ2,2+3) > 0. For A > A1, R(λ2,2+3) < 0. As long as
λ2,4 < 0, Steady State 2 is stable, confirming the occurrence of a transcritical bifurcation
between Steady State 1 and Steady State 2. For λ2,4 = 0, another bifurcation occurs,
A2 =
kdh(a+ b)
knkh − (a+ b) , (Bif 2)
a = kde(kdn + k−1n ),
b = kdnkn
k−1a + kda
ka
.
At this value, the second and third steady states meet (Steady State 2=Steady State 3),
again pointing to a transcritical bifurcation. The Jacobian matrix evaluated at Steady
State 3 is
J3 =

−A− kdh 0 0 0
A −kn k
−1
a +kda
ka
− kde −knM3htt + k−1n 0
0 kn k
−1
a +kda
ka
k−1a
kda
[−knM3htt+k−1n +kdn] −kda
0 0 k
−1
a +kda
kda
[knM3htt−k−1n −kdn] 0
 . (B.6)
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The associated characteristic equation is
(−A− kdh − λ)
[
−λ3 +
(
−knk
−1
a + kda
ka
− kde + k
−1
a
kda
(−knM3htt + k−1n + kn)
)
λ2+
{
k−1a
kda
(−knM3htt + k−1n + kn)
(
kn
k−1a + kda
ka
+ kde
)
+ (k−1a + kda)(−knM3htt + k−1n + kn)
+ (−knM3htt + k−1n )kn
k−1a + kda
ka
}
λ+(
kn
k−1a + kda
ka
+ kde
)
(k−1a + kda)(−knM3htt + k−1n + kn)
]
= 0 (B.7)
When A = A2, Equation B.7 has a zero root, corresponding to a transcritical bifurcation.
Indeed, for A = A2, the constant term between the brackets in Equation B.7 vanishes,(
kn
k−1a + kda
ka
+ kde
)
(k−1a + kda)(−knM3htt|A=A2 + k−1n + kn) = 0 (B.8)
For A > A2, the this term is negative, providing no information on the positions of the
roots, so we look with Descartes’ Rule. For A < A2, there is, however, at least one positive
root, so Steady State 3 is unstable for A < A2. Descartes’ Rule provides states that the
maximum number of positive real roots a polynomial has is equal to the number of sign
changes in its coefficients. The third order polynomial between the brackets of Equation
B.7 have the following sign pattern: (-)(-)(-)(-), for the term −knM3htt|A>A2 + k−1n + kn is
negative. This means that the characteristic equation does not have positive real roots.
We can further check that if complex roots are existing, they have negative real part.
The third degree polynomial can be written −λ3 − c1λ2 − c2λ− c3 = 0 with ci > 0. The
condition for having the real part negative is c1c2 > c3. We can verify that this is indeed
the case.
The other roots have a negative real part. For A > A2, Steady State 1 and Steady
State 2 are unstable, as λ2,4 > 0 and λ2,4 < 0. A clear figure emerges from the steady
state analysis.
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Appendix C
List of Genes on the HD Microarray
AP1-regulated genes
Alternative AN Unigene hs Annotation
NM_000034 Hs.273415 aldolase A, fructose-bisphosphate
NM_000190 Hs.82609 hydroxymethylbilane synthase
NM_000399 Hs.1395 early growth response 2 (Krox-20 homolog, Drosophila)
NM_000518 Hs.155376 hemoglobin, beta
NM_000546 Hs.408312 tumor protein p53 (Li-Fraumeni syndrome)
NM_000558 Hs.449630 hemoglobin, alpha 2
NM_000586 Hs.89679 interleukin 2
NM_000586 Hs.89679 interleukin 2
NM_000588 Hs.694 interleukin 3 (colony-stimulating factor, multiple)
NM_000619 Hs.856 interferon, gamma
NM_000660 Hs.1103 transforming growth factor, beta 1 (Camurati-Engelmann
disease)
NM_000758 Hs.1349 colony stimulating factor 2 (granulocyte-macrophage)
NM_000758 Hs.1349 colony stimulating factor 2 (granulocyte-macrophage)
NM_000781 Hs.76205 cytochrome P450, family 11, subfamily A, polypeptide 1
NM_000879 Hs.2247 interleukin 5 (colony-stimulating factor, eosinophil)
NM_000905 Hs.1832 neuropeptide Y
NM_000948 Hs.1905 prolactin
NM_001005 Hs.387576 ribosomal protein S3
NM_001101 Hs.426930 actin, beta
NM_001442 Hs.391561 fatty acid binding protein 4, adipocyte
NM_001955 Hs.511899 endothelin 1
NM_002055 Hs.406397 glial fibrillary acidic protein
NM_002228 Hs.78465 v-jun sarcoma virus 17 oncogene homolog (avian)
NM_002421 Hs.83169 matrix metalloproteinase 1 (interstitial collagenase)
NM_002422 Hs.375129 matrix metalloproteinase 3 (stromelysin 1, progelatinase)
NM_002467 Hs.202453 v-myc myelocytomatosis viral oncogene homolog (avian)
NM_002689 Hs.201897 polymerase (DNA-directed), alpha (70kD)
NM_002984 Hs.75703 chemokine (C-C motif) ligand 4
NM_003254 Hs.446641 tissue inhibitor of metalloproteinase 1 (erythroid potentiating
activity, collagenase inhibitor)
NM_003254 Hs.446641 tissue inhibitor of metalloproteinase 1 (erythroid potentiating
activity, collagenase inhibitor)
NM_003380 Hs.435800 vimentin
NM_005252 Hs.25647 v-fos FBJ murine osteosarcoma viral oncogene homolog
NM_005354 Hs.2780 jun D proto-oncogene
NM_005953 Hs.418241 metallothionein 2A
NM_006563 Hs.37860 Kruppel-like factor 1 (erythroid)
X17650 Hs.404123 myogenic factor 3
AP2-regulated genes
Alternative AN Unigene hs Annotation
NM_000384 Hs.280226 apolipoprotein B (including Ag(x) antigen)
NM_000515 Hs.500468 growth hormone 1
NM_000526 Hs.355214 keratin 14 (epidermolysis bullosa simplex, Dowling-Meara,
Koebner)
NM_000619 Hs.856 interferon, gamma
NM_001124 Hs.441047 adrenomedullin
NM_001712 Hs.512682 carcinoembryonic antigen-related cell adhesion molecule 1
(biliary glycoprotein)
NM_001880 Hs.80285 activating transcription factor 2
NM_002026 Hs.418138 fibronectin 1
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NM_002055 Hs.406397 glial fibrillary acidic protein
NM_002228 Hs.78465 v-jun sarcoma virus 17 oncogene homolog (avian)
NM_002467 Hs.202453 v-myc myelocytomatosis viral oncogene homolog (avian)
NM_002539 Hs.443409 ornithine decarboxylase 1
NM_003220 Hs.210911 transcription factor AP-2 alpha (activating enhancer binding
protein 2 alpha)
NM_005953 Hs.418241 metallothionein 2A
NM_031966 Hs.23960 cyclin B1
U36308 Hs.406681 major intrinsic protein of lens fiber
AR-regulated genes
Alternative AN Unigene hs Annotation
AF153821 Hs.4 alcohol dehydrogenase IB (class I), beta polypeptide
M61856 Hs.511872 cytochrome P450, family 2, subfamily C, polypeptide 18
M99487 Hs.1915 folate hydrolase (prostate-specific membrane antigen) 1
NM_000348 Hs.1989 steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5
alpha-steroid delta 4-dehydrogenase alpha 2)
NM_000389 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_000689 Hs.76392 aldehyde dehydrogenase 1 family, member A1
NM_001093 Hs.234898 acetyl-Coenzyme A carboxylase beta
NM_001099 Hs.388677 acid phosphatase, prostate
NM_001509 Hs.248129 glutathione peroxidase 5 (epididymal androgen-related
protein)
NM_001628 Hs.75313 aldo-keto reductase family 1, member B1 (aldose reductase)
NM_003241 Hs.438265 transglutaminase 4 (prostate)
NM_003711 Hs.482121 phosphatidic acid phosphatase type 2A
NM_004104 Hs.83190 fatty acid synthase
NM_004117 Hs.7557 FK506 binding protein 5
NM_005437 Hs.422334 nuclear receptor coactivator 4
NM_005656 Hs.439309 transmembrane protease, serine 2
NM_007067 Hs.21907 MYST histone acetyltransferase 2
NM_007114 Hs.267632 TATA element modulatory factor 1
NM_014762 Hs.75616 24-dehydrocholesterol reductase
NM_016026 Hs.226007 retinol dehydrogenase 11 (all-trans and 9-cis)
NM_020168 Hs.21420 p21(CDKN1A)-activated kinase 6
Akt-regulated genes
Alternative AN Unigene hs Annotation
NM_000151 Hs.435783 glucose-6-phosphatase, catalytic (glycogen storage disease
type I, von Gierke disease)
NM_001467 Hs.132760 solute carrier family 37 (glycerol-6-phosphate transporter),
member 4
NM_004563 Hs.75812 phosphoenolpyruvate carboxykinase 2 (mitochondrial)
NM_006516 Hs.169902 solute carrier family 2 (facilitated glucose transporter),
member 1
c-myc-regulated genes
Alternative AN Unigene hs Annotation
D13639 Hs.376071 cyclin D2
H17434 Hs.79110 nucleolin
NM_001789 Hs.1634 cell division cycle 25A
NM_001968 Hs.79306 eukaryotic translation initiation factor 4E
NM_002467 Hs.202453 v-myc myelocytomatosis viral oncogene homolog (avian)
NM_002520 Hs.411098 nucleophosmin (nucleolar phosphoprotein B23, numatrin)
NM_002539 Hs.443409 ornithine decarboxylase 1
NM_002634 Hs.75323 prohibitin
NM_003219 Hs.439911 telomerase reverse transcriptase
NM_003467 Hs.421986 chemokine (C-X-C motif) receptor 4
NM_004448 Hs.446352 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian)
NM_006773 Hs.363492 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18
NM_006793 Hs.397062 peroxiredoxin 3
NM_016323 Hs.26663 cyclin-E binding protein 1
NM_020310 Hs.253552 MAX binding protein
NM_031966 Hs.23960 cyclin B1
R61502 Hs.183803 heat shock protein 75
T70920 Hs.848 FK506 binding protein 4, 59kDa
X16277 Hs.443409 ornithine decarboxylase 1
X54942 Hs.83758 CDC28 protein kinase regulatory subunit 2
C/EBP regulated genes
Original AN Unigene hs Annotation
NM_000201 Hs.386467 intercellular adhesion molecule 1 (CD54), human rhinovirus
receptor
NM_000567 Hs.76452 C-reactive protein, pentraxin-related
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NM_000576 Hs.126256 interleukin 1, beta
NM_000600 Hs.512234 interleukin 6 (interferon, beta 2)
NM_000613 Hs.426485 hemopexin
NM_000667 Hs.422855 alcohol dehydrogenase 1A (class I), alpha polypeptide
NM_000668 Hs.4 alcohol dehydrogenase IB (class I), beta polypeptide
NM_000669 Hs.2523 alcohol dehydrogenase 1C (class I), gamma polypeptide
NM_000882 Hs.673 interleukin 12A (natural killer cell stimulatory factor 1,
cytotoxic lymphocyte maturation factor 1, p35)
NM_000887 Hs.385521 integrin, alpha X (antigen CD11C (p150), alpha polypeptide)
NM_000927 Hs.21330 ATP-binding cassette, sub-family B (MDR/TAP), member 1
NM_002187 Hs.674 interleukin 12B (natural killer cell stimulatory factor 2,
cytotoxic lymphocyte maturation factor 2, p40)
NM_002569 Hs.59242 furin (paired basic amino acid cleaving enzyme)
NM_002985 Hs.489044 chemokine (C-C motif) ligand 5
NM_003286 Hs.253536 topoisomerase (DNA) I
NM_004563 Hs.75812 phosphoenolpyruvate carboxykinase 2 (mitochondrial)
NM_005252 Hs.25647 v-fos FBJ murine osteosarcoma viral oncogene homolog
NM_007115 Hs.407546 tumor necrosis factor, alpha-induced protein 6
NM_030754 Hs.1955 serum amyloid A2
NM_031226 Hs.187471 cytochrome P450, family 19, subfamily A, polypeptide 1
X01179 Hs.413083 coagulation factor VIII, procoagulant component (hemophilia
A)
CREB-regulated genes
Original AN Unigene hs Annotation
NM_000024 Hs.2551 adrenergic, beta-2-, receptor, surface
NM_000207 Hs.89832 insulin
NM_000315 Hs.37045 parathyroid hormone
NM_000399 Hs.1395 early growth response 2 (Krox-20 homolog, Drosophila)
NM_000486 Hs.130730 aquaporin 2 (collecting duct)
NM_000492 Hs.411882 cystic fibrosis transmembrane conductance regulator,
ATP-binding cassette (sub-family C, member 7)
NM_000576 Hs.126256 interleukin 1, beta
NM_000588 Hs.694 interleukin 3 (colony-stimulating factor, multiple)
NM_000596 Hs.401316 insulin-like growth factor binding protein 1
NM_000735 Hs.119689 glycoprotein hormones, alpha polypeptide
NM_000930 Hs.274404 plasminogen activator, tissue
NM_000931 Hs.274404 plasminogen activator, tissue
NM_001880 Hs.80285 activating transcription factor 2
NM_001964 Hs.326035 early growth response 1
NM_002026 Hs.418138 fibronectin 1
NM_002055 Hs.406397 glial fibrillary acidic protein
NM_002421 Hs.83169 matrix metalloproteinase 1 (interstitial collagenase)
NM_002616 Hs.445534 period homolog 1 (Drosophila)
NM_002690 Hs.180107 polymerase (DNA directed), beta
NM_003381 Hs.53973 vasoactive intestinal peptide
NM_003405 Hs.226755 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, eta polypeptide
NM_005252 Hs.25647 v-fos FBJ murine osteosarcoma viral oncogene homolog
NM_005566 Hs.2795 lactate dehydrogenase A
NM_033011 Hs.274404 plasminogen activator, tissue
U37218 Hs.401929 ribosomal protein L10
Z29078 Hs.371468 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
E2F-regulated genes
Original AN Unigene hs Annotation
BC031061 Hs.460184 MCM4 minichromosome maintenance deficient 4 (S.
cerevisiae)
NM_000321 Hs.408528 retinoblastoma 1 (including osteosarcoma)
NM_000791 Hs.83765 dihydrofolate reductase
NM_001034 Hs.226390 ribonucleotide reductase M2 polypeptide
NM_001071 Hs.87491 thymidylate synthetase
NM_001237 Hs.85137 cyclin A2
NM_001238 Hs.244723 cyclin E1
NM_001254 Hs.405958 CDC6 cell division cycle 6 homolog (S. cerevisiae)
NM_001759 Hs.376071 cyclin D2
NM_002592 Hs.78996 proliferating cell nuclear antigen
NM_002895 Hs.87 retinoblastoma-like 1 (p107)
NM_003504 Hs.114311 CDC45 cell division cycle 45-like (S. cerevisiae)
NM_003906 Hs.389037 MCM3 minichromosome maintenance deficient 3 (S.
cerevisiae) associated protein
NM_003914 Hs.417050 cyclin A1
NM_004091 Hs.231444 E2F transcription factor 2
NM_004153 Hs.17908 origin recognition complex, subunit 1-like (yeast)
NM_004526 Hs.57101 MCM2 minichromosome maintenance deficient 2, mitotin (S.
cerevisiae)
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NM_004688 Hs.54483 N-myc (and STAT) interactor
NM_005225 Hs.96055 E2F transcription factor 1
NM_005915 Hs.444118 MCM6 minichromosome maintenance deficient 6 (MIS5
homolog, S. pombe) (S. cerevisiae)
NM_005916 Hs.438720 MCM7 minichromosome maintenance deficient 7 (S.
cerevisiae)
NM_012333 Hs.78221 c-myc binding protein
NM_016937 Hs.267289 polymerase (DNA directed), alpha
NM_057182 Hs.244723 cyclin E1
Elk-1 regulated genes
Original AN Unigene hs Annotation
NM_000616 Hs.17483 CD4 antigen (p55)
NM_003131 Hs.444086 serum response factor (c-fos serum response element-binding
transcription factor)
NM_004907 Hs.737 immediate early protein
NM_005966 Hs.107474 NGFI-A binding protein 1 (EGR1 binding protein 1)
NM_006186 Hs.82120 nuclear receptor subfamily 4, group A, member 2
Fatty acid metabolism
genes
Alternative AN Unigene hs Annotation
NM_000016 Hs.254593 acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain
NM_000017 Hs.348900 acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain
NM_000019 Hs.37 acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl
Coenzyme A thiolase)
NM_000664 Hs.449863 acetyl-Coenzyme A carboxylase alpha
NM_000786 Hs.417077 cytochrome P450, family 51, subfamily A, polypeptide 1
NM_001093 Hs.234898 acetyl-Coenzyme A carboxylase beta
NM_001607 Hs.166160 acetyl-Coenzyme A acyltransferase 1 (peroxisomal
3-oxoacyl-Coenzyme A thiolase)
NM_001608 Hs.430108 acyl-Coenzyme A dehydrogenase, long chain
NM_001875 Hs.443292 carbamoyl-phosphate synthetase 1, mitochondrial
NM_001919 Hs.403436 dodecenoyl-Coenzyme A delta isomerase (3,2
trans-enoyl-Coenzyme A isomerase)
NM_001995 Hs.511920 fatty-acid-Coenzyme A ligase, long-chain 2
NM_002004 Hs.335918 farnesyl diphosphate synthase (farnesyl pyrophosphate
synthetase, dimethylallyltranstransferase,
geranyltranstransferase)
NM_002107 Hs.181307 H3 histone, family 3A
NM_002130 Hs.397729 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
NM_004035 Hs.379991 acyl-Coenzyme A oxidase 1, palmitoyl
NM_004104 Hs.83190 fatty acid synthase
NM_005215 Hs.172562 deleted in colorectal carcinoma
NM_014324 Hs.49598 alpha-methylacyl-CoA racemase
FOXO3
(FKHRL1)-regulated
genes
Original AN Unigene hs Annotation
NM_000127 Hs.184161 exostoses (multiple) 1
NM_000636 Hs.384944 superoxide dismutase 2, mitochondrial
NM_000639 Hs.2007 tumor necrosis factor (ligand) superfamily, member 6
NM_001924 Hs.80409 growth arrest and DNA-damage-inducible, alpha
NM_003620 Hs.286073 protein phosphatase 1D magnesium-dependent, delta isoform
NM_004052 Hs.79428 BCL2/adenovirus E1B 19kDa interacting protein 3
NM_004064 Hs.238990 cyclin-dependent kinase inhibitor 1B (p27, Kip1)
NM_004354 Hs.13291 cyclin G2
NM_005410 Hs.275775 selenoprotein P, plasma, 1
NM_005606 Hs.18069 legumain
NM_005611 Hs.283604 retinoblastoma-like 2 (p130)
NM_006538 Hs.84063 BCL2-like 11 (apoptosis facilitator)
NM_006705 Hs.9701 growth arrest and DNA-damage-inducible, gamma
NM_014454 Hs.14125 sestrin 1
NM_138621 Hs.84063 BCL2-like 11 (apoptosis facilitator)
Genes coding heat shock
proteins
Original AN Unigene hs Annotation
L12723 Hs.90093 heat shock 70kDa protein 4
NM_003192 Hs.75064 tubulin-specific chaperone c
NM_003193 Hs.445778 tubulin-specific chaperone e
NM_004281 Hs.15259 BCL2-associated athanogene 3
NM_004282 Hs.55220 BCL2-associated athanogene 2
NM_004607 Hs.355627 tubulin-specific chaperone a
NM_004873 Hs.5443 BCL2-associated athanogene 5
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NM_004874 Hs.194726 BCL2-associated athanogene 4
NM_005125 Hs.5002 copper chaperone for superoxide dismutase
NM_005993 Hs.435541 tubulin-specific chaperone d
NM_006145 Hs.82646 DnaJ (Hsp40) homolog, subfamily B, member 1
NM_006597 Hs.180414 heat shock 70kDa protein 8
NM_006819 Hs.257827 stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing
protein)
NM_006948 Hs.352341 stress 70 protein chaperone, microsome-associated, 60kDa
NM_007355 Hs.74335 heat shock 90kDa protein 1, beta
NM_012266 Hs.237506 DnaJ (Hsp40) homolog, subfamily B, member 5
NM_012267 Hs.53066 hsp70-interacting protein
NM_016299 Hs.430666 likely ortholog of mouse heat shock protein, 70 kDa 4
NM_016306 Hs.317192 DnaJ (Hsp40) homolog, subfamily B, member 11
NM_020247 Hs.273186 chaperone, ABC1 activity of bc1 complex like (S. pombe)
NM_153201 Hs.180414 heat shock 70kDa protein 8
Irf1-regulated genes
Original AN Unigene hs Annotation
AF039291 Hs.102267 lysyl oxidase
BC002666 Hs.62661 guanylate binding protein 1, interferon-inducible, 67kDa
M90100 Hs.196384 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase)
NM_000246 Hs.126714 MHC class II transactivator
NM_000389 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_000585 Hs.168132 interleukin 15
NM_000593 Hs.352018 transporter 1, ATP-binding cassette, sub-family B
(MDR/TAP)
NM_000639 Hs.2007 tumor necrosis factor (ligand) superfamily, member 6
NM_001223 Hs.2490 caspase 1, apoptosis-related cysteine protease (interleukin 1,
beta, convertase)
NM_001227 Hs.9216 caspase 7, apoptosis-related cysteine protease
NM_001547 Hs.169274 interferon-induced protein with tetratricopeptide repeats 2
NM_002053 Hs.62661 guanylate binding protein 1, interferon-inducible, 67kDa
NM_002176 Hs.93177 interferon, beta 1, fibroblast
NM_002187 Hs.674 interleukin 12B (natural killer cell stimulatory factor 2,
cytotoxic lymphocyte maturation factor 2, p40)
NM_002198 Hs.80645 interferon regulatory factor 1
NM_002534 Hs.442936 2’,5’-oligoadenylate synthetase 1, 40/46kDa
NM_002535 Hs.414332 2’-5’-oligoadenylate synthetase 2, 69/71kDa
NM_003064 Hs.251754 secretory leukocyte protease inhibitor (antileukoproteinase)
NM_004705 Hs.177574 protein-kinase, interferon-inducible double stranded RNA
dependent inhibitor, repressor of (P58 repressor)
NM_005101 Hs.458485 interferon, alpha-inducible protein (clone IFI-15K)
NM_006186 Hs.82120 nuclear receptor subfamily 4, group A, member 2
NM_006187 Hs.129895 2’-5’-oligoadenylate synthetase 3, 100kDa
NM_016816 Hs.442936 2’,5’-oligoadenylate synthetase 1, 40/46kDa
NM_016817 Hs.414332 2’-5’-oligoadenylate synthetase 2, 69/71kDa
NM_024013 Hs.37026 interferon, alpha 1
NM_033340 Hs.9216 caspase 7, apoptosis-related cysteine protease
NM_078467 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_139266 Hs.21486 signal transducer and activator of transcription 1, 91kDa
U04636 Hs.196384 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H
synthase and cyclooxygenase)
LEF1-regulated genes
Original AN Unigene hs Annotation
BC035872 Hs.512765 axin 1
NM_000038 Hs.75081 adenomatosis polyposis coli
NM_000165 Hs.74471 gap junction protein, alpha 1, 43kDa (connexin 43)
NM_000545 Hs.371279 transcription factor 1, hepatic; LF-B1, hepatic nuclear factor
(HNF1), albumin proximal factor
NM_001426 Hs.271977 engrailed homolog 1
NM_001804 Hs.1545 caudal type homeo box transcription factor 1
NM_002026 Hs.418138 fibronectin 1
NM_002423 Hs.2256 matrix metalloproteinase 7 (matrilysin, uterine)
NM_002467 Hs.202453 v-myc myelocytomatosis viral oncogene homolog (avian)
NM_002659 Hs.179657 plasminogen activator, urokinase receptor
NM_003257 Hs.74614 tight junction protein 1 (zona occludens 1)
NM_004360 Hs.194657 cadherin 1, type 1, E-cadherin (epithelial)
NM_005438 Hs.283565 FOS-like antigen 1
NM_005992 Hs.173984 T-box 1
NM_021801 Hs.204732 matrix metalloproteinase 26
NFAT-ergulated genes
Original AN Unigene hs Annotation
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NM_000074 Hs.652 tumor necrosis factor (ligand) superfamily, member 5
(hyper-IgM syndrome)
NM_000399 Hs.1395 early growth response 2 (Krox-20 homolog, Drosophila)
NM_000586 Hs.89679 interleukin 2
NM_000588 Hs.694 interleukin 3 (colony-stimulating factor, multiple)
NM_000589 Hs.73917 interleukin 4
NM_000619 Hs.856 interferon, gamma
NM_000639 Hs.2007 tumor necrosis factor (ligand) superfamily, member 6
NM_000879 Hs.2247 interleukin 5 (colony-stimulating factor, eosinophil)
NM_002188 Hs.845 interleukin 13
NM_002341 Hs.376208 lymphotoxin beta (TNF superfamily, member 3)
NM_004430 Hs.74088 early growth response 3
NM_004862 Hs.76507 lipopolysaccharide-induced TNF factor
NM_005593 Hs.178023 myogenic factor 5
NM_006140 Hs.520937 colony stimulating factor 2 receptor, alpha, low-affinity
(granulocyte-macrophage)
NM_006264 Hs.387553 protein tyrosine phosphatase, non-receptor type 13
(APO-1/CD95 (Fas)-associated phosphatase)
NF?B-regulated genes
Original AN Unigene hs Annotation
BC020864 Hs.65425 calbindin 1, 28kDa
M13994 Hs.79241 B-cell CLL/lymphoma 2
M14113 Hs.413083 coagulation factor VIII, procoagulant component (hemophilia
A)
NM_000029 Hs.19383 angiotensinogen (serine (or cysteine) proteinase inhibitor,
clade A (alpha-1 antiproteinase, antitrypsin), member 8)
NM_000043 Hs.82359 tumor necrosis factor receptor superfamily, member 6
NM_000201 Hs.386467 intercellular adhesion molecule 1 (CD54), human rhinovirus
receptor
NM_000331 Hs.332053 serum amyloid A1
NM_000417 Hs.130058 interleukin 2 receptor, alpha
NM_000450 Hs.89546 selectin E (endothelial adhesion molecule 1)
NM_000546 Hs.408312 tumor protein p53 (Li-Fraumeni syndrome)
NM_000567 Hs.76452 C-reactive protein, pentraxin-related
NM_000584 Hs.624 interleukin 8
NM_000586 Hs.89679 interleukin 2
NM_000593 Hs.352018 transporter 1, ATP-binding cassette, sub-family B
(MDR/TAP)
NM_000595 Hs.36 lymphotoxin alpha (TNF superfamily, member 1)
NM_000600 Hs.512234 interleukin 6 (interferon, beta 2)
NM_001078 Hs.109225 vascular cell adhesion molecule 1
NM_001511 Hs.789 chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)
NM_001710 Hs.69771 B-factor, properdin
NM_002089 Hs.75765 chemokine (C-X-C motif) ligand 2
NM_002090 Hs.89690 chemokine (C-X-C motif) ligand 3
NM_002160 Hs.98998 tenascin C (hexabrachion)
NM_002176 Hs.93177 interferon, beta 1, fibroblast
NM_002229 Hs.400124 jun B proto-oncogene
NM_002522 Hs.84154 neuronal pentraxin I
NM_002658 Hs.77274 plasminogen activator, urokinase
NM_002852 Hs.2050 pentaxin-related gene, rapidly induced by IL-1 beta
NM_003152 Hs.437058 signal transducer and activator of transcription 5A
NM_003998 Hs.160557 nuclear factor of kappa light polypeptide gene enhancer in
B-cells 1 (p105)
NM_004929 Hs.65425 calbindin 1, 28kDa
NM_021975 Hs.132594 v-rel reticuloendotheliosis viral oncogene homolog A, nuclear
factor of kappa light polypeptide gene enhancer in B-cells 3,
p65 (avian)
NM_030754 Hs.1955 serum amyloid A2
X14322 Hs.384944 superoxide dismutase 2, mitochondrial
X60459 Hs.181315 interferon (alpha, beta and omega) receptor 1
Z23115 Hs.305890 BCL2-like 1
p53-regulated genes
Original AN Unigene hs Annotation
AF012535 Hs.51233 tumor necrosis factor receptor superfamily, member 10b
AF019742 Hs.74034 caveolin 1, caveolae protein, 22kDa
AF029081 Hs.184510 stratifin
AK000121 Hs.6241 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1
(p85 alpha)
D00618 Hs.208641 actin, alpha 2, smooth muscle, aorta
NM_000021 Hs.3260 presenilin 1 (Alzheimer disease 3)
NM_000038 Hs.75081 adenomatosis polyposis coli
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NM_000043 Hs.82359 tumor necrosis factor receptor superfamily, member 6
NM_000136 Hs.253236 Fanconi anemia, complementation group C
NM_000156 Hs.81131 guanidinoacetate N-methyltransferase
NM_000208 Hs.438669 insulin receptor
NM_000321 Hs.408528 retinoblastoma 1 (including osteosarcoma)
NM_000546 Hs.408312 tumor protein p53 (Li-Fraumeni syndrome)
NM_000586 Hs.89679 interleukin 2
NM_000589 Hs.73917 interleukin 4
NM_000598 Hs.450230 insulin-like growth factor binding protein 3
NM_000600 Hs.512234 interleukin 6 (interferon, beta 2)
NM_000657 Hs.79241 B-cell CLL/lymphoma 2
NM_000927 Hs.21330 ATP-binding cassette, sub-family B (MDR/TAP), member 1
NM_001188 Hs.93213 BCL2-antagonist/killer 1
NM_001402 Hs.439552 eukaryotic translation elongation factor 1 alpha 1
NM_001702 Hs.194654 brain-specific angiogenesis inhibitor 1
NM_001909 Hs.343475 cathepsin D (lysosomal aspartyl protease)
NM_001924 Hs.80409 growth arrest and DNA-damage-inducible, alpha
NM_002066 Hs.86161 GPI anchored molecule like protein
NM_002231 Hs.323949 kangai 1 (suppression of tumorigenicity 6, prostate; CD82
antigen (R2 leukocyte antigen, antigen detected by
monoclonal and antibody IA4))
NM_002307 Hs.99923 lectin, galactoside-binding, soluble, 7 (galectin 7)
NM_002375 Hs.31095 microtubule-associated protein 4
NM_002592 Hs.78996 proliferating cell nuclear antigen
NM_003236 Hs.170009 transforming growth factor, alpha
NM_003246 Hs.164226 thrombospondin 1
NM_003620 Hs.286073 protein phosphatase 1D magnesium-dependent, delta isoform
NM_003824 Hs.86131 Fas (TNFRSF6)-associated via death domain
NM_003842 Hs.51233 tumor necrosis factor receptor superfamily, member 10b
NM_004060 Hs.79101 cyclin G1
NM_004324 Hs.159428 BCL2-associated X protein
NM_004530 Hs.367877 matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase,
72kDa type IV collagenase)
NM_004879 Hs.343911 etoposide induced 2.4 mRNA
NM_004881 Hs.50649 tumor protein p53 inducible protein 3
NM_005027 Hs.211586 phosphoinositide-3-kinase, regulatory subunit, polypeptide 2
(p85 beta)
NM_005228 Hs.77432 epidermal growth factor receptor (erythroblastic leukemia
viral (v-erb-b) oncogene homolog, avian)
NM_005343 Hs.37003 v-Ha-ras Harvey rat sarcoma viral oncogene homolog
NM_005978 Hs.413843 S100 calcium binding protein A2
NM_006024 Hs.5437 Tax1 (human T-cell leukemia virus type I) binding protein 1
NM_006142 Hs.184510 stratifin
NM_006497 Hs.72956 hypermethylated in cancer 1
NM_006705 Hs.9701 growth arrest and DNA-damage-inducible, gamma
NM_006819 Hs.257827 stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing
protein)
NM_006882 Hs.212217 Mdm2, transformed 3T3 cell double minute 2, p53 binding
protein (mouse)
NM_007233 Hs.274329 TP53 activated protein 1
NM_013229 Hs.373575 apoptotic protease activating factor
NM_014417 Hs.87246 BCL2 binding component 3
NM_016426 Hs.122552 G-2 and S-phase expressed 1
NM_021127 Hs.96 phorbol-12-myristate-13-acetate-induced protein 1
NM_022112 Hs.160953 p53-regulated apoptosis-inducing protein 1
NM_022121 Hs.149620 PERP, TP53 apoptosis effector
NM_022470 Hs.386299 p53 target zinc finger protein
NM_030983 Hs.31095 microtubule-associated protein 4
NM_033295 Hs.2490 caspase 1, apoptosis-related cysteine protease (interleukin 1,
beta, convertase)
NM_078467 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_138924 Hs.81131 guanidinoacetate N-methyltransferase
NM_145887 Hs.438986 leucine-rich and death domain containing
NM_147184 Hs.50649 tumor protein p53 inducible protein 3
NM_147187 Hs.51233 tumor necrosis factor receptor superfamily, member 10b
NM_152240 Hs.386299 p53 target zinc finger protein
Proteasome coding genes
Original AN Unigene hs Annotation
NM_002786 Hs.82159 proteasome subunit, alpha type, 1
NM_002787 Hs.333786 proteasome subunit, alpha type, 2
NM_002788 Hs.246240 proteasome subunit, alpha type, 3
NM_002789 Hs.251531 proteasome subunit, alpha type, 4
NM_002790 Hs.76913 proteasome subunit, alpha type, 5
NM_002792 Hs.233952 proteasome subunit, alpha type, 7
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NM_002793 Hs.352768 proteasome subunit, beta type, 1
NM_002794 Hs.432607 proteasome subunit, beta type, 2
NM_002795 Hs.82793 proteasome subunit, beta type, 3
NM_002796 Hs.89545 proteasome subunit, beta type, 4
NM_002797 Hs.422990 proteasome subunit, beta type, 5
NM_002799 Hs.197071 proteasome subunit, beta type, 7
NM_002802 Hs.356654 proteasome 26S subunit, ATPase, 1
NM_002803 Hs.61153 proteasome 26S subunit, ATPase, 2
NM_002804 Hs.250758 proteasome 26S subunit, ATPase, 3
NM_002805 Hs.79387 proteasome 26S subunit, ATPase, 5
NM_002806 Hs.156171 proteasome 26S subunit, ATPase, 6
NM_002807 Hs.3887 proteasome 26S subunit, non-ATPase, 1
NM_002808 Hs.388921 proteasome 26S subunit, non-ATPase, 2
NM_002809 Hs.9736 proteasome 26S subunit, non-ATPase, 3
NM_002810 Hs.505059 proteasome 26S subunit, non-ATPase, 4
NM_002811 Hs.440604 proteasome 26S subunit, non-ATPase, 7 (Mov34 homolog)
NM_002812 Hs.78466 proteasome 26S subunit, non-ATPase, 8
NM_002815 Hs.443379 proteasome 26S subunit, non-ATPase, 11
NM_002816 Hs.4295 proteasome 26S subunit, non-ATPase, 12
NM_002817 Hs.279554 proteasome 26S subunit, non-ATPase, 13
NM_005805 Hs.178761 proteasome 26S subunit, non-ATPase, 14
NM_006503 Hs.211594 proteasome 26S subunit, ATPase, 4
NM_014814 Hs.350939 proteasome regulatory particle subunit p44S10
RUNX-regulated genes
Original AN Unigene hs Annotation
NM_000250 Hs.458272 myeloperoxidase
NM_000389 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_000588 Hs.694 interleukin 3 (colony-stimulating factor, multiple)
NM_000633 Hs.79241 B-cell CLL/lymphoma 2
NM_000757 Hs.173894 colony stimulating factor 1 (macrophage)
NM_000760 Hs.381027 colony stimulating factor 3 receptor (granulocyte)
NM_001870 Hs.646 carboxypeptidase A3 (mast cell)
NM_002965 Hs.112405 S100 calcium binding protein A9 (calgranulin B)
NM_003364 Hs.314828 uridine phosphorylase 1
NM_005311 Hs.512118 growth factor receptor-bound protein 10
NM_005356 Hs.1765 lymphocyte-specific protein tyrosine kinase
NM_006875 Hs.80205 pim-2 oncogene
NM_014793 Hs.200596 leucine carboxyl methyltransferase 2
NM_078467 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
Sp1-regulated genes
Original AN Unigene hs Annotation
AB052946 Hs.57735 scavenger receptor class F, member 1
AF004877 Hs.232115 collagen, type I, alpha 2
AF019742 Hs.74034 caveolin 1, caveolae protein, 22kDa
J00289 Hs.500457 chorionic somatomammotropin hormone 2
K02401 Hs.347963 chorionic somatomammotropin hormone 1 (placental
lactogen)
M59423 Hs.376032 platelet-derived growth factor alpha polypeptide
NM_000022 Hs.407135 adenosine deaminase
NM_000034 Hs.273415 aldolase A, fructose-bisphosphate
NM_000041 Hs.110675 apolipoprotein E
NM_000043 Hs.82359 tumor necrosis factor receptor superfamily, member 6
NM_000050 Hs.160786 argininosuccinate synthetase
NM_000088 Hs.172928 collagen, type I, alpha 1
NM_000121 Hs.127826 erythropoietin receptor
NM_000190 Hs.82609 hydroxymethylbilane synthase
NM_000208 Hs.438669 insulin receptor
NM_000365 Hs.512711 triosephosphate isomerase 1
NM_000384 Hs.280226 apolipoprotein B (including Ag(x) antigen)
NM_000457 Hs.54424 hepatocyte nuclear factor 4, alpha
NM_000485 Hs.28914 adenine phosphoribosyltransferase
NM_000500 Hs.278430 cytochrome P450, family 21, subfamily A, polypeptide 2
NM_000515 Hs.500468 growth hormone 1
NM_000558 Hs.449630 hemoglobin, alpha 2
NM_000559 Hs.449631 hemoglobin, gamma A
NM_000619 Hs.856 interferon, gamma
NM_000632 Hs.172631 integrin, alpha M (complement component receptor 3, alpha;
also known as CD11b (p170), macrophage antigen alpha
polypeptide)
NM_000660 Hs.1103 transforming growth factor, beta 1 (Camurati-Engelmann
disease)
NM_000668 Hs.4 alcohol dehydrogenase IB (class I), beta polypeptide
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NM_000791 Hs.83765 dihydrofolate reductase
NM_000805 Hs.2681 gastrin
NM_000905 Hs.1832 neuropeptide Y
NM_000927 Hs.21330 ATP-binding cassette, sub-family B (MDR/TAP), member 1
NM_000930 Hs.274404 plasminogen activator, tissue
NM_001005 Hs.387576 ribosomal protein S3
NM_001020 Hs.397609 ribosomal protein S16
NM_001042 Hs.371905 solute carrier family 2 (facilitated glucose transporter),
member 4
NM_001071 Hs.87491 thymidylate synthetase
NM_001511 Hs.789 chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)
NM_001783 Hs.79630 CD79A antigen (immunoglobulin-associated alpha)
NM_001880 Hs.80285 activating transcription factor 2
NM_002026 Hs.418138 fibronectin 1
NM_002055 Hs.406397 glial fibrillary acidic protein
NM_002100 Hs.438658 glycophorin B (includes Ss blood group)
NM_002101 Hs.81994 glycophorin C (Gerbich blood group)
NM_002228 Hs.78465 v-jun sarcoma virus 17 oncogene homolog (avian)
NM_002385 Hs.408543 myelin basic protein
NM_002467 Hs.202453 v-myc myelocytomatosis viral oncogene homolog (avian)
NM_002539 Hs.443409 ornithine decarboxylase 1
NM_002569 Hs.59242 furin (paired basic amino acid cleaving enzyme)
NM_002592 Hs.78996 proliferating cell nuclear antigen
NM_002690 Hs.180107 polymerase (DNA directed), beta
NM_002736 Hs.77439 protein kinase, cAMP-dependent, regulatory, type II, beta
NM_003122 Hs.407856 serine protease inhibitor, Kazal type 1
NM_003219 Hs.439911 telomerase reverse transcriptase
NM_003246 Hs.164226 thrombospondin 1
NM_003258 Hs.164457 thymidine kinase 1, soluble
NM_004324 Hs.159428 BCL2-associated X protein
NM_004360 Hs.194657 cadherin 1, type 1, E-cadherin (epithelial)
NM_004364 Hs.76171 CCAAT/enhancer binding protein (C/EBP), alpha
NM_004502 Hs.436181 homeo box B7
NM_005159 Hs.118127 actin, alpha, cardiac muscle
NM_005228 Hs.77432 epidermal growth factor receptor (erythroblastic leukemia
viral (v-erb-b) oncogene homolog, avian)
NM_005330 Hs.117848 hemoglobin, epsilon 1
NM_005332 Hs.272003 hemoglobin, zeta
NM_005343 Hs.37003 v-Ha-ras Harvey rat sarcoma viral oncogene homolog
NM_005345 Hs.75452 heat shock 70kDa protein 1A
NM_005354 Hs.2780 jun D proto-oncogene
NM_005953 Hs.418241 metallothionein 2A
NM_006288 Hs.134643 Thy-1 cell surface antigen
NM_006398 Hs.44532 ubiquitin D
NM_017512 Hs.475848 rTS beta protein
NM_022727 Hs.63609 HpaII tiny fragments locus 9C
NM_033016 Hs.1976 platelet-derived growth factor beta polypeptide (simian
sarcoma viral (v-sis) oncogene homolog)
NM_033295 Hs.2490 caspase 1, apoptosis-related cysteine protease (interleukin 1,
beta, convertase)
NM_078467 Hs.370771 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
NM_080649 Hs.73722 APEX nuclease (multifunctional DNA repair enzyme) 1
U36308 Hs.406681 major intrinsic protein of lens fiber
U37218 Hs.401929 ribosomal protein L10
X12784 Hs.437173 collagen, type IV, alpha 1
Z29078 Hs.371468 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
Sp3-regulated genes
Original AN Unigene hs Annotation
M85247 Hs.2624 dopamine receptor D1
NM_001511 Hs.789 chemokine (C-X-C motif) ligand 1 (melanoma growth
stimulating activity, alpha)
U36308 Hs.406681 major intrinsic protein of lens fiber
Stat1-regulated genes
Original AN Unigene hs Annotation
NM_000201 Hs.386467 intercellular adhesion molecule 1 (CD54), human rhinovirus
receptor
NM_000246 Hs.126714 MHC class II transactivator
NM_000247 Hs.90598 MHC class I polypeptide-related sequence A
NM_000547 Hs.71304 thyroid peroxidase
NM_001085 Hs.76353 serine (or cysteine) proteinase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3
NM_001223 Hs.2490 caspase 1, apoptosis-related cysteine protease (interleukin 1,
beta, convertase)
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NM_001224 Hs.433103 caspase 2, apoptosis-related cysteine protease (neural
precursor cell expressed, developmentally down-regulated 2)
NM_001233 Hs.139851 caveolin 2
NM_001786 Hs.334562 cell division cycle 2, G1 to S and G2 to M
NM_001867 Hs.430075 cytochrome c oxidase subunit VIIc
NM_002053 Hs.62661 guanylate binding protein 1, interferon-inducible, 67kDa
NM_002162 Hs.353214 intercellular adhesion molecule 3
NM_002164 Hs.840 indoleamine-pyrrole 2,3 dioxygenase
NM_002178 Hs.274313 insulin-like growth factor binding protein 6
NM_002184 Hs.71968 interleukin 6 signal transducer (gp130, oncostatin M receptor)
NM_002198 Hs.80645 interferon regulatory factor 1
NM_002222 Hs.149900 inositol 1,4,5-triphosphate receptor, type 1
NM_002227 Hs.436004 Janus kinase 1 (a protein tyrosine kinase)
NM_002421 Hs.83169 matrix metalloproteinase 1 (interstitial collagenase)
NM_002427 Hs.2936 matrix metalloproteinase 13 (collagenase 3)
NM_003235 Hs.433680 thyroglobulin
NM_003299 Hs.192374 tumor rejection antigen (gp96) 1
NM_003373 Hs.75350 vinculin
NM_003902 Hs.118962 far upstream element (FUSE) binding protein 1
NM_003932 Hs.377199 suppression of tumorigenicity 13 (colon carcinoma) (Hsp70
interacting protein)
NM_004048 Hs.48516 beta-2-microglobulin
NM_004322 Hs.76366 BCL2-antagonist of cell death
NM_004346 Hs.141125 caspase 3, apoptosis-related cysteine protease
NM_004530 Hs.367877 matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase,
72kDa type IV collagenase)
NM_005516 Hs.381008 major histocompatibility complex, class I, E
NM_005529 Hs.211573 heparan sulfate proteoglycan 2 (perlecan)
NM_005931 Hs.211580 MHC class I polypeptide-related sequence B
NM_006472 Hs.179526 thioredoxin interacting protein
NM_006835 Hs.369110 cyclin I
NM_006889 Hs.27954 CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)
NM_007111 Hs.79353 transcription factor Dp-1
NM_012333 Hs.78221 c-myc binding protein
NM_021960 Hs.86386 myeloid cell leukemia sequence 1 (BCL2-related)
NM_031966 Hs.23960 cyclin B1
NM_148954 Hs.381081 proteasome subunit, beta type, 9 (large multifunctional
protease 2)
TFEB-regulated genes
Original AN Unigene hs Annotation
NM_000550 Hs.75219 tyrosinase-related protein 1
NM_002019 Hs.347713 fms-related tyrosine kinase 1 (vascular endothelial growth
factor/vascular permeability factor receptor)
NM_003215 Hs.278005 tec protein tyrosine kinase
NM_003376 Hs.73793 vascular endothelial growth factor
Genes coding for
vesicular transport
proteins
Original AN Unigene hs Annotation
AB024494 Hs.4014 huntingtin interacting protein 14
AF049527 Hs.19121 adaptor-related protein complex 2, alpha 2 subunit
AF114488 Hs.66392 intersectin 1 (SH3 domain protein)
AF149825 Hs.334639 protein kinase C and casein kinase substrate in neurons 3
AF242529 Hs.441281 protein kinase C and casein kinase substrate in neurons 1
AF277897 Hs.77432 epidermal growth factor receptor (erythroblastic leukemia
viral (v-erb-b) oncogene homolog, avian)
AF393369 Hs.387648 adaptor-related protein complex 1, sigma 3 subunit
AK055003 Hs.177193 similar to synaptotagmin V
BC034044 Hs.12436 calcium/calmodulin-dependent protein kinase (CaM kinase)
II gamma
J03778 Hs.101174 microtubule-associated protein tau
L23958 Hs.7720 dynein, cytoplasmic, heavy polypeptide 1
NM_000944 Hs.272458 protein phosphatase 3 (formerly 2B), catalytic subunit, alpha
isoform (calcineurin A alpha)
NM_001221 Hs.111460 calcium/calmodulin-dependent protein kinase (CaM kinase)
II delta
NM_001365 Hs.23731 discs, large homolog 4 (Drosophila)
NM_001635 Hs.173034 amphiphysin (Stiff-Man syndrome with breast cancer 128kDa
autoantigen)
NM_001833 Hs.207052 clathrin, light polypeptide (Lca)
NM_001834 Hs.380749 clathrin, light polypeptide (Lcb)
NM_001981 Hs.79095 epidermal growth factor receptor pathway substrate 15
NM_002628 Hs.91747 profilin 2
NM_003081 Hs.221974 synaptosomal-associated protein, 25kDa
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NM_003178 Hs.445503 synapsin II
NM_003490 Hs.125878 synapsin III
NM_003941 Hs.182469 Wiskott-Aldrich syndrome-like
NM_004068 Hs.433892 adaptor-related protein complex 2, mu 1 subunit
NM_004082 Hs.74617 dynactin 1 (p150, glued homolog, Drosophila)
NM_004408 Hs.436132 dynamin 1
NM_004522 Hs.6641 kinesin family member 5C
NM_004582 Hs.78948 Rab geranylgeranyltransferase, beta subunit
NM_004712 Hs.416959 hepatocyte growth factor-regulated tyrosine kinase substrate
NM_004859 Hs.187416 clathrin, heavy polypeptide (Hc)
NM_004945 Hs.432832 dynamin 2
NM_005228 Hs.77432 epidermal growth factor receptor (erythroblastic leukemia
viral (v-erb-b) oncogene homolog, avian)
NM_005550 Hs.23131 kinesin family member C3
NM_005552 Hs.512578 kinesin 2 60/70kDa
NM_005605 Hs.75206 protein phosphatase 3 (formerly 2B), catalytic subunit,
gamma isoform (calcineurin A gamma)
NM_005735 Hs.2477 ARP1 actin-related protein 1 homolog B, centractin beta
(yeast)
NM_005817 Hs.140452 cargo selection protein (mannose 6 phosphate receptor
binding protein)
NM_006006 Hs.356349 zinc finger protein 145 (Kruppel-like, expressed in
promyelocytic leukemia)
NM_006178 Hs.431279 N-ethylmaleimide-sensitive factor
NM_006277 Hs.444708 intersectin 2
NM_006400 Hs.289123 dynactin 2 (p50)
NM_006597 Hs.180414 heat shock 70kDa protein 8
NM_006888 Hs.282410 calmodulin 1 (phosphorylase kinase, delta)
NM_006950 Hs.225936 synapsin I
NM_007097 Hs.380749 clathrin, light polypeptide (Lcb)
NM_007166 Hs.39252 phosphatidylinositol binding clathrin assembly protein
NM_007229 Hs.454530 protein kinase C and casein kinase substrate in neurons 2
NM_012310 Hs.279766 kinesin family member 4A
NM_014231 Hs.20021 vesicle-associated membrane protein 1 (synaptobrevin 1)
NM_014666 Hs.132853 enthoprotin
NM_014841 Hs.304330 synaptosomal-associated protein, 91kDa homolog (mouse)
NM_014964 Hs.7407 epsin 2
NM_015074 Hs.444757 kinesin family member 1B
NM_015254 Hs.15711 kinesin family member 13B
NM_016009 Hs.136309 SH3-domain GRB2-like endophilin B1
NM_016131 Hs.236494 RAB10, member RAS oncogene family
NM_016223 Hs.334639 protein kinase C and casein kinase substrate in neurons 3
NM_016530 Hs.365655 RAB-8b protein
NM_016830 Hs.20021 vesicle-associated membrane protein 1 (synaptobrevin 1)
NM_017957 Hs.165904 epsin 3
NM_019028 Hs.163091 HIP14-related protein
NM_019595 Hs.444708 intersectin 2
NM_020145 Hs.30002 SH3-domain GRB2-like endophilin B2
NM_020804 Hs.441281 protein kinase C and casein kinase substrate in neurons 1
NM_021132 Hs.187543 protein phosphatase 3 (formerly 2B), catalytic subunit, beta
isoform (calcineurin A beta)
NM_021980 Hs.390162 optineurin
NM_022113 Hs.146286 kinesin family member 13A
NM_022342 Hs.373627 kinesin family member 9
NM_022822 Hs.280792 likely ortholog of kinesin light chain 2
NM_023019 Hs.74617 dynactin 1 (p150, glued homolog, Drosophila)
NM_032559 Hs.226805 kinesin protein
NM_053024 Hs.91747 profilin 2
NM_133499 Hs.225936 synapsin I
NM_133625 Hs.445503 synapsin II
NM_133633 Hs.125878 synapsin III
NM_139316 Hs.173034 amphiphysin (Stiff-Man syndrome with breast cancer 128kDa
autoantigen)
NM_147152 Hs.444708 intersectin 2
NM_147180 Hs.283852 glutamate receptor, ionotropic, N-methyl-D-aspartate 3A
NM_148921 Hs.7407 epsin 2
U01828 Hs.167 microtubule-associated protein 2
U16850 Hs.282410 calmodulin 1 (phosphorylase kinase, delta)
U53530 Hs.7720 dynein, cytoplasmic, heavy polypeptide 1
Luthi-Carter data 2000
and 2002 overlap
AF026537 Mm.6239 Hs.22584 prodynorphin
D13003 Mm.4876 Hs.167791 reticulocalbin 1, EF-hand calcium binding domain
L01695 Mm.62 Hs.512605 phosphodiesterase 1B, calmodulin-dependent
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M13227 Mm.2899 Preproenkephalin 1 (Penk1)
M22326 Mm.181959 Hs.326035 early growth response 1
M69109 Mm.392 Hs.840 indoleamine-pyrrole 2,3 dioxygenase
M74149 Mm.16831 Hs.173724 creatine kinase, brain
U06483 Mm.4629 Hs.151250 intercellular adhesion molecule 5, telencephalin
U13837 Mm.217787 Hs.409131 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A
U29762 Mm.3459 Hs.414480 D site of albumin promoter (albumin D-box) binding protein
U67187 Mm.28262 Hs.78944 regulator of G-protein signalling 2, 24kDa
U93862 Mm.290786 Hs.381172 ribosomal protein L41
U96746 Mm.247542 Hs.83383 peroxiredoxin 4
W12692 Mm.180873 Hs.337766 ribosomal protein L18a
W34429 Mm.195067 Hs.83672 actinin, alpha 2
X15373 Mm.227912 Hs.149900 inositol 1,4,5-triphosphate receptor, type 1
X16995 Mm.119 Hs.1119 nuclear receptor subfamily 4, group A, member 1
X51468 Mm.2453 Somatostatin
X55674 Mm.41970 Hs.73893 dopamine receptor D2
X70398 Mm.128733 Hs.508741 chromosome 5 open reading frame 13
X80502 Mm.252110 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3
X97281 Mm.1438 Hs.157818 potassium voltage-gated channel, shaker-related subfamily,
beta member 1
Z31174 Mm.28896 Hs.300446 START domain containing 10
Z31235 Mm.271947 Hs.209983 stathmin 1/oncoprotein 18
Z31269 Mm.29586 Brain abundant, membrane attached signal protein 1 (Basp1)
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